Novel enzyme

The modified Dda helicase addresses the challenge of controlling polynucleotide movement in nanopore sequencing by increasing velocity and reducing residence time variability, resulting in improved accuracy and reduced errors.

JP2026539008APending Publication Date: 2026-11-19OXFORD NANOPORE TECH LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026523360
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-18
Filing Date
2024-10-18
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing nanopore sequencing technologies face challenges in accurately controlling the movement of polynucleotides through transmembrane pores, leading to statistical noise and errors in nucleotide identification due to variable residence times, particularly in long homopolymer regions.

Method used

A modified Dda helicase with specific amino acid modifications enhances the control over polynucleotide movement through nanopores, increasing velocity and reducing residence time variability, thereby improving sequencing accuracy.

Benefits of technology

The modified Dda helicase achieves improved accuracy and reduced errors in nucleotide identification by increasing velocity and minimizing residence time variations, enhancing the reliability of nanopore sequencing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539008000001
    Figure 2026539008000001
  • Figure 2026539008000002
    Figure 2026539008000002
  • Figure 2026539008000003
    Figure 2026539008000003
Patent Text Reader

Abstract

This invention relates to a modified Dda helicase that can be used to control the migration of analytes such as polynucleotides. The modified Dda helicase is used for the detection and characterization of analytes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to a modified Dda helicase that can be used to control the migration of analytes such as polynucleotides. The modified Dda helicase is used for the detection and characterization of analytes. [Background technology]

[0002] Two essential components of analytes, particularly polymers, using nanopore sensing are (1) control of polymer migration through the pore, and (2) identification of the constituent elements as the polymer migrates through the pore. In nanopore sensing, the narrowest part of the pore typically corresponds to the most distinctive part of the nanopore with respect to the change in the measurement signal as a function of the analyte migrating across the nanopore. International Publications 2015 / 055981, 2015 / 166276, 2016 / 055777, and PCT / EP2023 / 059821, which are incorporated herein in their entirety by reference, describe polynucleotide-binding proteins, particularly Dda helicases, that can be used to control the migration of analytes across transmembrane protein pores, such as the CsgG pores described herein. [Overview of the Initiative] [Problems that the invention aims to solve]

[0003] The inventors have, surprisingly, identified a specific Dda variant (known herein as modified Dda helicase or modified helicase) that possesses an improved ability to control the movement of analytes through the pore. When sequencing polynucleotides using the pore, the system estimates together the number and identity of bases / nucleotides passing through the pore. Better control over variations in movement rate can reduce one of the sources of statistical noise and simplify the estimation task. A series of consecutive short residences of polynucleotides within the pore can lead to failures in the calling of the underlying nucleotide / base, resulting in deletion errors. Unusually long residences can lead to insertion errors. Ensuring that each nucleotide / base spends a sufficient time interval within the pore helps resolve the statistical uncertainty of nucleotide / base identity from noisy signal levels. Further information can be extracted from the dependence of residence time on nucleotide / base identity, for example, through interactions with motor enzymes. Reducing the overall variability of residence time can help extract more accurate information through this channel. In regions where the signal level provides limited information about movement (e.g., long homopolymer regions), the number of bases traversing the pore can be estimated using multinucleotide / base residence times. These estimates can be made more accurate by reducing the variability of residence times. [Means for solving the problem]

[0004] In some embodiments, the modified helicases of the present invention exhibit increased velocity when used in methods for controlling the movement of analytes through transmembrane pores and methods for characterizing analytes using transmembrane pores. The velocity at which the analyte passes through the pore / velocity relative to the pore may increase by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more, relative to the velocity at which the analyte moves through the pore when using the Dda helicase that does not contain the mutations of the present invention. The inventors have surprisingly found that these changes in velocity, such as an increase in velocity, have little to no effect on accurate readings. This is particularly advantageous in a method of characterizing an analyte as it comes into contact with a pore and the helicase of the present invention, such that a polynucleotide-binding protein controls the movement of the target analyte through / towards the pore.

[0005] In some embodiments, the modified helicases of the present invention exhibit improved accuracy when used in methods for controlling the movement of analytes through transmembrane pores and methods for characterizing analytes using transmembrane pores. In the context of analyte characterization (particularly polynucleotides), accuracy is interpreted as raw-read simplex accuracy; that is, a single pass of a single molecule through the transmembrane pore. Accuracy is a useful measure for tracking platform improvements of sequencing devices. Accuracy can also refer to consensus accuracy, or accuracy in detecting specific things, such as mutations in polynucleotide analytes. Additionally or alternatively, accuracy is interpreted as a percentage of the baseline above a particular confidence level, given that the confidence level has been calibrated beforehand. In some embodiments, the modified helicases of the present invention exhibit improved accuracy with minimal or no change in rate. In some embodiments, accuracy is improved to give errors of less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or less than 0.1%. The modified helicases identified by the inventors typically involve a combination of mutations, i.e., one or more modifications in the portion of the modified helicase that interacts with the transmembrane pore. Accuracy can also be affected by the rate at which the polymer passes through the pore under enzyme control, and this rate can be altered by changing the concentration of ATP supplied to the enzyme. The inventors have surprisingly found that the enzyme can exhibit rate changes during sequential polymer rearrangements within the same sequencing run under the same conditions, which can lead to a decrease in accuracy.

[0006] The accuracy can be influenced by many factors, including the shape and composition of the nanopores, the enzyme, and the interaction between the enzyme and the nanopores. It is also influenced by the rate at which the polymer rearranges within the pore under enzyme control, and the rearrangement rate can be increased or decreased by changing the concentration of ATP supplied to the enzyme. Surprisingly, the inventors have found that changes in rate occur during consecutive polymer rearrangements within the same sequencing run under the same sequencing conditions, which can lead to a decrease in sequencing accuracy. By measuring the variation in sequencing rate for several polymers, a normalized rate distribution can be obtained, and the inventors have found that, surprisingly, some modified enzymes can result in a lower normalized rate distribution, and therefore an improvement in sequencing accuracy.

[0007] The rate-diffusion ratio of the modified helicase is the normalized rate distribution of the modified helicase divided by the normalized rate distribution of the unmodified control helicase. In some embodiments, the modified helicases of the present invention exhibit a reduced rate-diffusion ratio when used in methods for controlling the movement of analytes through transmembrane pores and in methods for characterizing analytes using transmembrane pores. The rate-diffusion ratio may be reduced by at least about 21%, at least about 21.8%, at least about 22%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, and at least about 90% compared to the rate-diffusion ratio of the Dda helicase without the mutation of the present invention.

[0008] The present invention relates to a modified DNA-dependent ATPase (Dda) helicase, wherein the helicase (a) has one or more positions corresponding to the following amino acid positions in Dda 1993: F3, D4, I16, K24, K25, H26, H27, V28, P33, T42, F44, I46, A48, A60, P62, A65, K67, K68, I69, K72, K76, S79, I84, P104, K108, V117, Y120, R122, L124, I132, P134, W135, T137, N144, K145, E154, A157, Y158, P161, K166, Q170, T174, V176, N180 , A181, V190, Y197, V200, V201, R207, T213, A214, L215, M219, V220, I225, K227, L229, V23 7, M238, K247, L248, I251, R253, K254, F257, D262, V265, D282, I289, Q295, Y304, S306, V3 09, V314, G316, L319, R321, T329, G331, D333, L349, F352, T362, N365, N367, G369, G370, P 373, A380, Q383, S385, P391, S393, F395, M401, S402, V403, D404, R405, A406, I413, H414, V418, E419, A421, Q422, V427, V429, G432, Y434, D435 and F437 are modified or substituted, and / or (b) one or more of the following substitutions or one or more of the following substitutions at the positions corresponding to the following amino acid positions in Dda 1993: T2N, T2K, T2S, T2D, T2I, T2L, T2E, T2F, T2G, T2H, T2Q, T2R, T2A, T2M, T2P, or T2V, E47D, E47G, E47H, E47N, E47P, E47Q, E47S, E47T, E47A, or E47R, E54I, E54V, E54K, E54Y, E54T, E54L, E54N, E54A, E54F, E54M, E54D, E54H, E54P, E54Q, E54R, or E54S, T55F, T55V, T55H, T55I, T55L, T55M, T55W, T55Y, T55A, T55P, T55Q, or T55R, -S83E, S83D, S83A, S83P, S83G, or S83M, -K86N, K86G, K86D, K86E, K86H, K86Q, K86R, K86S, K86T, K86M, or K86P, -N88K, N88E, N88T, N88S, N88V, N88Q, N88A, N88L, N88D, N88G, N88M, N88I, or N88P, -P89G, P89K, P89M, P89Q, P89R, or P89D, -V90E, V90D, V90K, V90Q, V90N, V90S, V90A, V90I, V90L, V90M, V90P, V90R, V90F, V90Y, V90H or V90G, T91E, T91D, T91R, T91K, T91Y, T91H, T91P, T91A, T91V, T91L, T91I, T91S or T91M, Y92K, Y92E, Y92R, Y92P, Y92I, or Y92M, E93P, E93D, E93G, E93A, E93L, E93K, E93Q, E93S, E93T, E93H, E93N, or E93R, -V96K, V96T, V96P, V96D, V96G, V96S, V96I, V96N, V96A, V96H, or V96M, F98M or F98I, -K101R, K101T, K101S, K101V, K101E, K101I, K101G, K101L, K101M, K101P, K101Q, K101D, K101H or K101N, -V103K, V103N, V103L, V103I, V103T, V103R, V103Y, V103S, V103D, V103A, V103E, V103H, V103M, V103P, V103Q, or V103F, C114K or C114R, -D151G, D151V, D151N, D151K, D151T, D151A, D151H, D151P, D151Q, D151R or D151S, G153E, G153S, G153D, G153T, G153N, G153K, G153A, G153Q, G153R, G153L, G153H or G153P, -N155K, N155P, N155S, N155E, N155D, N155G, N155T, N155A, N155V, N155L, N155I, N155H, N155M, N155Q, or N155R, T156H, T156Q, T156R, or T156W, K177A or K177P, -W195F, W195Y, W195P, W195K, W195E, W195I, W195L, W195D, W195S, W195G, W195T, W195V, W195Q, W195N, W195R, W195M, or W195H, I196P, I196L, I196D, I196A, I196E, I196K, I196Q, I196S, I196T, I196F, I196M, I196V or I196Y, D198N, D198P, D198E, D198G, D198H, D198K, D198Q, D198R, D198S or D198T, T210A, T210M, T210P, T210Q, T210I, T210L, T210V, or T210F, N221P, N221S, or N221G, -K243R, K243E, K243D, K243A, K243S, K243M, K243N, K243P, K243T or K243Y, E258G, E258K, E258N, E258P, E258D, E258S, E258A, E258H, E258Q, E258R, or E258T, F276T, F276S, F276L, F276P, F276E, F276D, F276N or F276Q, -I281E, I281V, I281K, I281A, I281D, I281H, I281N, I281P, I281Q, I281R, I281S, I281T, I281F, I281L, I281M or I281Y, N292E, N292A, N292S, N292D, N292K, N292H, N292R, N292Q, or N292T, E301K, E301D, E301N, E301S, E301A, E301H, E301M, E301P, E301Q, E301R, or E301T, F308K, F308P, F308R, F308T, F308G, F308E, F308S, F308V, F308A, F308Y, F308N, F308M, F308D, F308H, F308Q or F308W, -Y335P, Y335K, Y335E, Y335F, Y335T, Y335Q, Y335S, Y335R, Y335D, Y335V, Y335N, Y335G, Y335H, Y335M, or Y335W, -Y336E, Y336H, Y336K, Y336I, Y336G, Y336S, Y336T, Y336D, Y336V, Y336P, Y336N, Y336R, Y336Q, Y336A, Y336F, Y336M, or Y336W, -R337E, R337K, R337T, R337Q, R337P, R337V, R337F, R337S, R337D, R337G, R337Y, R337A, R337H, or R337N, Y350P, -L354K, L354E, L354D, L354V, L354Y, L354R, L354S, L354N, L354H, L354M, L354P, L354T, L354F, or L354I, K358G or K358P, -T359V, T359M, T359A, T359I, T359Y, T359F, T359E, T359K, T359N, T359D, T359P, T359Q, T359R, T359S, T359W, or T359G, -K364N, K364Q, K364D, K364E, K364G, K364H, K364S, K364T, K364M, K364P, K364Y, K364I, K364L or K364V, -W366D, W366N, W366K, W366A, W366S, W366I, W366E, W366R, W366M, W366T, W366Q, W366Y, W366G, W366F, W366V, W366P, or W366H, -K368A, K368E, K368S, K368G, K368D, K368F, K368M, K368T, K368V, K368Y, K368H, K368N, K368P, K368Q or K368R, and The present invention provides a modified DNA-dependent ATPase (Dda) helicase comprising S382R, S382N, S382K, S382E, S382Q, S382A, S382H, S382M, S382T, S382D, S382G, or S382P.

[0009] The present invention also, -A construct comprising a helicase and a further polynucleotide binding moiety of the present invention, wherein the helicase is bound to the polynucleotide binding moiety and the construct has the ability to control the movement of an analyte; -Polynucleotides comprising a sequence encoding the helicase or construct of the present invention; - A vector comprising the polynucleotide of the present invention operably linked to a promoter; -Host cells containing the vector of the present invention; - A method for producing a helicase or construct of the present invention, comprising expressing a polynucleotide of the present invention, transfecting a vector of the present invention into a cell, or culturing a host cell of the present invention; - A method for controlling the movement of an analyte, comprising contacting the analyte with the helicase or construct of the present invention, thereby controlling the movement of the analyte; - A method for characterizing a target analyte, (a) bringing the target analyte into contact with the transmembrane pore and the helicase or construct of the present invention so that the helicase or construct of the present invention controls the movement of the target analyte through the pore; and (b) A method comprising obtaining one or more measurements as the target analyte moves toward the pore, wherein the measurements represent one or more characteristics of the target analyte, thereby characterizing the target analyte; - A method for forming a sensor for characterizing a target analyte, comprising forming a composite between (a) a pore and (b) a helicase or construct of the present invention, thereby forming a sensor for characterizing a target analyte; - A sensor for characterizing a target analyte, comprising a composite of (a) a pore and (b) the helicase or construct of the present invention; - Use of the helicase or construct of the present invention to control the movement of the target analyte through the pore; - A kit for characterizing target analytes, (a) The pores and helicases of the present invention or the structures of the present invention; or (b) A kit comprising the helicase or construct of the present invention and one or more loading parts; - An apparatus for characterizing a target analyte in a sample, comprising (a) a plurality of pores, and (b) a plurality of helicases or constructs of the present invention; -The present invention relates to a method for producing helicase, (a) To provide a helicase; and (b) A method comprising modifying a helicase to produce the helicase of the present invention; - A method for producing a construct of the present invention, comprising attaching the helicase of the present invention to a further polynucleotide binding site, thereby producing the construct of the present invention; - A series of two or more helicases bound to a polynucleotide, wherein at least one of the two or more helicases is the helicase of the present invention; and - A method for improving the movement of a target analyte to a transmembrane pore when the movement is controlled by a DNA-dependent ATPase (Dda) helicase, wherein the DNA-dependent ATPase (Dda) helicase is modified according to the present invention to improve the movement of the target analyte to the transmembrane pore. [Modes for carrying out the invention]

[0010] All publications, patents, and patent applications cited herein, whether above or below, are incorporated herein by reference in their entirety. All publications, patents, and patent applications referred to herein are incorporated herein by reference to the same extent as each individual publication, patent, or patent application is specifically and individually indicated as being incorporated by reference. To the extent that the publications and patents or patent applications incorporated by reference are in conflict with the disclosures contained herein, this specification is intended to supersede and / or take precedence over such conflicting material.

[0011] In all discussions herein, standard single-letter codes for amino acids are used. These are: alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine ​​(C), glutamic acid (E), glutamine (Q), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), and valine (V). Standard substitution notation is also used, namely Q42R, which means that Q at position 42 is replaced by R.

[0012] In paragraphs of this specification where different amino acids at specific positions are separated by a / symbol, the / symbol means "or". For example, Q87R / K means Q87R or Q87K. In paragraphs of this specification where different positions are separated by a / symbol, the / symbol means "and", such as Y51 / N55 means Y51 and N55.

[0013] definition Unless otherwise specifically defined herein, all terms used herein have the same meaning for those skilled in the art. Experts should refer to the definitions and terms of the art in particular Sambrook et al., Molecular Cloning: A Laboratory Manual, 4 th See ed., Cold Spring Harbor Press, Plainsview, New York (2012); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 114), John Wiley & Sons, New York (2016). The definitions provided herein should not be construed as having a narrower scope than that understood by those skilled in the art.

[0014] As used herein when referring to measurable values ​​such as quantity and duration, “about” means to include a variation of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and even more preferably ±0.1% from a particular value, such variation being suitable for performing the disclosed method.

[0015] The definitions in International Publication Nos. 2015 / 055981, 2015 / 166276, and 2016 / 055777, as well as in PCT / EP2023 / 059821, are incorporated herein by reference in their entirety.

[0016] A "homolog" or "homogram" of a protein includes peptides, oligopeptides, polypeptides, proteins, and enzymes that have amino acid substitutions, deletions, and / or insertions compared to the unmodified or wild-type protein in question and possess similar biological and functional activity to the unmodified protein from which they are derived. As used herein, the term "amino acid identity" refers to the degree to which sequences are identical amino acid-wise across a comparison window. Thus, the "percentage of sequence identity" is calculated by comparing two optimally aligned sequences across a comparison window, determining the number of positions in which identical amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) occur in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity.

[0017] Modified Dda Helicase The present invention provides a modified Dda helicase. One or more specific modifications are described in more detail below. The modifications according to the present invention include one or more substitutions described below.

[0018] The present invention relates to one or more of the following amino acid positions in Dda 1993: F3, D4, I16, K24, K25, H26, H27, V28, P33, T42, F44, I46, A48, A60, P62, A65, K67, K68, I69, K72, K76, S79, I84, P104, K108, V117, Y120, R122, L124, I132 , P134, W135, T137, N144, K145, E154, A157, Y158, P161, K166, Q170, T174, V176, N180, A181, V190, Y197, V200, V201, R207, T213, A214, L215, M219, V220, I225, K227, L229, V237, M238, K2 47, L248, I251, R253, K254, F257, D262, V265, D282, I289, Q295, Y304, S306, V309, V314, G31 6, L319, R321, T329, G331, D333, L349, F352, T362, N365, N367, G369, G370, P373, A380, Q383 The present invention provides a modified DNA-dependent ATPase (Dda) helicase in which S385, P391, S393, F395, M401, S402, V403, D404, R405, A406, I413, H414, V418, E419, A421, Q422, V427, V429, G432, Y434, D435, and F437 are modified or substituted. The advantages of substitutions at these positions are explained in Table 8.

[0019] In all embodiments described herein, the corresponding positions or locations corresponding to specific amino acid positions can be determined by standard techniques of the art. For example, the sequence of Dda helicase can be aligned with Dda 1993 (SEQ ID NO: 118) using the PILEUP and BLAST algorithms described above, and thus the corresponding residues can be identified.

[0020] The modified Dda helicase of the present invention preferably includes a variant of Sequence ID No. 118 that includes substitution or modification of one or more of the above 113 positions (i.e., one or more of positions F3 to F437).

[0021] The modified Dda helicase of the present invention may include modification or substitution at any number and combination of the 113 positions corresponding to the above amino acid positions. The modified helicase of the present invention includes modification or substitution at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 5 corresponding to the above amino acid positions (i.e., F3 to F437). This may include modifications or substitutions of 6, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, or 113 items.

[0022] The modified Dda helicase is preferably one in which one or more of the following amino acid positions in Dda 1993 are modified or substituted: A60, P62, K68, K72, K76, N144, R207, V237, Y304, V309, G316, L319, G331, D333, L349, P373, S385, P391, M401, R405, A406 and H414. The modified Dda helicase of the present invention preferably includes the variant of SEQ ID NO: 118, which includes modification or substitution of one or more of these 22 positions.

[0023] The modified Dda helicase of the present invention may include modifications or substitutions at any number and combinations of positions corresponding to the above 22 amino acid positions. The modified Dda helicase of the present invention may include modifications or substitutions at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 corresponding to the above amino acid positions (i.e., A60 to H414).

[0024] The modified Dda helicase is preferably one in which one or more of the following amino acid positions in Dda 1993 are modified or substituted: A60, P62, K68, K72, K76, N144, R207, V237, Y304, V309, G316, L319, G331, D333, L349, P373, S385, P391, M401, A406, and H414. The modified Dda helicase of the present invention preferably includes the variant of SEQ ID NO: 118, which includes modification or substitution of one or more of these 21 positions.

[0025] The modified Dda helicase of the present invention may include modifications or substitutions at any number and combinations of positions corresponding to the above 21 amino acid positions. The modified Dda helicase of the present invention may include modifications or substitutions at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 corresponding to the above amino acid positions (i.e., A60 to H414).

[0026] The modified Dda helicase is preferably one in which the position corresponding to amino acid position R405 in Dda 1993 is modified or substituted. The modified Dda helicase of the present invention preferably includes a variant of SEQ ID NO: 118 that includes modification or substitution at R405.

[0027] The amino acid position F3 of Dda 1993 may be substituted with K, Y, I, E, G, L, A, S, D, R, V, T, N, H, M, P, Q, or W. Preferably, the amino acid position F3 of Dda 1993 is substituted with K (e.g., F3K) or Y (e.g., F3Y).

[0028] The position corresponding to amino acid position D4 of Dda 1993 may be substituted with I, L, K, P, S, E, Y, T, F, M, V, A, G, H, N, or Q. Preferably, the position corresponding to amino acid position D4 of Dda 1993 is substituted with I (e.g., D4I) or L (e.g., D4L).

[0029] The position corresponding to amino acid position I16 of Dda 1993 may be substituted with G, A, E, L, K, D, N, S, F, M, T, V, or Y. Preferably, the position corresponding to amino acid position I16 of Dda 1993 is substituted with G (e.g., I16G).

[0030] The position corresponding to amino acid position K24 in Dda 1993 may be substituted with G, P, A, D, N, S, E, H, M, Q, R, or T. Preferably, the position corresponding to amino acid position K24 in Dda 1993 is substituted with G (e.g., K24G) or P (e.g., K24P).

[0031] The amino acid position K25 of Dda 1993 may be substituted with A, N, G, D, E, I, L, M, P, Q, R, S, T, V, or H. Preferably, the amino acid position K25 of Dda 1993 is substituted with A (e.g., K25A).

[0032] The position corresponding to amino acid position H26 in Dda 1993 may be substituted with L, K, R, Q, S, M, A, T, N, P, G, E, I, V, F, Y, or D. Preferably, the position corresponding to amino acid position H26 in Dda 1993 is substituted with K (e.g., H26K) or L (e.g., H26L).

[0033] The position corresponding to amino acid position H27 in Dda 1993 may be substituted with F, I, V, L, Y, A, T, S, M, W, D, E, K, N, Q, or R. Preferably, the position corresponding to amino acid position H27 in Dda 1993 is substituted with F (e.g., H27F).

[0034] The position corresponding to amino acid position V28 in Dda 1993 may be substituted with I, F, A, L, M, T, or Y. Preferably, the position corresponding to amino acid position V28 in Dda 1993 is substituted with I (e.g., V28I).

[0035] The position corresponding to amino acid position P33 of Dda 1993 may be substituted with A, Y, F, G, E, I, K, L, M, Q, R, S, T, V, D, H, or W. Preferably, the position corresponding to amino acid position P33 of Dda 1993 is substituted with A (e.g., P33A) or Y (e.g., P33Y).

[0036] The position corresponding to amino acid position T42 of Dda 1993 may be substituted with I, L, A, F, M, V, Y, D, E, K, N, P, Q, R, or S. Preferably, the position corresponding to amino acid position T42 of Dda 1993 is substituted with I (e.g., T42I).

[0037] The position corresponding to amino acid position F44 in Dda 1993 may be substituted with K, A, R, Y, G, H, T, S, Q, L, N, E, M, V, D, P, I, or W. Preferably, the position corresponding to amino acid position F44 in Dda 1993 is substituted with K (e.g., F44K).

[0038] The position corresponding to amino acid position I46 of Dda 1993 may be substituted with V, A, F, L, M, T, or Y. Preferably, the position corresponding to amino acid position I46 of Dda 1993 is substituted with V (e.g., I46V).

[0039] The position corresponding to amino acid position A48 of Dda 1993 may be substituted with K, H, Y, R, E, N, Q, S, T, D, M, P, G, I, L, V, F, or W. The position corresponding to amino acid position A46 of Dda 1993 is preferably substituted with H (e.g., A48H), K (e.g., A48K), or Y (e.g., A48Y).

[0040] The position corresponding to amino acid position A60 of Dda 1993 may be substituted with T, D, E, I, K, L, M, N, P, Q, R, S, V, or G. Preferably, the position corresponding to amino acid position A60 of Dda 1993 is substituted with T (e.g., A60T).

[0041] The position corresponding to amino acid position P62 of Dda 1993 may be substituted with S, A, D, E, G, H, K, M, N, Q, R, or T. Preferably, the position corresponding to amino acid position P62 of Dda 1993 is substituted with S (e.g., P62S).

[0042] The position corresponding to amino acid position A65 of Dda 1993 may be substituted with V, Q, K, G, R, Y, L, I, F, T, M, H, E, P, S, D, or N. Preferably, the position corresponding to amino acid position A65 of Dda 1993 is substituted with Q (e.g., A65Q) or V (e.g., A65V).

[0043] The amino acid position K67 of Dda 1993 may be substituted with A, V, T, S, R, M, E, G, I, L, P, Q, D, H, N, F, or Y. Preferably, the amino acid position K67 of Dda 1993 is substituted with A (e.g., K67A) or V (e.g., K67V).

[0044] The position corresponding to amino acid position K68 in Dda 1993 may be substituted with A, N, E, G, I, L, M, P, Q, R, S, T, V, D, or H. Preferably, the position corresponding to amino acid position K68 in Dda 1993 is substituted with A (e.g., K68A).

[0045] The position corresponding to amino acid position I69 of Dda 1993 may be substituted with E, V, R, Q, N, A, K, T, S, D, L, H, M, P, F, or Y. Preferably, the position corresponding to amino acid position I69 of Dda 1993 is substituted with E (e.g., I69E) or L (e.g., I69V).

[0046] The position corresponding to amino acid position K72 in Dda 1993 may be substituted with A, E, G, I, L, M, P, Q, R, S, T, V, D, H, or N. Preferably, the position corresponding to amino acid position K72 in Dda 1993 is substituted with A (e.g., K72A).

[0047] The position corresponding to amino acid position K76 of Dda 1993 may be substituted with M, Y, F, I, V, R, A, L, Q, S, T, W, D, E, H, N, or P. Preferably, the position corresponding to amino acid position K76 of Dda 1993 is substituted with M (e.g., K76M) or Y (e.g., K76Y).

[0048] The position corresponding to amino acid position S79 of Dda 1993 may be substituted with T, K, R, V, E, A, D, I, L, M, N, P, Q, G, or H. Preferably, the position corresponding to amino acid position S79 of Dda 1993 is substituted with T (e.g., S79T).

[0049] The position corresponding to amino acid position I84 of Dda 1993 may be substituted with L, V, F, A, M, T, or Y. Preferably, the position corresponding to amino acid position I84 of Dda 1993 is substituted with L (or, for example, I84L).

[0050] The position corresponding to amino acid position P104 of Dda 1993 may be substituted with Y, K, E, F, H, I, L, M, Q, V, W, A, D, S, or T. Preferably, the position corresponding to amino acid position P104 of Dda 1993 is substituted with Y (e.g., P104Y).

[0051] The position corresponding to amino acid position K108 of Dda 1993 may be substituted with Y, E, D, H, N, S, G, F, I, L, M, Q, V, W, A, P, R, or T. Preferably, the position corresponding to amino acid position K108 of Dda 1993 is substituted with D (e.g., K108D), E (e.g., K108E), or Y (e.g., K108Y).

[0052] The position corresponding to amino acid position V117 of Dda 1993 may be substituted with A, S, E, G, I, K, L, M, P, Q, R, T, F, or Y. Preferably, the position corresponding to amino acid position V117 of Dda 1993 is substituted with A (e.g., V117A).

[0053] The position corresponding to amino acid position Y120 in Dda 1993 may be substituted with V, L, I, M, F, A, T, S, H, Q, or W. Preferably, the position corresponding to amino acid position Y120 in Dda 1993 is substituted with V (e.g., Y120V).

[0054] The position corresponding to amino acid position R122 in Dda 1993 may be substituted with E, K, N, D, L, T, S, A, V, I, P, Q, H, or M. Preferably, the position corresponding to amino acid position R122 in Dda 1993 is substituted with E (e.g., R122E).

[0055] The position corresponding to amino acid position L124 of Dda 1993 may be substituted with T, A, D, E, I, K, M, N, P, Q, R, S, V, F, or Y. Preferably, the position corresponding to amino acid position L124 of Dda 1993 is substituted with T (e.g., L124T).

[0056] The position corresponding to amino acid position I132 of Dda 1993 may be substituted with T, V, L, A, D, E, K, M, N, P, Q, R, S, F, or Y. Preferably, the position corresponding to amino acid position I132 of Dda 1993 is substituted with T (e.g., I132T).

[0057] The position corresponding to amino acid position P134 of Dda 1993 may be substituted with D, E, K, S, L, A, R, I, N, V, T, G, H, or Q. Preferably, the position corresponding to amino acid position P134 of Dda 1993 is substituted with D (e.g., P134D).

[0058] The position corresponding to amino acid position W135 of Dda 1993 may be substituted with D, H, T, N, E, G, S, K, Y, Q, R, F, A, P, or M. Preferably, the position corresponding to amino acid position W135 of Dda 1993 is substituted with D (e.g., W135D) or H (e.g., W135H).

[0059] The position corresponding to amino acid position T137 of Dda 1993 may be substituted with K, R, I, V, A, D, E, H, M, N, P, Q, S, or L. Preferably, the position corresponding to amino acid position T137 of Dda 1993 is substituted with K (e.g., T137K).

[0060] The position corresponding to amino acid position N144 of Dda 1993 may be substituted with S, P, K, T, R, E, A, D, I, L, Q, Y, H, V, M, or G. Preferably, the position corresponding to amino acid position N144 of Dda 1993 is substituted with S (e.g., N144S).

[0061] The position corresponding to amino acid position K145 of Dda 1993 may be substituted with D, A, H, R, G, N, E, P, Q, S, T, or M. Preferably, the position corresponding to amino acid position K145 of Dda 1993 is substituted with D (e.g., K145D).

[0062] The position corresponding to amino acid position E154 of Dda 1993 may be substituted with N, S, V, I, T, D, G, H, K, Q, R, A, or P. Preferably, the position corresponding to amino acid position E154 of Dda 1993 is substituted with N (e.g., K154N).

[0063] The position corresponding to amino acid position A157 of Dda 1993 may be substituted with E, D, S, K, P, N, H, Q, R, T, G, I, L, M, or V. Preferably, the position corresponding to amino acid position A157 of Dda 1993 is substituted with E (e.g., A157E).

[0064] The position corresponding to amino acid position Y158 of Dda 1993 may be substituted with Q, S, E, L, D, A, I, K, F, N, G, R, V, T, H, P, M, or W. Preferably, the position corresponding to amino acid position Y158 of Dda 1993 is substituted with E (e.g., Y158E), Q (e.g., Y158Q), or S (e.g., Y158S).

[0065] The position corresponding to amino acid position P161 of Dda 1993 may be substituted with E, D, K, S, N, R, Q, T, A, or H. Preferably, the position corresponding to amino acid position P161 of Dda 1993 is substituted with E (e.g., P161E).

[0066] The position corresponding to amino acid position K166 in Dda 1993 may be substituted with N, P, D, E, G, H, Q, R, S, T, A, or M. Preferably, the position corresponding to amino acid position K166 in Dda 1993 is substituted with N (e.g., K166N).

[0067] The position corresponding to amino acid position Q170 of Dda 1993 may be substituted with K, I, V, T, S, E, R, N, H, Y, F, A, D, M, or P. Preferably, the position corresponding to amino acid position Q170 of Dda 1993 is substituted with K (e.g., Q170K).

[0068] The position corresponding to amino acid position T174 of Dda 1993 may be substituted with S, A, D, E, G, H, K, M, N, P, Q, R, I, L, or V. Preferably, the position corresponding to amino acid position T174 of Dda 1993 is substituted with S (e.g., T174S).

[0069] The position corresponding to amino acid position V176 of Dda 1993 may be substituted with I, G, P, A, T, R, S, Q, K, L, E, F, M, or Y. Preferably, the position corresponding to amino acid position V176 of Dda 1993 is substituted with I (e.g., V176I).

[0070] The position corresponding to amino acid position N180 of Dda 1993 may be substituted with D, E, K, A, G, H, P, Q, S, T, or R. Preferably, the position corresponding to amino acid position N180 of Dda 1993 is substituted with D (e.g., N180D).

[0071] The position corresponding to amino acid position A181 of Dda 1993 may be substituted with G, N, L, S, R, T, D, K, Q, H, E, I, M, P, or V. Preferably, the position corresponding to amino acid position A181 of Dda 1993 is substituted with G (e.g., A180G) or N (e.g., A180N).

[0072] The position corresponding to amino acid position V190 of Dda 1993 may be substituted with I, A, F, L, M, T, or Y. Preferably, the position corresponding to amino acid position V190 of Dda 1993 is substituted with I (e.g., V190I).

[0073] The position corresponding to amino acid position Y197 of Dda 1993 may be substituted with K, P, R, S, E, G, D, T, L, N, I, V, F, A, H, M, Q, or W. Preferably, the position corresponding to amino acid position Y197 of Dda 1993 is substituted with K (e.g., Y197K).

[0074] The position corresponding to amino acid position V200 of Dda 1993 may be substituted with I, T, F, K, D, L, N, E, S, Y, P, A, or M. Preferably, the position corresponding to amino acid position V200 of Dda 1993 is substituted with I (e.g., V200I).

[0075] The position corresponding to amino acid position V201 in Dda 1993 may be substituted with F, Y, I, K, L, H, M, W, A, or T. Preferably, the position corresponding to amino acid position V201 in Dda 1993 is substituted with F (e.g., V201F).

[0076] The position corresponding to amino acid position R207 of Dda 1993 may be substituted with I, H, K, V, F, Y, L, T, E, A, M, N, Q, S, or D. Preferably, the position corresponding to amino acid position R207 of Dda 1993 is substituted with H (e.g., R207H) or I (e.g., R207I).

[0077] The position corresponding to amino acid position T213 of Dda 1993 may be substituted with D, N, E, K, S, G, A, Q, H, P, I, L, M, R, or V. Preferably, the position corresponding to amino acid position T213 of Dda 1993 is substituted with D (e.g., T213D).

[0078] The position corresponding to amino acid position A214 of Dda 1993 may be substituted with G, S, E, K, D, L, N, I, T, V, M, P, Q, R, or H. Preferably, the position corresponding to amino acid position A214 of Dda 1993 is substituted with G (e.g., A214G) or S (e.g., A214S).

[0079] The position corresponding to amino acid position L215 of Dda 1993 may be substituted with Y, I, E, F, D, H, M, Q, V, W, A, T, K, N, P, R, or S. Preferably, the position corresponding to amino acid position L215 of Dda 1993 is substituted with E (e.g., L215E), I (e.g., L215I), or Y (e.g., L215Y).

[0080] The position corresponding to amino acid position M219 of Dda 1993 may be substituted with L, I, V, A, F, Y, K, D, E, S, T, Q, R, or W. Preferably, the position corresponding to amino acid position M219 of Dda 1993 is substituted with L (e.g., M219L).

[0081] The amino acid position V220 of Dda 1993 may be substituted with K, E, N, A, D, R, S, T, Q, L, I, G, H, M, P, F, or Y. Preferably, the amino acid position V220 of Dda 1993 is substituted with K (e.g., V220K).

[0082] The position corresponding to amino acid position I225 of Dda 1993 may be substituted with V, K, T, D, N, S, E, G, R, Q, P, A, H, L, Y, F, or M. Preferably, the position corresponding to amino acid position I225 of Dda 1993 is substituted with V (e.g., I225V).

[0083] The position corresponding to amino acid position K227 of Dda 1993 may be substituted with G, A, D, N, S, E, H, M, P, Q, R, or T. Preferably, the position corresponding to amino acid position K227 of Dda 1993 is substituted with G (e.g., K227G).

[0084] The position corresponding to amino acid position L229 of Dda 1993 may be substituted with S, K, V, I, N, E, D, T, G, A, R, Q, H, M, P, F, or Y. Preferably, the position corresponding to amino acid position L229 of Dda 1993 is substituted with K (e.g., L229K) or S (e.g., L229S).

[0085] The position corresponding to amino acid position V237 of Dda 1993 may be substituted with M, I, A, L, F, K, Q, R, S, T, W, or Y. Preferably, the position corresponding to amino acid position V237 of Dda 1993 is substituted with M (e.g., V237M).

[0086] The position corresponding to amino acid position M238 of Dda 1993 may be substituted with I, L, V, F, A, T, Y, K, Q, R, S, or W. Preferably, the position corresponding to amino acid position M238 of Dda 1993 is substituted with I (e.g., M238I).

[0087] The position corresponding to amino acid position K247 of Dda 1993 may be substituted with N, E, R, D, G, H, Q, S, T, A, M, or P. Preferably, the position corresponding to amino acid position K247 of Dda 1993 is substituted with N (e.g., K247N).

[0088] The position corresponding to amino acid position L248 of Dda 1993 may be substituted with F, I, H, M, V, W, Y, A, or T. Preferably, the position corresponding to amino acid position L248 of Dda 1993 is substituted with F (e.g., L248F).

[0089] The position corresponding to amino acid position I251 of Dda 1993 may be substituted with F, L, E, Y, A, T, H, M, V, or W. Preferably, the position corresponding to amino acid position I251 of Dda 1993 is substituted with F (e.g., I251F).

[0090] The position corresponding to amino acid position R253 of Dda 1993 may be substituted with Q, A, D, E, H, K, M, N, P, S, T, or Y. Preferably, the position corresponding to amino acid position R253 of Dda 1993 is substituted with Q (e.g., R253Q).

[0091] The position corresponding to amino acid position K254 of Dda 1993 may be substituted with N, S, D, E, G, H, Q, R, T, A, M, or P. Preferably, the position corresponding to amino acid position K254 of Dda 1993 is substituted with N (e.g., K254N) or S (e.g., K254S).

[0092] The position corresponding to amino acid position F257 of Dda 1993 may be substituted with Y, H, I, L, M, Q, V, or W. Preferably, the position corresponding to amino acid position F257 of Dda 1993 is substituted with Y (e.g., F257Y).

[0093] The position corresponding to amino acid position D262 of Dda 1993 may be substituted with P, E, A, K, Q, S, T, G, H, or N. Preferably, the position corresponding to amino acid position D262 of Dda 1993 is substituted with P (e.g., D262P).

[0094] The position corresponding to amino acid position V265 of Dda 1993 may be substituted with E, P, A, K, S, G, D, N, T, H, Q, R, F, I, L, M, or Y. Preferably, the position corresponding to amino acid position V265 of Dda 1993 is substituted with E (e.g., V265E).

[0095] The position corresponding to amino acid position D282 of Dda 1993 may be substituted with P, A, E, K, Q, S, T, G, H, or N. Preferably, the position corresponding to amino acid position D282 of Dda 1993 is substituted with P (e.g., D282P).

[0096] The position corresponding to amino acid position I289 of Dda 1993 may be substituted with L, V, M, K, E, G, A, F, T, or Y. Preferably, the position corresponding to amino acid position I289 of Dda 1993 is substituted with L (e.g., I289L).

[0097] The position corresponding to amino acid position Q295 of Dda 1993 may be substituted with D, E, M, S, G, H, K, N, P, T, A, R, or Y. Preferably, the position corresponding to amino acid position Q295 of Dda 1993 is substituted with D (e.g., Q295D).

[0098] The position corresponding to amino acid position Y304 of Dda 1993 may be substituted with K, E, L, P, D, N, S, G, A, R, T, Q, H, V, I, M, F, or W. Preferably, the position corresponding to amino acid position Y304 of Dda 1993 is substituted with K (e.g., Y304K).

[0099] The position corresponding to amino acid position S306 in Dda 1993 may be substituted with E, Y, D, K, T, G, F, V, N, A, H, P, Q, R, or M. Preferably, the position corresponding to amino acid position S306 in Dda 1993 is substituted with E (e.g., S306E).

[0100] The position corresponding to amino acid position V309 of Dda 1993 may be substituted with F, K, I, H, L, M, W, Y, A, or T. Preferably, the position corresponding to amino acid position V309 of Dda 1993 is substituted with F (e.g., V309F).

[0101] The position corresponding to amino acid position V314 of Dda 1993 may be substituted with I, K, E, L, A, F, M, T, or Y. Preferably, the position corresponding to amino acid position V314 of Dda 1993 is substituted with I (e.g., V314I).

[0102] The position corresponding to amino acid position G316 in Dda 1993 may be substituted with E, K, D, V, I, N, L, A, H, P, Q, R, S, or T. Preferably, the position corresponding to amino acid position G316 in Dda 1993 is substituted with E (e.g., G316E).

[0103] The position corresponding to amino acid position L319 of Dda 1993 may be substituted with E, K, I, V, T, N, D, G, A, H, P, Q, R, S, F, M, or Y. Preferably, the position corresponding to amino acid position L319 of Dda 1993 is substituted with E (e.g., L319E).

[0104] The position corresponding to amino acid position R321 in Dda 1993 may be substituted with K, N, E, V, I, D, L, A, H, M, P, Q, S, or T. Preferably, the position corresponding to amino acid position R321 in Dda 1993 is substituted with K (e.g., R321K).

[0105] The position corresponding to amino acid position T329 of Dda 1993 may be substituted with P, S, G, K, A, E, D, I, V, L, N, R, Y, F, Q, or M. Preferably, the position corresponding to amino acid position T329 of Dda 1993 is substituted with P (e.g., T329P).

[0106] The position corresponding to amino acid position G331 of Dda 1993 may be substituted with D, E, K, L, S, I, N, T, V, H, P, Q, or A. Preferably, the position corresponding to amino acid position G331 of Dda 1993 is substituted with D (e.g., G331D).

[0107] The position corresponding to amino acid position D333 of Dda 1993 may be substituted with G, K, E, I, A, N, S, H, P, Q, or T. Preferably, the position corresponding to amino acid position D333 of Dda 1993 is substituted with G (e.g., D333G).

[0108] The position corresponding to amino acid position L349 of Dda 1993 may be substituted with E, N, K, Q, A, T, S, D, V, R, I, H, P, F, M, or Y. Preferably, the position corresponding to amino acid position L349 of Dda 1993 is substituted with E (e.g., L349E).

[0109] The position corresponding to amino acid position F352 of Dda 1993 may be substituted with Y, L, K, E, R, I, A, N, D, H, M, Q, V, or W. Preferably, the position corresponding to amino acid position F352 of Dda 1993 is substituted with Y (e.g., F352Y).

[0110] The position corresponding to amino acid position T362 of Dda 1993 may be substituted with A, I, V, L, E, K, M, D, R, Y, N, Q, S, F, G, or P. Preferably, the position corresponding to amino acid position T362 of Dda 1993 is substituted with A (e.g., T362A).

[0111] The position corresponding to amino acid position N365 of Dda 1993 may be substituted with K, E, A, S, R, D, H, M, P, Q, T, or G. Preferably, the position corresponding to amino acid position N365 of Dda 1993 is substituted with K (e.g., N365K). Preferably, the position corresponding to amino acid position N367 of Dda 1993 is substituted with S, K, L, E, A, T, I, V, Q, R, Y, F, M, D, G, H, or P. Preferably, the position corresponding to amino acid position N367 of Dda 1993 is substituted with S (e.g., N367S).

[0112] The position corresponding to amino acid position N367 of Dda 1993 may be substituted with S, K, L, E, A, T, I, V, Q, R, Y, F, M, D, G, H, or P. Preferably, the position corresponding to amino acid position N367 of Dda 1993 is substituted with S (e.g., N367S).

[0113] The position corresponding to amino acid position G369 in Dda 1993 may be substituted with E, K, D, N, S, T, R, L, I, A, Y, H, P, or Q. Preferably, the position corresponding to amino acid position G369 in Dda 1993 is substituted with E (e.g., G369E).

[0114] The position corresponding to amino acid position G370 of Dda 1993 may be substituted with K, V, E, I, S, A, N, D, H, M, P, Q, R, or T. Preferably, the position corresponding to amino acid position G370 of Dda 1993 is substituted with K (e.g., G370K).

[0115] The position corresponding to amino acid position P373 in Dda 1993 may be substituted with H, L, N, K, M, Y, F, I, V, S, E, T, A, R, D, G, Q, or W. Preferably, the position corresponding to amino acid position P373 in Dda 1993 is substituted with H (e.g., P373) or L (e.g., P373L).

[0116] The position corresponding to amino acid position A380 of Dda 1993 may be substituted with V, L, T, I, K, M, F, Y, E, G, P, Q, R, or S. Preferably, the position corresponding to amino acid position A380 of Dda 1993 is substituted with V (e.g., A380V).

[0117] The position corresponding to amino acid position Q383 in Dda 1993 may be substituted with L, T, M, Y, K, F, I, V, R, A, E, S, N, D, G, H, or P. Preferably, the position corresponding to amino acid position Q383 in Dda 1993 is substituted with L (e.g., Q383L).

[0118] The position corresponding to amino acid position S385 of Dda 1993 may be substituted with I, T, A, Y, K, H, R, F, L, M, V, D, E, G, N, P, or Q. Preferably, the position corresponding to amino acid position S385 of Dda 1993 is substituted with I (e.g., S385I).

[0119] The position corresponding to amino acid position P391 in Dda 1993 may be substituted with G, Y, F, H, A, V, D, N, S, E, K, Q, or T. Preferably, the position corresponding to amino acid position P391 in Dda 1993 is substituted with G (e.g., P391G).

[0120] The position corresponding to amino acid position S393 of Dda 1993 may be substituted with I, V, L, T, E, D, M, F, A, Y, G, H, K, N, P, Q, or R. Preferably, the position corresponding to amino acid position S393 of Dda 1993 is substituted with I (e.g., S393I).

[0121] The position corresponding to amino acid position F395 of Dda 1993 may be substituted with I, V, Y, L, T, A, M, H, or W. Preferably, the position corresponding to amino acid position F395 of Dda 1993 is substituted with I (e.g., F395I).

[0122] The position corresponding to amino acid position M401 of Dda 1993 may be substituted with L, S, V, I, G, D, E, R, Q, A, W, N, T, F, Y, K, H, or P. Preferably, the position corresponding to amino acid position M401 of Dda 1993 is substituted with L (e.g., M401L), S (e.g., M401S), or V (e.g., M401V).

[0123] The position corresponding to amino acid position S402 of Dda 1993 may be substituted with T, V, R, I, K, L, E, H, Q, M, A, D, N, P, or G. Preferably, the position corresponding to amino acid position S402 of Dda 1993 is substituted with T (e.g., S402T).

[0124] The position corresponding to amino acid position V403 in Dda 1993 may be substituted with F, Y, I, H, L, M, W, A, or T. Preferably, the position corresponding to amino acid position V403 in Dda 1993 is substituted with F (e.g., V403F).

[0125] The position corresponding to amino acid position D404 of Dda 1993 may be substituted with N, K, R, E, G, H, Q, S, T, or P. Preferably, the position corresponding to amino acid position D404 of Dda 1993 is substituted with N (e.g., D404N).

[0126] The position corresponding to amino acid position R405 of Dda 1993 may be substituted with N, K, D, E, G, H, Q, S, T, A, M, or P. Preferably, the position corresponding to amino acid position R405 of Dda 1993 is substituted with K (e.g., R405K) or N (e.g., R405N).

[0127] The position corresponding to amino acid position A406 of Dda 1993 may be substituted with T, V, I, D, E, K, L, M, N, P, Q, R, S, G, F, or Y. Preferably, the position corresponding to amino acid position A406 of Dda 1993 is substituted with T (e.g., A406T) or V (e.g., A406V).

[0128] The position corresponding to amino acid position I413 of Dda 1993 may be substituted with E, L, K, S, D, G, N, P, Y, F, T, R, A, H, Q, M, or V. Preferably, the position corresponding to amino acid position I413 of Dda 1993 is substituted with E (e.g., I413E).

[0129] The position corresponding to amino acid position H414 in Dda 1993 may be substituted with Y, D, F, Q, K, N, S, E, G, P, R, T, L, I, A, M, V, or W. Preferably, the position corresponding to amino acid position H414 in Dda 1993 is substituted with D (e.g., H414D) or Y (e.g., H414Y).

[0130] The position corresponding to amino acid position V418 of Dda 1993 may be substituted with K, E, P, R, D, T, A, S, N, L, I, Y, G, H, M, Q, or F. Preferably, the position corresponding to amino acid position V418 of Dda 1993 is substituted with K (e.g., V418K).

[0131] The position corresponding to amino acid position E419 of Dda 1993 may be substituted with Q, D, A, H, K, M, N, P, R, S, T, or Y. Preferably, the position corresponding to amino acid position E419 of Dda 1993 is substituted with E (e.g., E419Q).

[0132] The position corresponding to amino acid position A421 of Dda 1993 may be substituted with Q, L, R, N, S, K, D, E, H, M, P, T, Y, G, I, V, or F. Preferably, the position corresponding to amino acid position A421 of Dda 1993 is substituted with L (e.g., A421L) or Q (e.g., A421Q).

[0133] The position corresponding to amino acid position Q422 of Dda 1993 may be substituted with K, R, L, N, A, D, E, H, M, P, S, T, or Y. Preferably, the position corresponding to amino acid position Q422 of Dda 1993 is substituted with K (e.g., Q422K).

[0134] The position corresponding to amino acid position V427 of Dda 1993 may be substituted with T, E, D, A, I, K, L, M, N, P, Q, R, S, F, or Y. Preferably, the position corresponding to amino acid position V427 of Dda 1993 is substituted with T (e.g., V427T).

[0135] The position corresponding to amino acid position V429 of Dda 1993 may be substituted with I, L, A, F, M, T, or Y. Preferably, the position corresponding to amino acid position V429 of Dda 1993 is substituted with I (e.g., V429I).

[0136] The position corresponding to amino acid position G432 of Dda 1993 may be substituted with P, A, S, T, D, E, K, Q, or N. Preferably, the position corresponding to amino acid position G432 of Dda 1993 is substituted with P (e.g., G432P).

[0137] The position corresponding to amino acid position Y434 in Dda 1993 may be substituted with K, I, V, R, E, T, N, D, L, S, Q, H, G, A, M, P, F, or W. Preferably, the position corresponding to amino acid position Y434 in Dda 1993 is substituted with K (e.g., Y434K).

[0138] The position corresponding to amino acid position D435 of Dda 1993 may be substituted with E, Q, A, H, K, N, P, R, S, T, or G. Preferably, the position corresponding to amino acid position D435 of Dda 1993 is substituted with E (e.g., D435E).

[0139] The position corresponding to amino acid position F437 of Dda 1993 may be substituted with Y, I, H, L, M, Q, V, or W. Preferably, the position corresponding to amino acid position F437 of Dda 1993 is substituted with Y (e.g., F437Y).

[0140] The modified Dda helicase of the present invention may further include one or more of the 45 or 31 substitutions shown below, or one or more of the 45 or 31 substitutions at positions corresponding to the 45 or 31 amino acid positions in Dda 1993 shown below.

[0141] The present invention also involves one or more of the following substitutions at the positions corresponding to the following amino acid positions in Dda 1993: T2N, T2K, T2S, T2D, T2I, T2L, T2E, T2F, T2G, T2H, T2Q, T2R, T2A, T2M, T2P or T2V, preferably T2N, E47D, E47G, E47H, E47N, E47P, E47Q, E47S, E47T, E47A, or E47R, preferably E47D, E54I, E54V, E54K, E54Y, E54T, E54L, E54N, E54A, E54F, E54M, E54D, E54H, E54P, E54Q, E54R or E54S, preferably E54I, T55F, T55V, T55H, T55I, T55L, T55M, T55W, T55Y, T55A, T55P, T55Q or T55R, HondaT55F or T55V, S83E, S83D, S83A, S83P, S83G, or S83M, preferably S83E, -K86N, K86G, K86D, K86E, K86H, K86Q, K86R, K86S, K86T, K86M, or K86P, preferably K86N, -N88K, N88E, N88T, N88S, N88V, N88Q, N88A, N88L, N88D, N88G, N88M, N88I, or N88P, preferably N88K, -P89G, P89K, P89M, P89Q, P89R, or P89D, -V90E, V90D, V90K, V90Q, V90N, V90S, V90A, V90I, V90L, V90M, V90P, V90R, V90F, V90Y, V90H or V90G, preferably V90D or V90E, T91E, T91D, T91R, T91K, T91Y, T91H, T91P, T91A, T91V, T91L, T91I, T91S, or T91M, preferably T91E. Y92K, Y92E, Y92R, Y92P, Y92I, or Y92M, E93P, E93D, E93G, E93A, E93L, E93K, E93Q, E93S, E93T, E93H, E93N, or E93R, preferably E93P, -V96K, V96T, V96P, V96D, V96G, V96S, V96I, V96N, V96A, V96H, or V96M, F98M or F98I, -K101R, K101T, K101S, K101V, K101E, K101I, K101G, K101L, K101M, K101P, K101Q, K101D, K101H or K101N, preferably K101R, -V103K, V103N, V103L, V103I, V103T, V103R, V103Y, V103S, V103D, V103A, V103E, V103H, V103M, V103P, V103Q or V103F, preferably V103K, C114K or C114R, -D151G, D151V, D151N, D151K, D151T, D151A, D151H, D151P, D151Q, D151R, or D151S, G153E, G153S, G153D, G153T, G153N, G153K, G153A, G153Q, G153R, G153L, G153H or G153P, Yokohama G153E, -N155K, N155P, N155S, N155E, N155D, N155G, N155T, N155A, N155V, N155L, N155I, N155H, N155M, N155Q or N155R, cubeN155K, T156H, T156Q, T156R, or T156W, K177A or K177P, -W195F, W195Y, W195P, W195K, W195E, W195I, W195L, W195D, W195S, W195G, W195T, W195V, W195Q, W195N, W195R, W195M, or W195H, cubing W195Y, W195P, W195K, W195E, W195I, W195G, W195T, W195Q, W195N, W195R, W195M, or W195H, more preferably W195F or W195Y, I196P, I196L, I196D, I196A, I196E, I196K, I196Q, I196S, I196T, I196F, I196M, I196V, or I196Y, preferably I196L or I196P, D198N, D198P, D198E, D198G, D198H, D198K, D198Q, D198R, D198S or D198T, preferably D198N, D198P, D198E, D198G, D198H, D198K, D198Q, D198R or D198T, more preferably D198N, T210A, T210M, T210P, T210Q, T210I, T210L, T210V, or T210F, N221P, N221S, or N221G, K243R, K243E, K243D, K243A, K243S, K243M, K243N, K243P, K243T, or K243Y, preferably K243R or K243E, E258G, E258K, E258N, E258P, E258D, E258S, E258A, E258H, E258Q, E258R or E258T, preferably E258G, E258K, E258N, E258P, E258D, E258H, E258Q, E258R or E258T, more preferably E258G, F276T, F276S, F276L, F276P, F276E, F276D, F276N, or F276Q, preferably F276T, -I281E, I281V, I281K, I281A, I281D, I281H, I281N, I281P, I281Q, I281R, I281S, I281T, I281F, I281L, I281M, or I281Y, preferably I281E, N292E, N292A, N292S, N292D, N292K, N292H, N292R, N292Q or N292T, preferably N292E, E301K, E301D, E301N, E301S, E301A, E301H, E301M, E301P, E301Q, E301R, or E301T, preferably E301K. F308K, F308P, F308R, F308T, F308G, F308E, F308S, F308V, F308A, F308Y, F308N, F308M, F308D, F308H, F308Q or F308W, preferably F308K or F308P, -Y335P, Y335K, Y335E, Y335F, Y335T, Y335Q, Y335S, Y335R, Y335D, Y335V, Y335N, Y335G, Y335H, Y335M or Y335W, preferably Y335P, -Y336E, Y336H, Y336K, Y336I, Y336G, Y336S, Y336T, Y336D, Y336V, Y336P, Y336N, Y336R, Y336Q, Y336a, Y336F, Y336M or Y336W, Preferably Y336E, -R337E, R337K, R337T, R337Q, R337P, R337V, R337F, R337S, R337D, R337G, R337Y, R337A, R337H, or R337N, Y350P, -L354K, L354E, L354D, L354V, L354Y, L354R, L354S, L354N, L354H, L354M, L354P, L354T, L354F, or L354I, preferably L354K, K358G or K358P, T359V, T359M, T359A, T359I, T359Y, T359F, T359E, T359K, T359N, T359D, T359P, T359Q, T359R, T359S, T359W or T359G, preferably T359A, T359V, T359I or T359M, more preferably T359V, -K364N, K364Q, K364D, K364E, K364G, K364H, K364S, K364T, K364M, K364P, K364Y, K364I, K364L, or K364V, preferably K364N or K364Q, -W366D, W366N, W366K, W366A, W366S, W366I, W366E, W366R, W366M, W366T, W366Q, W366Y, W366G, W366F, W366V, W366P, or W366H, ☐W366D or W366N, -K368A, K368E, K368S, K368G, K368D, K368F, K368M, K368T, K368V, K368Y, K368H, K368N, K368P, K368Q or K368R, and The present invention provides a modified DNA-dependent ATPase (Dda) helicase comprising S382R, S382N, S382K, S382E, S382Q, S382A, S382H, S382M, S382T, S382D, S382G, or S382P, preferably S382N or S382R.

[0142] These are the 45 substitutions mentioned above. The advantages of these substitutions are explained in Table 8.

[0143] The modified Dda helicase of the present invention preferably includes a variant of SEQ ID NO: 118 that contains one or more of the above 45 substitutions.

[0144] The modified Dda helicase of the present invention may include any number and combination of the above substitutions. The modified Dda helicase of the present invention may include substitutions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45. The modified Dda helicase of the present invention may further have one or more positions corresponding to the 113, 22, or 21 amino acid positions of Dda 1993 listed above modified or substituted as described above.

[0145] The present invention also involves one or more of the following substitutions at the positions corresponding to the following amino acid positions in Dda 1993: T2N, T2K, T2S, T2D, T2I, T2L, T2E, T2F, T2G, T2H, T2Q, T2R, T2A, T2M, T2P or T2V, preferably T2N, E47D, E47G, E47H, E47N, E47P, E47Q, E47S, E47T, E47A, or E47R, preferably E47D, E54I, E54V, E54K, E54Y, E54T, E54L, E54N, E54A, E54F, E54M, E54D, E54H, E54P, E54Q, E54R or E54S, preferably E54I, T55F, T55V, T55H, T55I, T55L, T55M, T55W, T55Y, T55A, T55P, T55Q or T55R, HondaT55F or T55V, S83E, S83D, S83A, S83P, S83G, or S83M, preferably S83E, -K86N, K86G, K86D, K86E, K86H, K86Q, K86R, K86S, K86T, K86M, or K86P, preferably K86N, -N88K, N88E, N88T, N88S, N88V, N88Q, N88A, N88L, N88D, N88G, N88M, N88I, or N88P, preferably N88K, -V90E, V90D, V90K, V90Q, V90N, V90S, V90A, V90I, V90L, V90M, V90P, V90R, V90F, V90Y, V90H or V90G, preferably V90D or V90E, T91E, T91D, T91R, T91K, T91Y, T91H, T91P, T91A, T91V, T91L, T91I, T91S, or T91M, preferably T91E. E93P, E93D, E93G, E93A, E93L, E93K, E93Q, E93S, E93T, E93H, E93N, or E93R, preferably E93P, -K101R, K101T, K101S, K101V, K101E, K101I, K101G, K101L, K101M, K101P, K101Q, K101D, K101H or K101N, preferably K101R, -V103K, V103N, V103L, V103I, V103T, V103R, V103Y, V103S, V103D, V103A, V103E, V103H, V103M, V103P, V103Q or V103F, preferably V103K, G153E, G153S, G153D, G153T, G153N, G153K, G153A, G153Q, G153R, G153L, G153H or G153P, Yokohama G153E, -N155K, N155P, N155S, N155E, N155D, N155G, N155T, N155A, N155V, N155L, N155I, N155H, N155M, N155Q or N155R, cubeN155K, -W195F, W195Y, W195P, W195K, W195E, W195I, W195L, W195D, W195S, W195G, W195T, W195V, W195Q, W195N, W195R, W195M, or W195H, cubing W195Y, W195P, W195K, W195E, W195I, W195G, W195T, W195Q, W195N, W195R, W195M, or W195H, more preferably W195F or W195Y, I196P, I196L, I196D, I196A, I196E, I196K, I196Q, I196S, I196T, I196F, I196M, I196V, or I196Y, preferably I196L or I196P, D198N, D198P, D198E, D198G, D198H, D198K, D198Q, D198R, D198S or D198T, preferably D198N, D198P, D198E, D198G, D198H, D198K, D198Q, D198R or D198T, more preferably D198N, K243R, K243E, K243D, K243A, K243S, K243M, K243N, K243P, K243T, or K243Y, preferably K243R or K243E, E258G, E258K, E258N, E258P, E258D, E258S, E258A, E258H, E258Q, E258R or E258T, preferably E258G, E258K, E258N, E258P, E258D, E258H, E258Q, E258R or E258T, more preferably E258G, F276T, F276S, F276L, F276P, F276E, F276D, F276N, or F276Q, preferably F276T, -I281E, I281V, I281K, I281A, I281D, I281H, I281N, I281P, I281Q, I281R, I281S, I281T, I281F, I281L, I281M, or I281Y, preferably I281E, N292E, N292A, N292S, N292D, N292K, N292H, N292R, N292Q or N292T, preferably N292E, E301K, E301D, E301N, E301S, E301A, E301H, E301M, E301P, E301Q, E301R, or E301T, preferably E301K. F308K, F308P, F308R, F308T, F308G, F308E, F308S, F308V, F308A, F308Y, F308N, F308M, F308D, F308H, F308Q or F308W, preferably F308K or F308P, -Y335P, Y335K, Y335E, Y335F, Y335T, Y335Q, Y335S, Y335R, Y335D, Y335V, Y335N, Y335G, Y335H, Y335M or Y335W, preferably Y335P, -Y336E, Y336H, Y336K, Y336I, Y336G, Y336S, Y336T, Y336D, Y336V, Y336P, Y336N, Y336R, Y336Q, Y336a, Y336F, Y336M or Y336W, Preferably Y336E, -L354K, L354E, L354D, L354V, L354Y, L354R, L354S, L354N, L354H, L354M, L354P, L354T, L354F, or L354I, preferably L354K, T359V, T359M, T359A, T359I, T359Y, T359F, T359E, T359K, T359N, T359D, T359P, T359Q, T359R, T359S, T359W or T359G, preferably T359A, T359V, T359I or T359M, more preferably T359V, -K364N, K364Q, K364D, K364E, K364G, K364H, K364S, K364T, K364M, K364P, K364Y, K364I, K364L, or K364V, preferably K364N or K364Q, W366D, W366N, W366K, W366A, W366S, W366I, W366E, W366R, W366M, W366T, W366Q, W366Y, W366G, W366F, W366V, W366P, or W366H, preferably W366D or W366N, and The present invention provides a modified DNA-dependent ATPase (Dda) helicase comprising S382R, S382N, S382K, S382E, S382Q, S382A, S382H, S382M, S382T, S382D, S382G, or S382P, preferably S382N or S382R.

[0146] These are the 31 substitutions mentioned above. The advantages of these substitutions are explained in Table 8.

[0147] The modified Dda helicase of the present invention preferably includes a variant of SEQ ID NO: 118 that contains one or more of the 31 substitutions described above.

[0148] The modified Dda helicase of the present invention may include any number and combination of the above substitutions. The modified Dda helicase of the present invention may include substitutions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31. The modified Dda helicase of the present invention may further have one or more positions corresponding to the 113, 22, or 21 amino acid positions of Dda 1993 listed above modified or substituted as described above.

[0149] The modified Dda helicase of the present invention preferably has one or more of the following substitutions at the positions corresponding to the following amino acid positions in Dda 1993: I196P, I196L, I196D, I196A, I196E, I196K, I196Q, I196S, I196T, I196F, I196M, I196V, or I196Y, preferably I196L or I196P, -Y336E, Y336H, Y336K, Y336I, Y336G, Y336S, Y336T, Y336D, Y336V, Y336P, Y336N, Y336R, Y336Q, Y336a, Y336F, Y336M or Y336W, Preferably Y336E, T359V, T359M, T359A, T359I, T359Y, T359F, T359E, T359K, T359N, T359D, T359P, T359Q, T359R, T359S, T359W or T359G, preferably T359A, T359V, T359I or T359M, more preferably T359V, -K364N, K364Q, K364D, K364E, K364G, K364H, K364S, K364T, K364M, K364P, K364Y, K364I, K364L or K364V, preferably K364N or K364Q, and Includes S382R, S382N, S382K, S382E, S382Q, S382A, S382H, S382M, S382T, S382D, S382G, or S382P, preferably S382N or S382R.

[0150] The modified Dda helicase of the present invention preferably includes a variant of SEQ ID NO: 118 that contains one or more of the above five substitutions.

[0151] The modified Dda helicase of the present invention may include any number and combination of these five substitutions. The modified Dda helicase of the present invention may include 1, 2, 3, 4, or 5 substitutions. The modified Dda helicase of the present invention may further have one or more positions corresponding to the 113, 22, or 21 amino acid positions of Dda 1993 listed above modified or substituted as described above.

[0152] The helicase is preferably substituted with the following: -W195 / K358 / Q422, for example, W195F / K358I / Q422K, W195R / K358M / Q422N, W195K / K358P / Q422D, W195Y / K358I / Q422K, W195K / K358I / Q422N, W195F / K358M / Q422K, W195Y / K358G / Q422A, W195I / K358I / Q422K, W195F / K358I / Q422D or W195I / K358G / Q422A; -W195 / K364 / K368, for example W195K / K364D / K368Q, W195Y / K364Q / K368A, W195I / K364Q / K368A, W195R / K364D / K368T, W195Y / K364I / K368T, W195F / K364Q / K368Q, W195R / K364Q / K368A, W195I / K364P / K368T, W195F / K364Q / K368A or W195R / K364I / K368Y; -W195 / K364 / Q422, for example W195S / K364I / Q422A, W195Y / K364I / Q422A, W195F / K364I / Q422D, W195Y / K364P / Q422N, W195S / K364P / Q422A, W195R / K364I / Q422A, W195Y / K364Q / Q422K, W195F / K364Q / Q422K, W195K / K364P / Q422N or W195R / K364D / Q422D; -W195 / K368 / Q422, for example W195Y / K368A / Q422K, W195K / K368Q / Q422N, W195F / K368A / Q422K, W195S / K368A / Q422K, W195F / K368Q / Q422D, W195Y / K368T / Q422K, W195V / K368T / Q422A, W195K / K368V / Q422K, W195V / K368T / Q422D or W195S / K368V / Q422A; -W195 / Y350 / K368, for example W195Y / Y350E / K368A, W195Y / Y350D / K368T, W195K / Y350I / K368P, W195R / Y350S / K368Q, W195I / Y350D / K368I, W195S / Y350K / K368T, W195R / Y350F / K368V, W195F / Y350E / K368A, W195F / Y350I / K368T, or W195K / Y350W / K368Q; -K67 / M401 models such as K67M / M401L, K67A / M401V, K67Q / M401S, or K67N / M401W; -G153 / M401 such as G153E / M401S, G153Q / M401G, G153E / M401V, or G153L / M401W; -G153 / V403 such as G153E / V403F, G153L / V403L, G153Q / V403M, or G153N / V403H; -M401 / V403 models such as M401S / V403I, M401L / V403H, M401V / V403F, or M401R / V403A; -K67 / G153 such as K67M / G153L, K67A / G153E, K67L / G153H, or K67Q / G153A; -K67 / K368 such as K67M / K368Q, K67N / K368E, K67Q / K368R, or K67A / K368A; -K368 / M401, for example K368A / M401V, K368E / M401S, K368Q / M401G or K368R / M401W; K368 / V403, for example K368N / V403A, K368P / V403H, K368A / V403F, or K368F / V403L; A60K / K368, for example, A60K / K368N, A60T / K368A, A60L / K368E, or A60D / K368R; K67 / V403 models such as K67M / V403H, K67L / V403I, K67N / V403A, or K67A / V403F; G153 / W195 / M401, for example, G153E / W195Q / M401G, G153N / W195K / M401L, G153Q / W195F / M401S, G153N / W195Q / M401G, G153E / W195Q / M401L, G153L / W195Q / M401L, G153L / W195Q / M401G, G153E / W195F / M401S, G153Q / W195Q / M401L, G153L / W195K / M401G or G153N / W195R / M401W; K25 / P134 such as K25N / P134T, K25D / P134G, K25A / P134D, or K25V / P134E; P134 / W135 / C136, for example P134E / W135N / C136M, P134K / W135A / C136F, P134G / W135A / C136T, P134E / W135A / C136F, P134K / W135N / C136F, P134K / W135D / C136M, P134E / W135D / C136V, P134K / W135N / C136T, P134T / W135A / C136M or P134G / W135F / C136F; W195 / V220, for example W195K / V220A, W195R / V220P, W195F / V220K, or W195I / V220Y; W195 / Q422, for example W195F / Q422K, W195I / Q422N, W195P / Q422A or W195K / Q422D; or These are variants of sequence number 118 that include V220 / Q422, such as V220P / Q422A, V220I / Q422D, V220A / Q422T, or V220K / Q422K.

[0153] Preferred combinations in SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133 include amino acid combinations corresponding to the combination in SEQ ID NO: 118.

[0154] The present invention also provides a modified DNA-dependent ATPase (Dda) helicase comprising one or more modifications or substitutions at one or more positions in one or more of the (i) tower domain, (ii) 1A domain, and (iii) 2A domain, and when used in a method for controlling the movement of an analyte through a transmembrane pore and / or a method for characterizing an analyte using a transmembrane pore, exhibiting one or more of (a) increased velocity, (b) improved accuracy, and (c) decreased velocity-diffusion ratio. The modified Dda helicase of the present invention may comprise any number and combination of the above modifications or substitutions. The modified Dda helicase of the present invention may comprise one or more modifications or substitutions at one or more positions in (i), (ii), and (iii). The modified Dda helicases of the present invention may present (a), (b), (c), (a) and (b), (a) and (c), (b) and (c), or (a), (b) and (c). One or more positions in the 2A domain may be proximal to motif V / Va. One or more positions in the 1A domain may be within motif Ia. Motifs V and Ia are helicase motifs associated with the energy conversion from ATP hydrolysis to DNA rearrangement. Domains (i) to (iii) are defined in more detail below. The modified Dda helicases of the present invention may include one or more modifications or substitutions in any of the above or below positions, and / or one or more of the above or below substitutions.

[0155] Either of the above-described modified Dda helicases of the present invention or variants of SEQ ID NO: 118 may further include the substitution M1G.

[0156] The modified Dda helicase or variant of Sequence ID No. 118 of the present invention may further include any of the modifications, mutations, or substitutions discussed below.

[0157] The modified Dda helicase according to the present invention may be any of SEQ ID NOs: 118 to 133. SEQ ID NO: 118 is Dda 1993. The modified Dda helicase preferably includes a variant of any of SEQ ID NOs: 118 to 133. The variant may have any percentage of sequence homology / identity to any of SEQ ID NOs: 118 to 113 shown below.

[0158] Table 1 below summarizes preferred Dda helicases that may be modified according to the present invention. [Table 1] TIFF2026539008000002.tif122152

[0159] One or more of the positions 55, 114, 156, 177, 210, 221, 350, and 358 in Dda 1993 The modified helicases of the present invention may further have one or more positions corresponding to amino acid positions 55, 114, 156, 177, 210, 221, 350, and 358 in Dda 1993 modified or substituted. The positions corresponding to positions 55, 114, 156, 177, 210, 221, 350, and 358 in Dda 1993 are described in more detail below. Positions 55, 114, 156, and 177 are located in the 1A domain of Dda 1993. Positions 210 and 221 are located in the 2A domain of Dda 1993. Positions 350 and 358 are located in the tower domain of Dda 1993. The modified Dda helicase of the present invention may further include modifications or substitutions in any number and combinations of positions corresponding to amino acid positions (a)55, (b)114, (c)156, (d)177, (e)210, (f)221, (g)350 and (h)358, including: (a); (b); (c); (d); (e); (f); (g); (h); (a) and (b); (a) and (c); (a) and (d); (a) and (e); (a) and (f); (a) and (g); (a) and (h); (b) and (c); (b) and (d); (b) and (e); (b) and (f); (b) and (g); (b) and (h); (c) and (d); (c) and (e); (c) and (f); (c) and (g); (c) and (h); (d) and (e); (d) and (f); (d) and (g); (d) and (h); (e) and (f); (e) and ( g); (e) and (h); (f) and (g); (f) and (h); (g) and (h); (a), (b) and (c); (a), (b) and (d); (a), (b) and (e); (a), (b) and (f); (a), (b) and (g); (a), (b) and (h); (a), (c) and (d); (a), (c) and (e); (a), (c) and (f); (a), (c) and (g); (a), (c) and (h); (a), (d) and (e); (a), (d) and (f); (a), (d) and (g); (a), (d) and (h); (a), (e) and (f); (a), (e) and (g); (a), (e) and (h); (a), (f) and (g); (a), (f) and (h); (a), (g) and (h); (b), (c) and (d); (b), (c) and (e); (b), (c) and (f); (b), (c) and (g);(b), (c) and (h); (b), (d) and (e); (b), (d) and (f); (b), (d) and (g); (b), (d) and (h); (b), (e) and (f); (b), (e) and (g); (b), (e) and (h); (b), (f) and (g); (b), (f) and (h); (b), (g) and (h); (c), (d) and (e); (c), (d) and (f); (c), (d) and (g); (c), (d) and (h); (c), (e) and (f); (c), (e) and (g); (c), (e) and (h); (c ), (f) and (h); (c), (g) and (h); (d), (e) and (f); (d), (e) and (g); (d), (e) and (h); (d), (f) and (g); (d), (f) and (h); (d), (g) and (h); (e), (f) and (g); (e), (f) and (h); (e), (g) and (h); (f), (g) and (h); (a), (b), (c) and (d); (a), (b), (c) and (e); (a), (b), (c) and (f); (a), (b), (c) and (g); (a), (b), (c) and (h); (a), (b), (d) and (e); (a), (b), (d) and (f); (a), (b), (d) and (g); (a), (b), (d) and (h); (a), (b), (e) and (f); (a), (b), (e) and (g); (a), (b), (e) and (h); (a), (b), (f) and (g); (a), (b), (f) and (h); (a), (b), (g) and (h); (a), (c), (d) and (e); (a), (c), (d) and (f); (a), (c), (d) and (g); (a), (c), (d) and (h); (a), (c), (e) and (f); (a), ( c), (e) and (g); (a), (c), (e) and (h); (a), (c), (f) and (g); (a), (c), (f) and (h); (a), (c), (g) and (h); (a), (d), (e) and (f); (a), (d), (e) and (g); (a), (d), (e) and (h); (a), (d), (f) and (g); (a), (d), (f) and (h); (a), (d), (g) and (h); (a), (e), (f) and (g); (a), (e), (f) and (h); (a), (e), (g) and (h); (a), (f), (g) and (h);(b), (c), (d) and (e); (b), (c), (d) and (f); (b), (c), (d) and (g); (b), (c), (d) and (h); (b), (c), (e) and (f); (b), (c), (e) and (g); (b), (c), (e) and (h); (b), (c), (f) and (g); (b), (c), (f) and (h); (b), (c), (g) and (h); (b), (d), (e) and (f); (b), (d), (e) and (g); (b), (d), (e) and (h); (b), (d), (f) and (g); (b), (d), (f) ) and (h); (b), (d), (g) and (h); (b), (e), (f) and (g); (b), (e), (f) and (h); (b), (e), (g) and (h); (b), (f), (g) and (h); (c), (d), (e) and (f); (c), (d), (e) and (g); (c), (d), (e) and (h); (c), (d), (f) and (g); (c), (d), (f) and (h); (c), (d), (g) and (h); (c), (e), (f) and (g); (c), (e), (f) and (h); (c), (e), (g) and (h); (c), (f), (g) and (h); (d), (e), (f) and (g); (d), (e), (f) and (h); (d), (e), (g) and (h); (d), (f), (g) and (h); (e), (f), (g) and (h); (a), (b), (c), (d) and (e); (a), (b), (c), (d) and (f); (a), (b), (c), (d) and (g); (a), (b), (c), (d) and (h); (a), (b), (c), (e) and (f); (a), (b), (c), (e) and (g); (a), (b), (c), (e) and (h); (a) , (b), (c), (f) and (g); (a), (b), (c), (f) and (h); (a), (b), (c), (g) and (h); (a), (b), (d), (e) and (f); (a), (b), (d), (e) and (g); (a), (b), (d), (e) and (h); (a), (b), (d), (f) and (g); (a), (b), (d), (f) and (h); (a), (b), (d), (g) and (h); (a), (b), (e), (f) and (g); (a), (b), (e), (f) and (h); (a), (b), (e), (g) and (h);(a), (b), (f), (g) and (h); (a), (c), (d), (e) and (f); (a), (c), (d), (e) and (g); (a), (c), (d), (e) and (h); (a), (c), (d), (f) and (g); (a), (c), (d), (f) and (h); (a), (c), (d), (g) and (h); (a), (c), (e), (f) and (g); (a), (c), (e), (g) and (h); (a), (c), (e), (g) and (h); (a), (c), (f), (g) and (h); (a), (d), (e), ( f) and (g); (a), (d), (e), (f) and (h); (a), (d), (e), (g) and (h); (a), (d), (f), (g) and (h); (a), (e), (f), (g) and (h); (b), (c), (d), (e) and (f); (b), (c), (d), (e) and (g); (b), (c), (d), (e) and (h); (b), (c), (d), (f) and (g); (b), (c), (d), (f) and (h); (b), (c), (d), (g) and (h); (b), (c), (e), (f) and (g); (b), ( c), (e), (f) and (h); (b), (c), (e), (g) and (h); (b), (c), (f), (g) and (h); (b), (d), (e), (f) and (g); (b), (d), (e), (f) and (h); (b), (d), (e), (g) and (h); (b), (d), (f), (g) and (h); (b), (e), (f), (g) and (h); (c), (d), (e), (f) and (g); (c), (d), (e), (f) and (h); (c), (d), (e), (g) and (h); (c), (d), (f), (g) and ( h); (c), (e), (f), (g) and (h); (d), (e), (f), (g) and (h); (a), (b), (c), (d), (e) and (f); (a), (b), (c), (d), (e) and (g); (a), (b), (c), (d), (e) and (h); (a), (b), (c), (d), (f) and (g); (a), (b), (c), (d), (f) and (h); (a), (b), (c), (d), (g) and (h); (a), (b), (c), (e), (f) and (g); (a), (b), (c), (e), (f) and (h);(a), (b), (c), (e), (g) and (h); (a), (b), (c), (f), (g) and (h); (a), (b), (d), (e), (f) and (g); (a), (b), (d), (e), (f) and (h); (a), (b), (d), (e), (g) and (h); (a), (b), (d), (f), (g) and (h); (a), (b), (e), (f), (g) and (h); (a), (c), (d), (e), (f) and (g); (a), (c), (d), (e), (f) and (h); (a), (c), (d), (e), (g) and (h); (a), (c), (d), (f), (g) and (h); (a), (c), (e), (f), (g) and (h); (a), (d), (e), (f), (g) and (h); (b), (c), (d), (e), (f) and (g); (b), (c), (d), (e), (f) and (h); (b), (c), (d), (e), (g) and (h); (b), (c), (d), (f), (g) and (h); (b), (c), (e), (f), (g) and (h); (b), (d), (e), (f), (g) and (h); (c), (d), (e), (f), (g) and (h); (a), (b), (c), (d), (e), (f) and (g); (a), (b), (c), (d), (e), (f) and (h); (a), (b), (c), (d), ( e), (g) and (h); (a), (b), (c), (d), (f), (g) and (h); (a), (b), (c), (e), (f), (g) and (h); (a), (b), (d), (e), (f), (g) and (h); (a), (c), (d), (e), (f), (g) and (h); (b), (c), (d), (e), (f), (g) and (h); or (a), (b), (c), (d), (e), (f), (g) and (h).

[0160] The modified Dda helicase of the present invention may further have one or more positions corresponding to amino acid positions 114, 177, 350, and 358 in Dda 1993 modified or substituted. Positions 114, 177, 350, and 358 in Dda 1993 are described in more detail below. Positions 114 and 177 are located in the 1A domain of Dda 1993. Positions Y350 and K358 are located in the tower domain of Dda 1993. The modified Dda helicase of the present invention may further include modification or substitution in any number and combination of positions corresponding to amino acid positions (a)114, (b)177, (c)350 and (d)358 in Dda 1993, including (a);(b);(c);(d);(a) and (b);(a) and (c);(a) and (d);(b) and (c);(b) and (d);(c) and (d);(a), (b) and (c);(a), (c) and (d);(b), (c) and (d); or (a), (b), (c) and (d).

[0161] The position corresponding to amino acid position 55 of Dda 1993 is preferably substituted with D, E, K, N, or S. The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with K (T55K). These substitutions increase the rate and improve accuracy when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821). These substitutions also reduce the normalized rate distribution when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821).

[0162] The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with A, V, I, L, M, F, Y, W, G, P, S, T, N, or Q. The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with A, G, I, L, M, P, S, T, or V. The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with G, L, S, or T. These substitutions reduce the rate when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with A, I, M, P, or V. These substitutions increase the rate when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with G(C11G). This substitution reduces the rate and increases the accuracy when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with I or P. These substitutions increase the rate and decrease the accuracy when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 114 of Dda 1993 is preferably substituted with G, I or P. These substitutions reduce the normalized rate distribution when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 114 of Dda 1993 is most preferably substituted with I(C114I).

[0163] The position corresponding to amino acid position 156 of Dda 1993 is preferably substituted with A, E, F, G, I, L, M, P, S, V, Y, D, K, or N. The position corresponding to amino acid position 156 of Dda 1993 is preferably substituted with F (T156F). This substitution increases the rate and improves the accuracy when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821). This substitution also reduces the normalized rate distribution when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821).

[0164] The position corresponding to amino acid position 177 in Dda 1993 is preferably substituted with D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W, or Y. The position corresponding to amino acid position 177 in Dda 1993 is preferably substituted with F, G, S, V, W, or Y. These substitutions reduce the rate when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 177 in Dda 1993 is preferably substituted with D, E, G, H, I, L, M, N, Q, R, or T. These substitutions increase the rate when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 177 in Dda 1993 is preferably substituted with F, H, I, L, M, N, or W. These substitutions, when used to characterize polynucleotide analytes, reduce accuracy and normalized velocity distribution (Example 2 of PCT / EP2023 / 059821). They have different effects on velocity (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 177 of Dda 1993 is preferably substituted with N(K177N). This substitution, when used to characterize polynucleotide analytes, reduces accuracy and increases normalized velocity distribution (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 177 of Dda 1993 is most preferably substituted with M(K177M).

[0165] The position corresponding to amino acid position 210 of Dda 1993 is preferably substituted with D, E, K, S, N, R, H, or Y. The position corresponding to amino acid position 210 of Dda 1993 is preferably substituted with R(T210R), H(T210H), or K(T210K). The position corresponding to amino acid position 210 of Dda 1993 is preferably substituted with K(T210K). This substitution increases the rate and improves the accuracy when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821). This substitution also reduces the normalized rate distribution when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821).

[0166] The position corresponding to amino acid position 221 of Dda 1993 is preferably substituted with D, K, E, Q, R, A, H, L, T, or Y. The position corresponding to amino acid position 221 of Dda 1993 is preferably substituted with D(N221D) or E(N221E). It is preferable that the position corresponding to amino acid position 221 of Dda 1993 is substituted with E(N221E). This substitution increases the rate and improves the accuracy when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821). This substitution also reduces the normalized rate distribution when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821).

[0167] The position corresponding to amino acid position 350 of Dda 1993 is preferably substituted with D, E, A, V, I, L, M, F, W, R, H, K, L, S, T, N, or Q. It is preferable that the position corresponding to amino acid position 350 of Dda 1993 is substituted with I, F, W, or S. It is preferable that the position corresponding to amino acid position 350 of Dda 1993 is substituted with I or S (Y350I or Y350S). It is preferable that the position corresponding to amino acid position 350 of Dda 1993 is substituted with I (Y350I). This substitution increases the rate and reduces accuracy and normalized rate distribution when used to characterize polynucleotide analytes (Example 3 of PCT / EP2023 / 059821). It is preferable that the position corresponding to amino acid position 350 of Dda 1993 is substituted with I or S (Y350I or Y350S). These substitutions, when used with the pore complex described therein, have the effects shown in Example 4 of PCT / EP2023 / 059821.

[0168] The position corresponding to amino acid position 350 of Dda 1993 is preferably substituted with A, D, E, G, K, L, N, Q, R, T, V, H, or M. The position corresponding to amino acid position 350 of Dda 1993 is preferably substituted with D(Y350D) or E(Y350E). The position corresponding to amino acid position 350 of Dda 1993 is preferably substituted with E(Y350E). This substitution increases the rate and improves the accuracy when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821). This substitution also reduces the normalized rate distribution when used to characterize polynucleotide analytes (Example 5 of PCT / EP2023 / 059821).

[0169] The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with D, E, A, V, I, L, M, F, Y, W, R, H, L, S, T, N, or Q.

[0170] The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with E, I, L, or M. These substitutions reduce the rate when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with I or M. These substitutions reduce the rate and improve accuracy when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with M (K358M). This substitution reduces the rate and increases accuracy and normalized rate distribution when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with I (K358I). This substitution reduces the rate and normalized rate distribution, improving accuracy when used to characterize polynucleotide analytes (Example 2 of PCT / EP2023 / 059821). Example 2 uses a CsgG pore that does not contain the CsgF peptide.

[0171] The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with A, E, F, I, M, or S. These substitutions improve accuracy when used to characterize polynucleotide analytes (Example 3 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with A, E, F, I, or M. These substitutions reduce the rate when used to characterize polynucleotide analytes (Example 3 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with S (K358S). This substitution increases the rate when used to characterize polynucleotide analytes (Example 3 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with A, E, I, M, or S. These substitutions reduce the normalized velocity distribution when used to characterize polynucleotide analytes (Example 3 of PCT / EP2023 / 059821). The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with (K358F). These substitutions increase the normalized velocity distribution when used to characterize polynucleotide analytes (Example 3 of PCT / EP2023 / 059821). Example 3 uses a CsgG pore complex containing the CsgF peptide.

[0172] The position corresponding to amino acid position 358 of Dda 1993 is preferably substituted with I, L, or Q. These substitutions reduce the rate and increase accuracy and normalized rate distribution when used to characterize polynucleotide analytes (Example 4 of PCT / EP2023 / 059821).

[0173] The position corresponding to amino acid position 358 of Dda 1993 is most preferably substituted with I(K358I).

[0174] Table 2 shows the amino acids of sequence numbers 119-133, corresponding to positions 40, 55, 114, 156, 177, 210, 221, 350, and 358 of sequence number 118. [Table 2]

[0175] The modified helicase of the present invention preferably comprises one or more of the following (a) to (h): (a) T55D, T55E, T55K, T55N or T55S, T55K. (b) C114A, C114V, C114I, C114L, C114M, C114F, C114Y, C114W, C114G, C114P, C114S, C114T, C114N, or C114Q, C114A, C114G, C114I, C114L, C114M, C114P, C114S, C114T, or C114V, C114G, C114L, C114S, or C114T, C114A, C114I, C114M, C114P, or C114V C11G, C114I or C114P C114G, C114I, or C114P, C114I; (c) T156A, T156E, T156F, T156G, T156I, T156L, T156M, T156P, T156S, T156V, T156Y, T156D, T156K or T156N, or T156F; (d) K177D, K177E, K177F, K177G, K177H, K177I, K177L, K177M, K177N, K177Q, K177R, K177S, K177T, K177V, K177W or K177Y, K177F, K177G, K177S, K177V, K177W, or K177Y, K177D, K177E, K177G, K177H, K177I, K177L, K177M, K177N, K177Q, K177R, or K177T, K177F, K177H, K177I, K177L, K177M, K177N, or K177W, K177N, or K177M; (e) T210D, T210E, T210K, T210S, T210N, T210R, T210H or T210Y, T210R, T210H or T210Y, or T210K; (f) N221D, N221K, N221E, N221Q, N221R, N221A, N221H, N221L, N221T, or N221Y, N221D or N221E, N221E; (g) Y350D, Y350E, Y350A, Y350V, Y350I, Y350L, Y350M, Y350F, Y350W, Y350R, Y350H, Y350K, Y350L, Y350S, Y350T, Y350N or Y350Q, Y350I or Y350S, Y350I, Y350S, Y350I, Y350F, Y350W, or Y350S, Y350A, Y350D, Y350E, Y350G, Y350K, Y350L, Y350N, Y350Q, Y350R, Y350T, Y350V, Y350H or Y350M, Y350D or Y350E, or Y350E; and (h) K358D, K358E, K358A, K358V, K358I, K358L, K358M, K358F, K358Y, K358W, K358R, K358H, K358L, K358S, K358T, K358N or K358Q, K358E, K358I, K358L, or K358M, K358I or K358M, K358M, K358I, K358A, K358E, K358F, K358I, K358M, or K358S, K358A, K358E, K358F, K358I or K358M, K358S, K358A, K358E, K358I, K358M, or K358S, K358F, K358I, K358L, or K358Q, Includes variants of sequence number 118, which further include K358I.

[0176] The variant may include any combination and permutation of (a) to (h) above.

[0177] The helicase of the present invention preferably comprises one or more of the following (a), (b), (c), and (d): (a) C114A, C114V, C114I, C114L, C114M, C114F, C114Y, C114W, C114G, C114P, C114S, C114T, C114N, or C114Q, C114A, C114G, C114I, C114L, C114M, C114P, C114S, C114T, or C114V, C114G, C114L, C114S, or C114T, C114A, C114I, C114M, C114P, or C114V C11G, C114I or C114P C114G, C114I, or C114P, C114I; (b) K177D, K177E, K177F, K177G, K177H, K177I, K177L, K177M, K177N, K177Q, K177R, K177S, K177T, K177V, K177W or K177Y, K177F, K177G, K177S, K177V, K177W, or K177Y, K177D, K177E, K177G, K177H, K177I, K177L, K177M, K177N, K177Q, K177R, or K177T, K177F, K177H, K177I, K177L, K177M, K177N, or K177W, K177N, or K177M; (c) Y350D, Y350E, Y350A, Y350V, Y350I, Y350L, Y350M, Y350F, Y350W, Y350R, Y350H, Y350K, Y350L, Y350S, Y350T, Y350N or Y350Q, Y350I or Y350S, Y350I, or Y350S; and (d) K358D, K358E, K358A, K358V, K358I, K358L, K358M, K358F, K358Y, K358W, K358R, K358H, K358L, K358S, K358T, K358N or K358Q, K358E, K358I, K358L, or K358M, K358I or K358M, K358M, K358I, K358A, K358E, K358F, K358I, K358M, or K358S, K358A, K358E, K358F, K358I or K358M, K358S, K358A, K358E, K358I, K358M, or K358S, K358F, K358I, K358L, or K358Q, K358I also includes variants of sequence number 118.

[0178] The variant may include (a);(b);(c);(d);(a) and (b);(a) and (c);(a) and (d);(b) and (c);(b) and (d);(c) and (d);(a), (b) and (c);(a), (b) and (d);(a), (c) and (d);(b), (c) and (d); or (a), (b), (c) and (d).

[0179] Preferred variants of Sequence ID No. 118 include C114I;K177M;Y350I;K358I;C114I and K177M;C114I and Y350I;C114I and K358I;K177M and Y350I;K177M and K358I;Y350I and K358I;C114I, K177M and Y350I;C114I, K177M and K358I;C114I, Y350I and K358I;K177M, Y350I and K358I; or C114I, K177M, Y350I and K358I.

[0180] The helicase preferably includes variants of SEQ ID NOs. 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, in which one or more positions corresponding to amino acid positions 55, 114, 156, 177, 210, 221, 350, and 358 of Dda 1993 are modified or substituted (including specific substitutions) as defined above. Various combinations and permutations of one or more of positions 55, 114, 156, 177, 210, 221, 350, and 358 of Dda 1993 are defined above with reference to (a) to (h).

[0181] The helicase preferably includes variants of SEQ ID NOs. 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, in which one or more positions corresponding to amino acid positions 114, 177, 350, and 358 of Dda 1993 are modified or substituted (including specific substitutions) as defined above. Various combinations and permutations of one or more of positions 114, 177, 350, and 358 of Dda 1993 are defined above with reference to (a) to (d).

[0182] The helicase preferably includes variants of SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, in which one or more positions corresponding to amino acid positions 114, 177, and 358 of Dda 1993 are modified or substituted (including specific substitutions) as defined above.

[0183] Position 40 in Dda 1993 Any of the modified helicases of the present invention may further include modifications or substitutions at the position corresponding to amino acid position 40 of Dda 1993. Position 40 or the corresponding position may be substituted with A, V, I, L, M, F, Y, or W. The positions corresponding to position T40 of Dda 1993 are shown in Table 2 above. The helicases of the present invention preferably include variants of SEQ ID NO: 118, which further include substitutions at T40 such as T40A, T40V, T40I, T40L, T40M, T40F, T40Y, or T40W, in addition to the modifications / substitutions described above. The substitution is preferably T40Y.

[0184] The modified Dda helicase of the present invention may further include a modification or substitution at the position corresponding to amino acid position 40 of Dda 1993. Position T40 is located within the tower domain of Dda 1993. The helicase of the present invention preferably includes a variant of SEQ ID NO: 118, further comprising substitutions at T40 such as T40A, T40V, T40I, T40L, T40M, T40F, T40Y, or T40W. The substitution is preferably T40Y. The modified Dda helicase of the present invention may further include a modification or substitution at one or more positions corresponding to amino acid positions (a)55, (b)114, (c)156, (d)177, (e)210, (f)221, (g)350, and (h)358, including any combination and permutation of (a) to (h) above. The modified Dda helicase of the present invention may further include modifications or substitutions at one or more of the positions corresponding to (a)114, (b)177, (c)350 and (d)358, including the amino acid positions in Dda 1993: (a); (b); (c); (d); (a) and (b); (a) and (c); (a) and (d); (b) and (c); (b) and (d); (a), (b) and (d); (a), (c) and (d); (b), (c) and (d); or (a), (b), (c) and (d). The helicase preferably includes variants of SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, in which the position corresponding to amino acid position 40 of Dda 1993 is modified or substituted (including specific substitutions).

[0185] The modified helicases of the present invention may further include any of the modifications, substitutions, combinations of modifications, or combinations of substitutions discussed below.

[0186] Other helicases of the present invention The use of Dda helicase in characterizing analytes is described in International Publications 2015 / 055981, 2015 / 166276, and 2016 / 055777 (all incorporated by reference).

[0187] The modified helicase of the present invention provides more consistent movement of target analytes to transmembrane pores, such as through transmembrane pores, resulting in improved accuracy. The helicase preferably provides more consistent movement of target analytes, such as polynucleotides, to pores, for example, from one k-mer to another, or from k-mer to k-mer, when moving through pores. The helicase enables smoother movement of target analytes, such as target polynucleotides, to transmembrane pores, for example, through transmembrane pores. The helicase preferably provides more regular or more irregular movement of target analytes, such as target polynucleotides, to transmembrane pores, for example, through transmembrane pores.

[0188] The modification typically improves accuracy by at least 0.1%, at least 0.5%, at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to the unmodified helicase.

[0189] The ability of helicase to control the movement of polynucleotides can be determined as described in the examples.

[0190] Modified helicases possess the ability to control the movement of polynucleotides. The ability of a helicase to control polynucleotide movement can be assayed using any method known in the art. For example, the helicase can be brought into contact with a polynucleotide, and the position of the polynucleotide can be determined using standard methods. The ability of a modified helicase to control polynucleotide movement is typically assayed using a nanopore system, such as those described below, particularly in the examples.

[0191] The modified helicases of the present invention can be isolated, substantially isolated, purified, or substantially purified. Helicases are isolated or purified if they do not contain any other components such as lipids, polynucleotides, pore monomers, or other proteins. Helicases are substantially isolated if they are mixed with a carrier or diluent that does not interfere with their intended use. For example, helicases are substantially isolated or substantially purified if they exist in a form containing less than 10%, less than 5%, less than 2%, or less than 1% of other components such as lipids, polynucleotides, pore monomers, or other proteins.

[0192] Dda Helical Case Any Dda helicase can be modified in accordance with the present invention. Preferred Dda helicases are discussed below and are described in International Publications 2015 / 055981, 2015 / 166276 and 2016 / 055777 (all incorporated by reference).

[0193] Dda helicase typically contains the following five domains: 1A (RecA-like motor) domain, 2A (RecA-like motor) domain, tower domain, pin domain, and hook domain (Xiaoping He et al., 2012, Structure; 20: 1189-1200). The domains include protein modeling, X-ray diffraction measurements of crystalline proteins (Rupp B (2009). Biomolecular Crystallography: Principles, Practice and Application to Structural Biology. New York: Garland Science.), nuclear magnetic resonance (NMR) spectroscopy of proteins in solution (Mark Rance; Cavanagh, John; Wayne J. Fairbrother; Arthur W. Hunt III; Skelton, N. Chocolas J. (2007). Protein NMR spectroscopy: principles and practice (2nd ed.). Boston: Academic Press.), or cryo-electron microscopy of freeze-hydrated proteins (van Heel M, Gowen B, Matadeen R, Orlova EV, Finn R, Pape T, Cohen D, Stark H, Schmidt R, Schatz M, Patwardhan A (2000). "Single-particle electron cryo-microscopy: toward atomic resolution." Q Rev The protein can be identified using Biophys.33:307-69). The structural information of the protein determined by the above method is publicly available from the Protein Bank (PDB) database.

[0194] In addition to the modifications or substitutions described above, the modified helicases of the present invention preferably further include any of the following further modifications, substitutions, combinations of modifications, or combinations of substitutions.

[0195] Modification of the present invention The helicase of the present invention may be one in which at least one amino acid that interacts with the transmembrane pore is further substituted. Any number of amino acids, for example 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, or 6 or more amino acids may be substituted. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids may be substituted. Amino acids that interact with the transmembrane pore can be identified using the protein modeling described above.

[0196] Base and / or sugar interaction The helicase of the present invention is preferably one in which at least one amino acid that interacts with the sugar and / or base of one or more nucleotides in single-stranded DNA (ssDNA) is further substituted with an amino acid comprising a larger side chain (R group). Any number of amino acids, for example 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, or 6 or more amino acids may be substituted. Each amino acid may interact with a base, a sugar, or both a base and a sugar. Amino acids that interact with the sugar and / or base of one or more nucleotides in single-stranded DNA can be identified using protein modeling as described above.

[0197] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 118, wherein at least one amino acid that interacts with the sugar and / or base of one or more nucleotides in ssDNA is at least one of H82, N88, P89, F98, D121, V150, P152, F240, F276, S287, H396 and Y415. These numbers correspond to the relevant positions in SEQ ID NO: 118, and may need to be changed in the case of variants in which one or more amino acids have been inserted or deleted as compared to SEQ ID NO: 118. A person skilled in the art can determine the corresponding positions in the variants as described above. The helicase of the present invention preferably comprises a variant of SEQ ID NO: 118, wherein at least one amino acid that interacts with the sugar and / or base of one or more nucleotides in ssDNA is F98 and one or more of H82, N88, P89, D121, V150, P152, F240, F276, S287, H396 and Y415, for example F98 / H82, F98 / N88, F98 / P89, F98 / D121, F98 / V150, F98 / P152, F98 / F240, F98 / F276, F98 / S287 or F98 / H396.

[0198] The helicase of the present invention is preferably a variant of SEQ ID NOs. 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, wherein at least one amino acid that interacts with the sugar and / or base of one or more nucleotides in the ssDNA is at least one of the amino acids corresponding to H82, N88, P89, F98, D121, V150, P152, F240, F276, S287, H396, and Y415 of SEQ ID NOs. 118. The helicase of the present invention preferably has at least one amino acid that interacts with the sugar and / or base of one or more nucleotides in ssDNA, which is one or more of the amino acids corresponding to F98 in SEQ ID NO: 118, and H82, N88, P89, D121, V150, P152, F240, F276, S287, H396 and Y415 in SEQ ID NO: 118, for example, F98 Includes variants of SEQ ID NOs. 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, which are amino acids corresponding to / H82, F98 / N88, F98 / P89, F98 / D121, F98 / V150, F98 / P152, F98 / F240, F98 / F276, F98 / S287, or F98 / H396.

[0199] Table 3 shows the amino acids in SEQ ID NOs. 119-133 that correspond to H82, N88, P89, F98, D121, V150, P152, F240, F276, S287, H396, and Y415 in SEQ ID NOs. 118. [Table 3]

[0200] At least one amino acid that interacts with the sugars and / or bases of one or more nucleotides in the ssDNA is preferably at least one amino acid that intercalates between nucleotides in the ssDNA. The amino acid that intercalates between nucleotides in the ssDNA can be modeled as described above. The at least one amino acid that intercalates between nucleotides in the ssDNA is preferably at least one of P89, F98, and V150 of SEQ ID NO: 118, for example, P89, F98, V150, P89 / F98, P89 / V150, F98 / V150, or P89 / F98 / V150.

[0201] At least one amino acid intercalating between nucleotides in the ssDNA of SEQ ID NOs. 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133 is preferably at least one of the amino acids corresponding to P89, F98, and V150 in SEQ ID NOs. 118, for example, P89, F98, V150, P89 / F98, P89 / V150, F98 / V150, or P89 / F98 / V150. The corresponding amino acids are shown in Table 3 above.

[0202] Larger R group Larger side chains (R groups) preferably (a) contain an increased number of carbon atoms, (b) have an increased length, (c) have an increased molecular volume, and / or (d) have an increased van der Waals volume. Larger side chains (R groups) are preferably (a);(b);(c);(d);(a) and (b);(a) and (c);(a) and (d);(b) and (c);(b) and (d);(c) and (d);(a), (b) and (c);(a), (b) and (d);(a), (c) and (d);(b), (c) and (d); or (a), (b), (c) and (d). Each of (a) to (d) can be measured using standard methods in the art.

[0203] A larger side chain (R group) preferably increases (i) electrostatic interactions, (ii) hydrogen bonding and / or (iii) cation-π (cation-π) interactions between at least one amino acid and one or more nucleotides in ssDNA, for example (i); (ii); (iii); (i) and (ii); (i) and (iii); (ii) and (iii); and increases (i), (ii) and (iii). A person skilled in the art can determine whether an R group increases any of these interactions. For example, in (i), positively charged amino acids, such as arginine (R), histidine (H), and lysine (K), have R groups that increase electrostatic interactions. For example, in (ii), amino acids such as asparagine (N), serine (S), glutamine (Q), threonine (T), and histidine (H) have R groups that increase hydrogen bonding. For example, in (iii), aromatic amino acids such as phenylalanine (F), tryptophan (W), tyrosine (Y), or histidine (H) have an R group that increases cation-π (cation-π) interactions. The following specific substitutions are labeled (i) to (iii) to reflect these changes. Other possible substitutions are labeled (iv). These (iv) substitutions typically increase the length of the side chain (R group).

[0204] Amino acids containing larger side chains (R) may be unnatural amino acids. Unnatural amino acids may be any of the following:

[0205] Amino acids containing larger side chains (R groups) are preferably not alanine (A), cysteine ​​(C), glycine (G), selenocysteine ​​(U), methionine (M), aspartic acid (D), or glutamic acid (E).

[0206] Histidine (H) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q) or asparagine (N), or (iii) phenylalanine (F), tyrosine (Y), or tryptophan (W). Histidine (H) is more preferably substituted with (a) N, Q, or W or (b) Y, F, Q, or K.

[0207] Asparagine (N) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q) or histidine (H), or (iii) phenylalanine (F), tyrosine (Y), or tryptophan (W). More preferably, asparagine (N) is substituted with R, H, W, or Y.

[0208] Proline (P) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N), threonine (T) or histidine (H), (iii) tyrosine (Y), phenylalanine (F) or tryptophan (W), or (iv) leucine (L), valine (V) or isoleucine (I). More preferably, proline (P) is substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N), threonine (T) or histidine (H), (iii) phenylalanine (F) or tryptophan (W), or (iv) leucine (L), valine (V) or isoleucine (I). Proline (P) is more preferably substituted with (a) F, (b) L, V, I, T or F or (c) W, F, Y, H, I, L or V.

[0209] Valine (V) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W), or (iv) isoleucine (I) or leucine (L). Valine (V) is more preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), (iii) tyrosine (Y) or tryptophan (W), or (iv) isoleucine (I) or leucine (L). Valine (V) is more preferably substituted with I or H or I, L, N, W or H.

[0210] Phenylalanine (F) is preferably substituted with (i) arginine (R) or lysine (K), (ii) histidine (H), or (iii) tyrosine (Y) or tryptophan (W). Phenylalanine (F) is more preferably substituted with (a) W, (b) W, Y, or H, (c) W, R, or K, or (d) K, H, W, or R.

[0211] Glutamine (Q) is preferably substituted with (i) arginine (R) or lysine (K) or (iii) phenylalanine (F), tyrosine (Y), or tryptophan (W).

[0212] Alanine (A) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W), or (iv) isoleucine (I) or leucine (L).

[0213] Serine (S) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W), or (iv) isoleucine (I) or leucine (L). Serine (S) is preferably substituted with K, R, W or F.

[0214] Lysine (K) is preferably substituted with (i) arginine (R) or (iii) tyrosine (Y) or tryptophan (W).

[0215] Arginine (R) is preferably substituted with (iii) tyrosine (Y) or tryptophan (W).

[0216] Methionine (M) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), or (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W).

[0217] Leucine (L) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q) or asparagine (N), or (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W).

[0218] Aspartic acid (D) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), or (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W). Aspartic acid (D) is more preferably substituted with H, Y or K.

[0219] Glutamic acid (E) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), or (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W).

[0220] Isoleucine (I) is preferably substituted with (i) arginine (R) or lysine (K), (ii) glutamine (Q), asparagine (N) or histidine (H), (iii) phenylalanine (F), tyrosine (Y) or tryptophan (W), or (iv) leucine (L).

[0221] Tyrosine (Y) is preferably substituted with (i) arginine (R) or lysine (K) or (iii) tryptophan (W). More preferably, tyrosine (Y) is substituted with W or R.

[0222] The helicase more preferably comprises the variant of sequence number 118, and includes (a) P89F, (b) F98W, (c) V150I, (d) V150H, (e) P89F and F98W, (f) P89F and V150I, (g) P89F and V150H, (h) F98W and V150I, (i) F98W and V150H, (j) P89F, F98W and V150I, or (k) P89F, F98W and V150H.

[0223] Helicase is more preferably: H82N; H82Q; H82W; N88R; N88H; N88W; N88Y; P89L; P89V; P89I; P89E; P89T; P89F; D121H; D121Y; D121K; V150I; V150L; V150N; V150W; V150H; P152W; P152F; P152Y; P152H; P152I; P152L; P152V; F240W; F240Y; F240H; F276W;F276R;F276K;F276H;S287K;S287R;S287W;S287F;H396Y;H396F;H396Q;H396K;Y415W;Y415R;F98W / H82N; F98W / H82Q;F98W / H82W;F98W / N88R;F98W / N88H;F98W / N88W;F98W / N88Y;F98W / P89L;F98W / P89V;F98W / P89I;F98W / P89T;F98W / P89F;F98W / D121H;F98W / D121Y;F98W / D121K;F98W / V150I;F98W / V150L;F98W / V150N;F98W / V150W;F9 8W / V150H;F98W / P152W;F98W / P152F;F98W / P152Y;F98W / P152H;F98W / P152I;F98W / P152L;F98W / P152V;F98W / F24 Includes variants of sequence number 118, including 0W;F98W / F240Y;F98W / F240H;F98W / F276W;F98W / F276R;F98W / F276K;F98W / F276H;F98W / S287K;F98W / S287R;F98W / S287W;F98W / S287F;F98W / H396Y;F98W / H396F;F98W / H396Q;F98W / Y415W; or F98W / Y415R.

[0224] Phosphate interactions The helicase of the present invention is preferably further substituted with at least one amino acid that interacts with one or more phosphate groups in one or more nucleotides in the ssDNA. Any number of amino acids, for example, one or more, two or more, three or more, four or more, five or more, or six or more amino acids may be substituted. Each nucleotide in the ssDNA contains three phosphate groups. Each substituted amino can interact with any number of phosphate groups at once, such as one, two, or three phosphate groups at a time. The amino acids that interact with one or more phosphate groups can be identified using the protein modeling described above.

[0225] The substitutions preferably increase (i) electrostatic interactions, (ii) hydrogen bonding, and / or (iii) cation-π interactions between at least one amino acid and one or more phosphate groups in the ssDNA. Preferred substitutions that increase (i), (ii), and (iii) are discussed below using labels (i), (ii), and (iii).

[0226] Substitutions preferably increase the net positive charge at that position. The net charge at any position can be measured using methods known in the art. For example, the net charge of an amino acid can be defined using an isovalue. The net charge is typically measured at about 7.5. Substitutions preferably involve the substitution of a negatively charged amino acid with a positively charged, uncharged, nonpolar, or aromatic amino acid. A negatively charged amino acid is an amino acid that has a net negative charge. Negatively charged amino acids include, but are not limited to, aspartic acid (D) and glutamic acid (E). A positively charged amino acid is an amino acid that has a net positive charge. Positively charged amino acids may be naturally occurring or not. Positively charged amino acids may be synthesized or modified. For example, a modified amino acid with a net positive charge may be specifically designed for use in the present invention. Several different types of modifications to amino acids are well known in the art. Preferred naturally occurring positively charged amino acids include, but are not limited to, histidine (H), lysine (K), and arginine (R).

[0227] Uncharged amino acids, nonpolar amino acids, or aromatic amino acids may or may not occur naturally. They may be synthesized or modified. Uncharged amino acids have no net charge. Suitable uncharged amino acids include, but are not limited to, cysteine ​​(C), serine (S), threonine (T), methionine (M), asparagine (N), and glutamine (Q). Nonpolar amino acids have nonpolar side chains. Suitable nonpolar amino acids include, but are not limited to, glycine (G), alanine (A), proline (P), isoleucine (I), leucine (L), and valine (V). Aromatic amino acids have aromatic side chains. Suitable aromatic amino acids include, but are not limited to, histidine (H), phenylalanine (F), tryptophan (W), and tyrosine (Y).

[0228] The helicase preferably includes a variant of SEQ ID NO: 118 in which at least one amino acid interacting with one or more phosphate groups of one or more nucleotides in the ssDNA is at least one of H64, T80, S83, N242, K243, N293, T394, and K397. These numbers correspond to the relevant positions in SEQ ID NO: 89 and may need to be changed in the case of a variant in which one or more amino acids are inserted or deleted compared to SEQ ID NO: 118. Those skilled in the art can determine the corresponding positions in the variant as described above.

[0229] The helicase preferably comprises variants of SEQ ID NOs. 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, and at least one amino acid that interacts with one or more phosphates of one or more nucleotides of ssDNA is at least one of the amino acids corresponding to H64, T80, S83, N242, K243, N293, T394, and K397 of SEQ ID NOs. 118.

[0230] Table 4 shows the amino acids of Sequence IDs 118-133, which correspond to H64, T80, S83, N242, K243, N293, T394, and K397 of Sequence ID 119. [Table 4]

[0231] Histidine (H) is preferably substituted with (i) arginine (R) or lysine (K), (ii) asparagine (N), serine (S), glutamine (Q) or threonine (T), or (iii) phenylalanine (F), tryptophan (W) or tyrosine (Y). Histidine (H) is preferably substituted with (a) N, Q, K or F or (b) N, Q or W.

[0232] Threonine (T) is preferably substituted with (i) arginine (R), histidine (H), or lysine (K), (ii) asparagine (N), serine (S), glutamine (Q), or histidine (H), or (iii) phenylalanine (F), tryptophan (W), tyrosine (Y), or histidine (H). More preferably, threonine (T) is substituted with (a) K, Q, or N, or (b) K, H, or N.

[0233] Serine (S) is preferably substituted with (i) arginine (R), histidine (H), or lysine (K), (ii) asparagine (N), glutamine (Q), threonine (T), or histidine (H), or (iii) phenylalanine (F), tryptophan (W), tyrosine (Y), or histidine (H). More preferably, serine (S) is substituted with H, N, K, T, R, or Q.

[0234] Asparagine (N) is preferably substituted with (i) arginine (R), histidine (H), or lysine (K), (ii) serine (S), glutamine (Q), threonine (T), or histidine (H), or (iii) phenylalanine (F), tryptophan (W), tyrosine (Y), or histidine (H). More preferably, asparagine (N) is substituted with (a) H or Q, or (b) Q, K, or H.

[0235] Lysine (K) is preferably substituted with (i) arginine (R) or histidine (H), (ii) asparagine (N), serine (S), glutamine (Q), threonine (T) or histidine (H), or (iii) phenylalanine (F), tryptophan (W), tyrosine (Y) or histidine (H). Lysine (K) is more preferably substituted with (a) Q or H or (b) R, H or Y.

[0236] The helicase more preferably comprises the variant of SEQ ID NO: 118, and includes one or more of the following, for example all of them: (a) H64N, H64Q, H64K or H64F, (b) T80K, T80Q or T80N, (c) S83H, S83N, S83K, S83T, S83R or S83Q, (d) N242H or N242Q, (e) K243Q or K243H, (f) N293Q, N293K or N293H, (g) T394K, T394H or T394N, or (h) K397R, K397H or K397Y.

[0237] combination The helicase is preferably F98 / H64 such as F98W / H64N, F98W / H64Q, F98W / H64K, F98W / H64F; F98 / T80 series such as F98W / T80K, F98W / T80Q, F98W / T80N, etc. F98 / H82 models such as F98W / H82N, F98W / H82Q, F98W / H82W, etc. F98W / S83H, F98W / S83N, F98W / S83K, F98W / S83T, F98W / S83R, F98W / S83Q, etc.; F98 / N242, such as F98W / N242H, F98W / N242Q, F98W / K243Q, F98W / K243H; F98 / N293 such as F98W / N293Q, F98W / N293K, F98W / N293H, F98W / T394K, F98W / T394H, F98W / T394N, F98W / H396Y, F98W / H396F, F98W / H396Q or F98W / H396K; or This is a variant of sequence number 118 that includes substitutions for F98 / K397, such as F98W / K397R, F98W / K397H, or F98W / K397Y.

[0238] Preferred combinations in SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133 include amino acid combinations corresponding to the combination in SEQ ID NO: 118.

[0239] Pore ​​interaction The helicases of the present invention are further comprising one or more modifications, preferably one or more substitutions, of the helicase portion that interacts with the transmembrane pore. The helicase portion that interacts with the transmembrane pore is typically the portion of the helicase that interacts with the transmembrane pore when the helicase is used to control the movement of polynucleotides through the pore, as will be discussed in more detail below, for example. This portion typically comprises amino acids that interact with or contact the pore when the helicase is used to control the movement of polynucleotides through the pore, as will be discussed in more detail below, for example. This portion typically comprises amino acids that interact with or contact the pore when the helicase is bound to or attached to an analyte, such as a polynucleotide moving through the pore under an applied potential.

[0240] In sequence number 118, the regions that interact with the transmembrane pores are typically 1, 2, 3, 4, 5, 6, 1, 176, 177, 178, 179, 180, 181, 185, 189, 191, 193, 194, 195, 197, 198, 199, 200, 201, 202, 203, 204, 207, 208, 209, 210, 211, 212, 213 The amino acids are located at positions 216, 219, 220, 221, 223, 224, 226, 227, 228, 229, 247, 254, 255, 256, 257, 258, 259, 260, 261, 298, 300, 304, 308, 318, 319, 321, 337, 347, 350, 351, 405, 415, 422, 434, 437, and 438. These numbers correspond to the relevant positions in SEQ ID NO: 118 and may need to be changed in the case of variants in which one or more amino acids are inserted or deleted compared to SEQ ID NO: 118. Those skilled in the art can determine the corresponding positions in the variant as described above. The portion that interacts with the transmembrane pore is preferably, (a) Positions 1, 2, 4, 51, 177, 178, 179, 180, 185, 193, 195, 197, 198, 199, 200, 202, 203, 204, 207, 208, 209, 210, 211, 212, 216, 221, 223, 224, 226, 227, 228, 229, 254, 255, 256, 257, 258, 260, 304, 318, 321, 347, 350, 351, 405, 415, 422, 434, 437 and 438 of Sequence ID No. 118; or (b) SEQ ID NO: 118 contains amino acids at positions 1, 2, 178, 179, 180, 185, 195, 197, 198, 199, 200, 202, 203, 207, 209, 210, 212, 216, 221, 223, 226, 227, 255, 258, 260, 304, 350 and 438.

[0241] The portion that interacts with the transmembrane pore preferably contains one or more amino acids, e.g., 2, 3, 4, or 5, at positions K194, W195, K198, K199, and E258 of SEQ ID NO: 118. Variants of SEQ ID NO: 118 preferably include modifications to one or more of (a) K194, (b) W195, (c) D198, (d) K199, and (d) E258. Variants of SEQ ID NO: 118 preferably include substitutions at one or more of (a) K194, e.g., K194L, (b) W195, e.g., W195A, (c) D198, e.g., D198V, (d) K199, e.g., K199L, and (e) E258, e.g., E258L. The variants are {a};{b};{c};{d};{e};{a,b};{a,c};{a,d};{a,e};{b,c};{b,d};{b,e};{c,d};{c,e};{d,e};{a,b,c};{a,b,d};{a,b,e};{a,c,d} {a,c,e};{a,d,e};{b,c,d};{b,c,e};{b,d,e};{c,d,e};{a,b,c,d};{a,b,c,e};{a,b,d,e};{a,c,d,e};{b,c,d,e}; or {a,b,c,d,e}. When a modified polynucleotide-binding protein interacts with a pore derived from MspA, particularly one of the modified pores discussed below, the modifications or substitutions shown in this paragraph are preferred.

[0242] The portion of the polynucleotide-binding protein that interacts with the transmembrane pore preferably contains the amino acid at position 194 or 199 of SEQ ID NO: 118. The variant preferably contains K194A, K194V, K194F, K194D, K194S, K194W or K194L and / or K199A, K199V, K199F, K199D, K199S, K199W or K199L. In SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132 or 133, the portion that interacts with the transmembrane pore typically contains an amino acid at the position corresponding to the amino acid of SEQ ID NO: 118 listed above. The amino acids in sequence numbers 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, and 133, which correspond to these positions in sequence number 118, can be identified using the alignment in Table 5 below. [Table 5]

[0243] Preferred combination The helicase of the present invention preferably includes a variant of SEQ ID NO: 118 further comprising substitutions in F98, such as F98R, F98K, F98Q, F98N, F98H, F98Y, F98F, or F98W, and substitutions in K194, such as K194A, K194V, K194F, K194D, K194S, K194W, or K194L, and / or K199, such as K199A, K199V, K199F, K199D, K199S, K199W, or K199L. The helicase of the present invention preferably comprises variants of SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, which further comprises substitutions at the position corresponding to F98 in SEQ ID NO: 118, and substitutions at the positions corresponding to K194 and / or K199 in SEQ ID NO: 118. These corresponding positions may be replaced with any of the amino acids listed above for F98, K194, and K119 in SEQ ID NO: 118.

[0244] Helicase is preferably, F98 / K194 / H64 models such as F98W / K194L / H64N, F98W / K194L / H64Q, F98W / K194L / H64K, or F98W / K194L / H64F; F98 / K194 / T80, such as F98W / K194L / T80K, F98W / K194L / T80Q, or F98W / K194L / T80N; F98W / K194L / H82N, F98W / K194L / H82Q, or F98W / K194L / H82W, etc. F98 / S83 / K194, such as F98W / S83H / K194L, F98W / S83T / K194L, F98W / S83R / K194L, F98W / S83Q / K194L, F98W / S83N / K194L, F98W / S83K / K194L, F98W / N88R / K194L, F98W / N88H / K194L, F98W / N88W / K194L, or F98W / N88Y / K194L; F98 / S83 / K194 / F276K and other F98 / S83 / K194 / F276 models; F98 / P89 / K194, such as F98W / P89L / K194L, F98W / P89V / K194L, F98W / P89I / K194L, or F98W / P89T / K194L; F98 / D121 / K194, such as F98W / D121H / K194L, F98W / D121Y / K194L, or F98W / D121K / K194L; F98 / V150 / K194, such as F98W / V150I / K194L, F98W / V150L / K194L, F98W / V150N / K194L, F98W / V150W / K194L, or F98W / V150H / K194L; F98 / P152 / K194, such as F98W / P152H / K194L, F98W / P152F / K194L, F98W / P152Y / K194L, F98W / P152H / K194L, F98W / P152I / K194L, F98W / P152L / K194L, or F98W / P152V / K194L; F98 / F240 / K194L, F98W / F240Y / K194L, or F98W / F240H / K194L, etc. F98 / N242 / K194, such as F98W / N242H / K194L or F98W / N242Q / K194L; F98 / K194 / F276 models such as F98W / K194L / F276K, F98W / K194L / F276H, F98W / K194L / F276W, or F98W / K194L / F276R; F98 / K194 / S287 models such as F98W / K194L / S287K, F98W / K194L / S287R, F98W / K194L / S287W, or F98W / K194L / S287F; F98 / N293 / K194 such as F98W / N293Q / K194L, F98W / N293K / K194L, or F98W / N293H / K194L; F98 / T394 / K194, such as F98W / T394K / K194L, F98W / T394H / K194L, or F98W / T394N / K194L; F98 / H396 / K194, such as F98W / H396Y / K194L, F98W / H396F / K194L, F98W / H396Q / K194L, or F98W / H396K / K194L; F98 / K397 / K194 such as F98W / K397R / K194L, F98W / K397H / K194L, or F98W / K397Y / K194L; or This is a variant of sequence number 118 that further includes substitutions for F98 / Y415 / K194, such as F98W / Y415W / K194L or F98W / Y415R / K194L.

[0245] In any of the above combinations, K194 can be replaced with any of W195, D198, K199, or E258.

[0246] The modified helicase preferably further includes modifications or substitutions at the positions corresponding to amino acid positions 98 and / or 194 in Dda 1993. Position 98 or the corresponding position may be substituted with R, H, K, S, T, N, Q, A, V, I, L, M, Y, or W. Position 98 or the corresponding position is preferably substituted with R, K, Q, N, H, Y, or W. Position 194 or the corresponding position may be substituted with A, V, I, L, M, F, Y, W, D, E, S, T, N, or Q. Positions 118 and 194 or the corresponding position are preferably substituted with A, V, F, D, S, W, or L. The helicase of the present invention preferably includes substitutions in F98 such as F98R, F98K, F98Q, F98N, F98H, F98Y, or F98W, and / or substitutions in K194, such as K194A, K194A, K194A, K194A, K194A, K194A, K194A, K194A, K, K194F, K194D, K194S, K194W, or K194L. The helicase of the present invention preferably includes a variant of SEQ ID NO: 118 further comprising F98W and K194L. The helicase of the present invention preferably includes variants of sequence numbers 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, further comprising substitution at the position corresponding to F98 of sequence number 118 and / or substitution at the position corresponding to K194 of sequence number 118.

[0247] In any of the above combinations, K194 can be replaced with any of W195, D198, K199, or E258.

[0248] Modifications in tower domains and / or pin domains and / or 1A domains The modified helicase preferably further includes a modification or substitution at the position corresponding to amino acid position 360 of Dda 1993. Position 360 or the corresponding position may be substituted with C, G, P, A, V, I, L, M, F, Y, or W. Position 360 or the corresponding position is preferably substituted with C or Y. The helicase of the present invention preferably includes a variant of SEQ ID NO: 118 further including a substitution at A360 such as A360C or A360Y. The helicase of the present invention preferably includes a variant of SEQ ID NO: 118 further including K358I and A360C. The helicase of the present invention preferably includes variants of SEQ ID NO: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133 which include a substitution at the position corresponding to A360 of SEQ ID NO: 118.

[0249] The modified helicase preferably further includes modification or substitution of one or more positions corresponding to amino acid positions 94, 98, and 109 in Dda 1993, for example, positions 94, 98, 109, 94 and 98, 94 and 109, 98 and 109, and 94, 98 and 109. All of these positions are in the pin domain. Position 94 or the corresponding position may be substituted with C, G, P, A, V, I, L, M, F, Y, or W. Position 94 or the corresponding position is preferably substituted with C or Y. Position 98 or the corresponding position may be substituted with R, H, K, S, T, N, Q, A, V, I, L, MY, or W. Position 98 or the corresponding position is preferably substituted with R, K, Q, N, H, Y, or W. Position 109 or the corresponding position may be substituted with A, V, I, L, M, F, Y, or W. Position 109 or the corresponding position is preferably substituted with A or V. The helicase of the present invention preferably includes a variant of SEQ ID NO: 118 further comprising substitution with one or more of E94, F98 and C109 (including all combinations set above). Preferred variants are: E94C or E94Y and E94 and F98 such as F98R, F98K, F98Q, F98N, F98H, F98Y, F98F or F98W; E94 and C109, such as E94C or E94Y and C109A or C109V; F98 and C109 such as F98R, F98K, F98Q, F98N, F98H, F98Y, F98F or F98W and C109A or C109V; or This includes substitutions for E94, F98, and C109, such as E94C or E94Y and F98R, F98K, F98Q, F98N, F98H, F98Y, F98F or F98W and C109A or C109V.

[0250] More preferred variants include E94C and F98W; E94C and C109A; F98W and C109A; or E94C, F98W and C109A. The helicases of the present invention preferably include variants of sequence numbers 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, which further include substitutions at positions corresponding to one or more of E94, F98, and C109 of sequence number 118.

[0251] Table 6 contains information on E94, C109, C136, and A360 (see the modified helicases disclosed above and below). [Table 6]

[0252] The helicase of the present invention preferably has at least one cysteine ​​residue (i.e., one or more cysteine ​​residues) and / or at least one non-natural amino acid (i.e., one or more non-natural amino acids) further introduced into (i) the tower domain and / or (ii) the pin domain and / or (iii) the 1A (RecA-like motor) domain, and the helicase has the ability to control the movement of polynucleotides. These types of modifications are disclosed in International Publication 2015 / 055981 (which is incorporated herein by reference in its entirety). At least one cysteine ​​residue and / or at least one non-natural amino acid may be introduced into the tower domain, pin domain, 1A domain, tower domain and pin domain, tower domain and 1A domain, or tower domain, pin domain and 1A domain.

[0253] The helicase of the present invention preferably has at least one cysteine ​​residue and / or at least one non-natural amino acid introduced into each of (i) the tower domain and (ii) the pin domain and / or the 1A (RecA-like motor) domain, i.e., the tower domain and the pin domain, the tower domain and the 1A domain, or the tower domain, the pin domain and the 1A domain.

[0254] Any number of cysteine ​​residues and / or non-natural amino acids can be introduced into each domain. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more cysteine ​​residues may be introduced, and / or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more non-natural amino acids may be introduced. Only one or more cysteine ​​residues may be introduced. Only one or more non-natural amino acids may be introduced. A combination of one or more cysteine ​​residues and one or more non-natural amino acids may be introduced.

[0255] At least one cysteine ​​residue and / or at least one non-natural amino acid are preferably introduced by substitution. Methods for doing so are known in the art.

[0256] These modifications do not prevent the helicase from binding to the polynucleotide. Instead, they reduce the polynucleotide's ability to debond or detach from the helicase. In other words, one or more modifications enhance the processability of the helicase by preventing dissociation from the polynucleotide chain. The thermal stability of the enzyme is also typically increased by one or more modifications, thereby providing improved structural stability that is beneficial in strand sequencing.

[0257] Non-natural amino acids are amino acids not found naturally in helicase. Preferably, non-natural amino acids are not histidine, alanine, isoleucine, arginine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, proline, serine, or tyrosine. More preferably, non-natural amino acids are not any of the 20 amino acids mentioned above or selenocysteine.

[0258] Preferred non-natural amino acids for use in the present invention include 4-azido-L-phenylalanine (Faz), 4-acetyl-L-phenylalanine, 3-acetyl-L-phenylalanine, 4-acetoacetyl-L-phenylalanine, O-allyl-L-tyrosine, 3-(phenylceranyl)-L-alanine, O-2-propyne-1-yl-L-tyrosine, 4-(dihydroxyboryl)-L-phenylalanine, 4-[(ethylsulfanyl)carbonyl]-L-phenylalanine, (2S)-2-amino-3-4- [(propan-2-ylsulfanyl)carbonyl]phenyl;propanoic acid;(2S)-2-amino-3-4-[(2-amino-3-sulfanylpropanoyl)amino]phenyl;propanoic acid, O-methyl-L-tyrosine, 4-amino-L-phenylalanine, 4-cyano-L-phenylalanine, 3-cyano-L-phenylalanine, 4-fluoro-L-phenylalanine, 4-iodo-L-phenylalanine, 4-bromo-L-phenylalanine, O-(trifluoromethyl)tyrosine, 4-nitro-L-phenyl Nylalanine, 3-hydroxy-L-tyrosine, 3-amino-L-tyrosine, 3-iodo-L-tyrosine, 4-isopropyl-L-phenylalanine, 3-(2-naphthyl)-L-alanine, 4-phenyl-L-phenylalanine, (2S)-2-amino-3-(naphthalene-2-ylamino)propanoic acid, 6-(methylsulfanyl)norleucine, 6-oxo-L-lysine, D-tyrosine, (2R)-2-hydroxy-3-(4-hydroxyphenyl)propanoic acid, (2R)-2-ammoriooctanoate-3- (2,2'-bipyridine-5-yl)-D-alanine, 2-amino-3-(8-hydroxy-3-quinolyl)propanoic acid, 4-benzoyl-L-phenylalanine, S-(2-nitrobenzyl)cysteine, (2R)-2-amino-3-[(2-nitrobenzyl)sulfanyl]propanoic acid, (2S)-2-amino-3-[(2-nitrobenzyl)oxy]propanoic acid, O-(4,5-dimethoxy-2-nitrobenzyl)-L-serine, (2S)-2-amino-6-([(2-nitrobenzyl)oxy]carbonyl;Amino)hexanoic acid, O-(2-nitrobenzyl)-L-tyrosine, 2-nitrophenylalanine, 4-[(E)-phenyldiazenyl]-L-phenylalanine, 4-[3-(trifluoromethyl)-3H-diadilen-3-yl]-D-phenylalanine, 2-amino-3-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]propanoic acid, (2S)-2-amino-4-(7-hydroxy-2-oxo-2H-chromen-4-yl)butanoic acid, (2S )-3-[(6-acetylnaphthalene-2-yl)amino]-2-aminopropanoic acid, 4-(carboxymethyl)phenylalanine, 3-nitro-L-tyrosine, O-sulfo-L-tyrosine, (2R)-acetamido-2-ammoniohexanoate, 1-methylhistidine, 2-aminohistidine, 2-aminodecanoic acid, L-homocysteine, 5-sulfanylnorvaline, 6-sulfanyl-L-norleucine, 5-(methylsulfanyl)-L-norvaline, N; 6 -[(2R,3R)-3-methyl-3,4-dihydro-2H-pyrrole-2-yl]carbonyl;-L-lysine, N 6 -[(benzyloxy)carbonyl]lysine, (2S)-2-amino-6-[(cyclopentylcarbonyl)amino]hexanoic acid, N 6 -[(cyclopentyloxy)carbonyl]-L-lysine, (2S)-2-amino-6-[(2R)-tetrahydrofuran-2-ylcarbonyl]aminohexanoic acid, (2S)-2-amino-8-[(2R,3S)-3-ethynyltetrahydrofuran-2-yl]-8-oxooctanoic acid, N 6 -(tert-butoxycarbonyl)-L-lysine, (2S)-2-hydroxy-6-([(2-methyl-2-propanyl)oxy]carbonyl;amino)hexanoic acid, N 6 -[(allyloxy)carbonyl]lysine, (2S)-2-amino-6-([(2-azidobenzyl)oxy]carbonyl;amino)hexanoic acid, N 6 -L-Prolyl-L-Lysine, (2S)-2-amino-6-[(propa-2-in-1-yloxy)carbonyl]amino;Hexanoic acid and N 6-[(2-azidoethoxy)carbonyl]-L-lysine is an example, but is not limited to, this. The most preferred non-natural amino acid is 4-azido-L-phenylalanine (Faz).

[0259] Table 7 below (separated into two parts) identifies the residues that make up each domain of each Dda homolog (SEQ ID NOs. 118-133). [Table 7] [Table 8]

[0260] The helicase of the present invention preferably comprises a variant of Sequence ID No. 118 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues D260-P274 and N292-A389) and / or (ii) the pin domain (residues K86-E102) and / or (iii) the 1A domain (residues M1-L85 and V103-K177). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residue N292-A389 of the tower domain.

[0261] The helicase of the present invention preferably comprises a variant of Sequence ID No. 119 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues G295-N309 and F316-Y421) and / or (ii) the pin domain (residues Y85-L112) and / or (iii) the 1A domain (residues M1-I84 and R113-Y211). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues F316-Y421 of the tower domain.

[0262] The helicase of the present invention preferably comprises a variant of Sequence ID No. 120 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues V328-P342 and N360-Y448) and / or (ii) the pin domain (residues K148-N165) and / or (iii) the 1A domain (residues M1-L147 and S166-V240). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N360-Y448 of the tower domain.

[0263] The helicase of the present invention preferably comprises a variant of Sequence ID No. 121 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues A261-T275 and T285-Y370) and / or (ii) the pin domain (residues G91-E107) and / or (iii) the 1A domain (residues M1-L90 and E108-H173). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues T285-Y370 of the tower domain.

[0264] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 122 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues G294-I307 and T314-Y407) and / or (ii) the pin domain (residues G116-T135) and / or (iii) the 1A domain (residues M1-L115 and N136-V205). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues T314-Y407 of the tower domain.

[0265] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 123 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues V288-E301 and N307-N393) and / or (ii) the pin domain (residues G97-P113) and / or (iii) the 1A domain (residues M1-L96 and F114-V194). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N307-N393 of the tower domain.

[0266] The helicase of the present invention preferably comprises a variant of Sequence ID No. 124 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues S250-P264 and E278-S371) and / or (ii) the pin domain (residues K78-E95) and / or (iii) the 1A domain (residues M1-L77 and V96-V166). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues E278-S371 of the tower domain.

[0267] The helicase of the present invention preferably comprises a variant of Sequence ID No. 125 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues K255-P269 and T284-S380) and / or (ii) the pin domain (residues K82-K98) and / or (iii) the 1A domain (residues M1-M81 and L99-M171). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues T284-S380 of the tower domain.

[0268] The helicase of the present invention preferably comprises a variant of Sequence ID No. 126 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues D242-P256 and T271-S366) and / or (ii) the pin domain (residues K69-K85) and / or (iii) the 1A domain (residues M1-M68 and M86-M158). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues T271-S366 of the tower domain.

[0269] The helicase of the present invention preferably comprises a variant of Sequence ID No. 127 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues T263-P277 and N295-P392) and / or (ii) the pin domain (residues K88-K107) and / or (iii) the 1A domain (residues M1-L87 and A108-M181). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N295-P392 of the tower domain.

[0270] The helicase of the present invention preferably comprises a variant of Sequence ID No. 128 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues D263-P277 and N295-A391) and / or (ii) the pin domain (residues K88-K107) and / or (iii) the 1A domain (residues M1-L87 and A108-M181). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N295-A391 of the tower domain.

[0271] The helicase of the present invention preferably comprises a variant of Sequence ID No. 129 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues A258-P272 and N290-P386) and / or (ii) the pin domain (residues K86-G102) and / or (iii) the 1A domain (residues M1-L85 and T103-K176). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N290-P386 of the tower domain.

[0272] The helicase of the present invention preferably comprises a variant of Sequence ID No. 130 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues L266-P280 and N298-A392) and / or (ii) the pin domain (residues K92-D108) and / or (iii) the 1A domain (residues M1-L91 and V109-M183). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N298-A392 of the tower domain.

[0273] The helicase of the present invention preferably comprises a variant of Sequence ID No. 131 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues D262-P276 and N294-A392) and / or (ii) the pin domain (residues K88-E104) and / or (iii) the 1A domain (residues M1-L87 and M105-M179). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues N294-A392 of the tower domain.

[0274] The helicase of the present invention preferably comprises a variant of Sequence ID No. 132 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues D261-P275 and N293-A389) and / or (ii) the pin domain (residues K87-E103) and / or (iii) the 1A domain (residues M1-L86 and V104-K178). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residue N293-A389 of the tower domain.

[0275] The helicase of the present invention preferably comprises a variant of Sequence ID No. 133 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into (i) the tower domain (residues E261-P275 and T293-A390) and / or (ii) the pin domain (residues K87-E103) and / or (iii) the 1A domain (residues M1-L86 and V104-M178). The at least one cysteine ​​residue and / or at least one non-natural amino acid is preferably introduced into residues T293-A390 of the tower domain.

[0276] The helicase of the present invention preferably comprises one variant of SEQ ID NOs: 118-133, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into each of (i) the tower domain and (ii) the pin domain and / or the 1A domain. The helicase of the present invention more preferably comprises one variant of SEQ ID NOs: 118-133, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into each of (i) the tower domain, (ii) the pin domain and (iii) the 1A domain. Any number and combination of cysteine ​​residues and non-natural amino acids can be introduced as described above.

[0277] The helicase of the present invention is preferably (i) E94C and / or A360C; (ii) E93C and / or K358C; (iii) E93C and / or A360C; (iv) E93C and / or E361C; (v) E93C and / or K364C; (vi) E94C and / or L354C; (vii) E94C and / or K358C; (viii) E93C and / or L354C; (ix) E94C and / or E361C; (x) E94C and / or K364C; (xi) L97C and / or L354C; (xii) L97C and / or K358C; ( xiii) L97C and / or A360C; (xiv) L97C and / or E361C; (xv) L97C and / or K364C; (xvi) K123C and / or L354C; (xvii) K123C and / or K358C; (xviii) K123C and / or A360C; (xix) K123C and / or E361C; (xx) K123C and / or K364C; (xxi) N155C and / or L354C; (xxii) N155C and / or K358C; (xxiii) N155C and / or A360C; (xxiv) N155C and / or E361C; (xxv)N155C and / or K364C; (xxvi)(i)~(xxv) and any of G357C; (xxvii)(i)~(xxv) and any of Q100C; (xxviii)(i)~(xxv) and any of I127C; (xxix)(i)~(xxv) and any of Q100C and I127C; (xxx)E94C and / or F377C; (xxxi)N95C; (xxxii)T91C; (xxxiii)Y92L, E94Y, Y350N, A360C and Y363N; (xxxiv)E94Y and A360C; (xxxv)A360C; (xxxvi)Y92L, E94C, Y350N, A360Y and Y363N; (xxxvii)Y92L, E94C and A360Y; (xxxviii)E94C and / or A360C and F276A; (xxxix)E94C and / or L356C; (xl)E93C and / or E356C; (xli)E93C and / or G357C; (xlii)E93C and / or A360C; (xliii)N95C and / or W378C; (xliv)T91C and / or S382C; (xlv)T91C and / or W378C;(xlvi)E93C and / or N353C; (xlvii)E93C and / or S382C; (xlviii)E93C and / or K381C; (xlix)E93C and / or D379C; (l)E93C and / or S375C; (li)E93C and / or W378C; (lii)E93C and / or W374C; (liii)E94C and / or N353C; (liv)E94C and / or S382C; (lv)E94C and / or K381C; (lvi)E94C and / or D379C; (lvii)E94C and / or S375C; (lviii)E94C and / or W378C; (lix)E94C and / or W374C; (lx)E94C and A360Y; (lxi)E94C, G357C and A360C or (lxii)T2C, E94C and A360C, further comprising variants of Sequence ID No. 118. It is preferable that any one of (i) to (lxii) is and / or and.

[0278] The helicase of the present invention preferably comprises one variant of SEQ ID NOs: 118-133, further comprising a cysteine ​​residue at the position corresponding to SEQ ID NOs: 119 as defined in any of (i)-(lxii). The position of any one of SEQ ID NOs: 119-133 corresponding to SEQ ID NOs: 118 can be identified using the following alignment of SEQ ID NOs: 118-133. The helicase of the present invention preferably comprises a variant of SEQ ID NOs: 92, further comprising (a) D99C and / or L341C, (b) Q98C and / or L341C, or (d) Q98C and / or A340C. The helicase of the present invention preferably comprises a variant of SEQ ID NOs: 96, further comprising D90C and / or A349C. The helicase of the present invention preferably comprises a variant of SEQ ID NOs: 102, further comprising D96C and / or A362C.

[0279] The helicase of the present invention preferably includes one variant of SEQ ID NOs. 118-133 as defined in any one of (i)-(lxii), wherein faz is further introduced in place of cysteine ​​at one or more specific positions. Faz may be introduced in place of cysteine ​​at each specific position. The helicase of the present invention preferably includes variants of Sequence ID No. 118, further comprising (i) E94Faz and / or A360C; (ii) E94C and / or A360Faz; (iii) E94Faz and / or A360Faz; (iv) Y92L, E94Y, Y350N, A360Faz and Y363N; (v) A360Faz; (vi) E94Y and A360Faz; (vii) Y92L, E94Faz, Y350N, A360Y and Y363N; (viii) Y92L, E94Faz and A360Y; (ix) E94Faz and A360Y; and (x) E94C, G357Faz and A360C.

[0280] The helicase of the present invention preferably further comprises one or more single amino acid deletions from the pin domain. Any number of single amino acid deletions may be made, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. The helicase preferably comprises a variant of SEQ ID NO: 118 further comprising a deletion of E93, a deletion of E95, or deletions of E93 and E95. The helicase preferably comprises a variant of SEQ ID NO: 118 comprising (a) deletions of E94C, N95 and A360C; (b) deletions of E93, E94, N95 and A360C; (c) deletions of E93, E94C, N95 and A360C, or (d) deletions of E93C, N95 and A360C. The helicase of the present invention preferably comprises one variant of sequence numbers 118 to 133, further comprising a deletion at the position corresponding to E93 of sequence number 119, a deletion at the position corresponding to E95 of sequence number 118, or deletions at the positions corresponding to E93 and E95 of sequence number 118.

[0281] The helicase of the present invention preferably further comprises one or more single amino acid deletions from the hook domain. Any number of single amino acid deletions may be made, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. The helicase preferably comprises a variant of SEQ ID NO: 118 further comprising any number of deletions at positions T278-S287. The helicase more preferably comprises a variant of SEQ ID NO: 118 further comprising (a) deletion of E94C, Y279-K284 and A360C, (b) deletion of E94C, T278, Y279, V286 and S287 and A360C, (c) deletion of E94C, I281 and K284 and substitution with a single G and A360C, (d) deletion of E94C, K280 and P2845 and substitution with a single G and A360C, or (e) deletion of Y279-K284, E94C, F276A and A230C. The helicase of the present invention preferably comprises one variant of SEQ ID NO: 118-133 further comprising deletions at any number of positions corresponding to 278-287 of SEQ ID NO: 119.

[0282] The helicase of the present invention preferably further comprises one or more single amino acid deletions from the pin domain and one or more single amino acid deletions from the hook domain.

[0283] The helicase of the present invention preferably has at least one cysteine ​​residue and / or at least one non-natural amino acid further introduced into the hook domain and / or 2A (RecA-like) domain. As described above for the tower domain, pin domain and 1A domain, any number and combination of cysteine ​​residues and non-natural amino acids can be introduced.

[0284] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 118, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L275-F291) and / or the 2A (RecA-like) domain (residues R178-T259 and L390-V439).

[0285] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 119, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues A310-L315) and / or the 2A (RecA-like) domain (residues R212-E294 and G422-S678).

[0286] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 120 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues V343-L359) and / or the 2A (RecA-like) domain (residues R241-N327 and A449-G496).

[0287] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 121 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues W276-L284) and / or the 2A (RecA-like) domain (residues R174-D260 and A371-V421).

[0288] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 122 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues R308-Y313) and / or the 2A (RecA-like) domain (residues R206-K293 and I408-L500).

[0289] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 123, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues M302-W306) and / or the 2A (RecA-like) domain (residues R195-D287 and V394-Q450).

[0290] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 124, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues V265-I277) and / or the 2A (RecA-like) domain (residues R167-T249 and L372-N421).

[0291] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 125 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues V270-F283) and / or the 2A (RecA-like) domain (residues R172-T254 and L381-K434).

[0292] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 126 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues V257-F270) and / or the 2A (RecA-like) domain (residues R159-T241 and L367-K420).

[0293] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 127, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L278-Y294) and / or the 2A (RecA-like) domain (residues R182-T262 and L393-V443).

[0294] The helicase of the present invention preferably comprises a variant of Sequence ID No. 128 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L278-Y294) and / or the 2A (RecA-like) domain (residues R182-T262 and L392-V442).

[0295] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 129, wherein at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L273-F289) and / or the 2A (RecA-like) domain (residues R177-N257 and L387-V438).

[0296] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 130 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L281-F297) and / or the 2A (RecA-like) domain (residues R184-T265 and L393-I442).

[0297] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 131 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues H277-F293) and / or the 2A (RecA-like) domain (residues R180-T261 and L393-V442).

[0298] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 132 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L276-F292) and / or the 2A (RecA-like) domain (residues R179-T260 and L390-I439).

[0299] The helicase of the present invention preferably comprises a variant of SEQ ID NO: 133 in which at least one cysteine ​​residue and / or at least one non-natural amino acid is further introduced into the hook domain (residues L276-F292) and / or the 2A (RecA-like) domain (residues R179-T260 and L391-V441).

[0300] The helicase of the present invention preferably includes a variant of Sequence ID No. 118, further comprising one or more of (i)I181C; (ii)Y279C; (iii)I281C; and (iv)E288C. The helicase may include any combination of (i) to (iv), for example, (i); (ii); (iii); (iv); (i) and (ii); (i) and (iii); (i) and (iv); (ii) and (iii); (ii) and (iv); (iii) and (iv); or (i), (ii), (iii) and (iv). The helicase more preferably includes a variant of Sequence ID No. 118, comprising (a)E94C, I281C and A360C or (b)E94C, I281C, G357C and A360C. The helicase of the present invention preferably comprises any one variant of SEQ ID NOs: 118-133, further comprising a cysteine ​​residue in one or more of the positions corresponding to those in SEQ ID NOs: 119 as defined in (i)-(iv), (a) and (b). The helicase may comprise any of these variants in which Faz is introduced in place of cysteine ​​at one or more specific positions (or each specific position).

[0301] The helicase of the present invention is preferably further modified to reduce its surface negative charge. Surface residues can be identified in the same manner as the Dda domain disclosed above. The surface negative charge is typically a surface negatively charged amino acid such as aspartic acid (D) and glutamic acid (E).

[0302] Helicases are modified to neutralize one or more surface negative charges, preferably by substituting one or more negatively charged amino acids with one or more positively charged amino acids, uncharged amino acids, nonpolar amino acids, and / or aromatic amino acids, or by introducing one or more positively charged amino acids, preferably one or more positively charged amino acids adjacent to one or more negatively charged amino acids. Suitable positively charged amino acids include, but are not limited to, histidine (H), lysine (K), and arginine (R). Uncharged amino acids have no net charge. Suitable uncharged amino acids include, but are not limited to, cysteine ​​(C), serine (S), threonine (T), methionine (M), asparagine (N), and glutamine (Q). Nonpolar amino acids have nonpolar side chains. Suitable nonpolar amino acids include, but are not limited to, glycine (G), alanine (A), proline (P), isoleucine (I), leucine (L), and valine (V). Aromatic amino acids have aromatic side chains. Suitable aromatic amino acids include, but are not limited to, histidine (H), phenylalanine (F), tryptophan (W), and tyrosine (Y).

[0303] Preferred substitutions include, but are not limited to, the substitution of E with R, E with K, E with N, D with K, and D with R.

[0304] The helicase of the present invention preferably comprises the variant of SEQ ID NO: 118, wherein one or more negatively charged amino acids are one or more of D5, E8, E23, E47, D167, E172, D202, D212, and E273. Any number of these amino acids, for example, 1, 2, 3, 4, 5, 6, 7, or 8, can be neutralized. Any combination can be neutralized. The helicase of the present invention preferably comprises one variant of SEQ ID NO: 119 to 133, wherein one or more negatively charged amino acids correspond to one or more of D5, E8, E23, E47, D167, E172, D202, D212, and E273 of SEQ ID NO: 118. The amino acids of Sequence IDs 118-133, corresponding to D5, E8, E23, E47, D167, E172, D202, D212, and E273 of Sequence ID 119, can be determined using the alignment of International Publication No. 2015 / 055981. The helicase of the present invention preferably comprises (a) E94C, E273G, and A360C or (b) a variant of Sequence ID 118 comprising E94C, E273G, N292G, and A360C.

[0305] The helicase of the present invention is preferably further modified by the removal of one or more native cysteine ​​residues. Any number of native cysteine ​​residues can be removed. One or more cysteine ​​residues are preferably removed by substitution. One or more cysteine ​​residues are preferably substituted with alanine (A), serine (S), or valine (V). The helicase of the present invention preferably comprises the variant of SEQ ID NO: 118, where one or more native cysteine ​​residues are one or more of C109, C114, C136, C171, and C412. Any number and combination of these cysteine ​​residues can be removed. For example, variants of sequence number 118 are C109;C114;C136;C171;C412;C109 and C114;C109 and C136;C109 and C171;C109 and C412;C114 and C136;C114 and C171;C114 and C412;C136 and C171;C136 and C412;C171 and C412;C109, C114 and C136;C109, C114 and C171;C109, C114 and C412;C109, C136 and C171;C109, C13 6 and C412; C109, C171 and C412; C114, C136 and C171; C114, C136 and C412; C114, C171 and C412; C136, C171 and C412; C109, C114, C136 and C171; C109, C114, C136 and C412; C109, C114, C171 and C412; C109, C136, C171 and C412; C114, C136, C171 and C412; or may include C109, C114, C136, C171 and C412.

[0306] The modified helicase preferably further includes modifications or substitutions at positions corresponding to amino acid positions 109 and / or 136 in Dda 1993. This results in the removal of one or two cysteine ​​residues. This may include modifications or substitutions at one or more positions corresponding to amino acid positions 55, 114, 156, 177, 210, 221, 350 and 358 of Dda 1993, as well as modifications or substitutions at one or more positions corresponding to amino acid positions 114, 177, 350 and 358 of Dda 1993, and / or modifications or substitutions at the position corresponding to position 40 of Dda 1993. Position 109 or the corresponding position may be substituted with A, V, I, L, M, F, Y or W. Position 109 or the corresponding position is preferably substituted with A or V. Position 136 or the corresponding position is preferably substituted with A, V, I, L, M, F, Y or W. Position 136 or the corresponding position is preferably substituted with A or V. The helicase of the present invention includes variants of SEQ ID NO: 118, further comprising substitution with C109, e.g., C109A, C109V, C109I, C109L, C109M, C109F, C109Y or C109W and / or C136, e.g., C136A, C136V, C136I, C136L, C136T, C136M, C136F, C136Y or C136W. The helicase of the present invention preferably includes variants of SEQ ID NO: 118, further comprising C109A and / or C136A. The helicase of the present invention preferably comprises variants of SEQ ID NOs: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133, which further include substitutions at positions corresponding to C109 and / or C136 of SEQ ID NO: 118. The helicase of the present invention preferably further comprises at least one cysteine ​​residue (i.e., one or more cysteine ​​residues) and / or at least one non-natural amino acid (i.e., one or more non-natural amino acids) introduced only into the tower domain. Appropriate modifications are discussed above.

[0307] The helicase of the present invention preferably has the following mutations: E93C and K364C; E94C and K364C; E94C and A360C; L97C and E361C; L97C and E361C and C412A; K123C and E361C; K123C, E361C and C412A; N155C and K358C; N155C, K358C and C412A; N155C and L354C; N155C, L354C and C412A; ΔE93, E94C, ΔN95 and A360C; E94C, ΔN95 and A360C; E94C, Q100C, I127C and A36 0C;L354C;G357C;E94C, G357C and A360C;E94C, Y279C and A360C;E94C, I281C and A360C;E94C, Y279Faz and A360C;Y279C and G357C;I281C and G357C;E94C, Y279C, G357C and A360C;E94C, I281C, G357C and A360C;E8R, E47K, E94C, D202K and A360C;D5K, E23N, E94C, D167K, E172R, D212R and A360C;D5K, E8R, E23N, E47K, E9 4C, D167K, E172R, D202K, D212R and A360C; E94C, C114A, C171A, A360C and C412D; E94C, C114A, C171A, A360C and C412S; E94C, C109A, C136A and A360C; E94C, C109A, C114A, C136A, C171A, A360C and C412S; E94C, C109V, C114V, C171A, A360C and C412S; C109A, C114A, C136A, G153C, C171A, E361C and C412A; C109A, C11 4A, C136A, G153C, C171A, E361C and C412D; C109A, C114A, C136A, G153C, C171A, E361C and C412S; C109A, C114A, C136A, G153C, C171A, K358C and C412A; C109A, C114A, C136A, G153C, C171A, K358C and C412D; C109A, C114A, C136A, G153C, C171A, K358C and C412S; C109A, C114A, C136A, N155C, C171A, K358C and C412A;C109A, C114A, C136A, N155C, C171A, K358C and C412D; C109A, C114A, C136A, N155C, C171A, K358C and C412S; C109A, C114A, C136A, N155C, C171A, L354C and C412A; C109A, C114A, C136A, N155C, C171A, L354C and C412D; C109A, C114A, C136A, N155C, C1 71A, L354C and C412S; C109A, C114A, K123C, C136A, C171A, E361C and C412A; C109A, C114A, K123C, C136A, C171A, E361C and C412D; C109A, C114A, K123C, C136A, C171A, E361C and C412S; C109A, C114A, K123C, C136A, C171A, K358C and C412A; C109A, C11 4A, K123C, C136A, C171A, K358C and C412D; C109A, C114A, K123C, C136A, C171A, K358C and C412S; C109A, C114A, C136A, G153C, C171A, E361C and C412A; E94C, C109A, C114A, C136A, C171A, A360C and C412D; E94C, C109A, C114V, C136A, C171A, A360C and Includes variants of sequence number 118, further including C412D;E94C, C109V, C114A, C136A, C171A, A360C and C412D;L97C, C109A, C114A, C136A, C171A, E361C and C412A;L97C, C109A, C114A, C136A, C171A, E361C and C412D;or L97C, C109A, C114A, C136A, C171A, E361C and C412S.

[0308] Modifications in the Hook Domain and / or 2A Domain In one embodiment, the helicase of the present invention further incorporates at least one cysteine ​​residue and / or at least one non-natural amino acid into the hook domain and / or the 2A(RecA-like motor) domain, and the helicase has the ability to control the movement of polynucleotides. At least one cysteine ​​residue and / or at least one non-natural amino acid are preferably incorporated into the hook domain and the 2A(RecA-like motor) domain.

[0309] Any number of cysteine ​​residues and / or non-natural amino acids can be introduced into each domain. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more cysteine ​​residues may be introduced, and / or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more non-natural amino acids may be introduced. Only one or more cysteine ​​residues may be introduced. Only one or more non-natural amino acids may be introduced. A combination of one or more cysteine ​​residues and one or more non-natural amino acids may be introduced.

[0310] At least one cysteine ​​residue and / or at least one non-natural amino acid are preferably introduced by substitution. Methods for doing so are known in the art. Appropriate modifications of the hook domain and / or 2A (RecA-like motor) domain are discussed above.

[0311] The helicase of the present invention is preferably a variant of SEQ ID NO: 118 further comprising (a) Y279C, I181C, E288C, Y279C and I181C, (b) Y279C and E288C, (c) I181C and E288C, or (d) Y279C, I181C and E288C. The helicase of the present invention preferably comprises any one variant of SEQ ID NO: 118 to 133, further comprising a mutation in one or more of the positions corresponding to SEQ ID NO: 199 as defined in (a) to (d).

[0312] Surface modification In one embodiment, the helicase is modified to reduce its surface negative charge, and the helicase has the ability to control the movement of polynucleotides. Appropriate modifications are discussed above. Any number of surface negative charges can be neutralized.

[0313] The helicase of the present invention preferably comprises the following mutations: E273G; E8R, E47K and D202K; D5K, E23N, D167K, E172R and D212R; or a variant of Sequence ID No. 118 further comprising D5K, E8R, E23N, E47K, D167K, E172R, D202K and D212R.

[0314] Other modified helicase In one embodiment, the helicase of the present invention includes a variant of SEQ ID NO: 118, further comprising A360K; Y92L and / or A360Y; Y92L, Y350N and Y363N; Y92L and / or Y363N; or Y92L.

[0315] Other modifications In addition to the specific mutations disclosed above, variants of Sequence ID No. 118 may include one or more of the following mutations: K38A; T91F; T91N; T91Q; T91W; V96E; V96F; V96L; V96Q; V96R; V96W; V96Y; P274G; V286F; V286W; V286Y; F291G; N292F; N292G; N292P; N292Y; G294Y; G294F; K364A; and W378A.

[0316] In addition to the specific mutations disclosed above, variants of Sequence ID No. 118 include K38A, E94C and A360C; H64K; E94C and A360C; H64N; E94C and A360C; H64Q; E94C and A360C; H64S; E94C and A360C; H64W, E94C and A360C; T80K, E94C and A360C; T80K, S83K, E94C, N242K, N293K and A360C; T80K, S83K, E94C, N242K, N293K, A360C and T394K; T80K, S83K, E94C, N293K and A360C; T80K, S83K, E94C, A360C and T394K; T80K, S83K, E94C, A360C and T394N; T80K, E94C, N242K and A360C; T80K, E94C, N242K, N293K and A360C; T80K, E94C, N293K and A360C; T80N, E94C and A360C; H82A, E94C and A360C; H82A, P89A, E94C, F98A and A360C; H82F, E94C and A360C; H82Q, E94C, A360C; H82R, E94C and A360C; H 82W, E94C and A360C; H82W, P89W, E94C, F98W and A360C; H82Y, E94C and A360C; S83K, E94C and A360C; S83K, T80K, E94C, A360C and T394K; S83N, E94C and A360C; S83T, E94C and A360C; N88H, E94C and A360C; N88Q, E94C and A360C; P89A, E94C and A360C; P89A, F98W, E94C and A360C; P89A, E94C, F98Y and A360C; P89A, E94C, F98A and A360C;P89F, E94C and A360C;P89S, E94C and A360C;P89T, E94C and A360C;P89W, E94C, F98W and A360C;P89Y, E94C and A360C;T91F, E94C and A360C;T91N, E94C and A360C;T91Q, E94C and A360C;T91W, E94C and A360C;E94C, V96E and A360C;E94C, V96F and A360C;E94C, V96L and A360C;E94C, V96Q and A360C;E94C, V96R and A360C;E94C, V96W and A360C; E94C, V96Y and A360C; E94C, F98A and A360C; E94C, F98L and A360C; E94C, F98V and A360C; E94C, F98Y and A360C; E94C; F98W and A360C; E94C, V150A and A360C; E94C, V150F and A360C; E94C, V150I and A360C; E94C, V150K and A360C; E94C, V150L and A360C; E94C, V150S and A360C; E94C, V150T and A360C; E94 C, V150W and A360C;E94C, V150Y and A360C;E94C, F240Y and A360C;E94C, F240W and A360C;E94C, N242K and A360C;E94C, N242K, N293K and A360C;E94C, P274G and A360C;E94C, L275G and A360C;E94C, F276A and A360C;E94C, F276I and A360C;E94C, F276M and A360C;E94C, F276V and A360C;E94C, F276W and A360C;E94C, F276Y and A360C;E94C, V286F and A360C;E94C, V286W and A360C;E94C, V286Y and A360C;E94C, S287F and A360C;E94C, S287W and A360C;E94C, S287Y and A360C;E94C, F291G and A360C;E94C, N292F and A360C;E94C, N292G and A360C;E94C, N292P and A360C;E94C, N292Y and A360C;E94C, N293F and A360C;E94C, N293K and A360C;E94C, N29 This may include 3Q and A360C; E94C, N293Y and A360C; E94C, G294F and A360C; E94C, G294Y and A360C; E94C, A36C and K364A; E94C, A360C, W378A; E94C, A360C and T394K; E94C, A360C and H396Q; E94C, A360C and H396S; E94C, A360C and H396W; E94C, A360C and Y415F; E94C, A360C and Y415K; E94C, A360C and Y415M; or E94C, A360C and Y415W.

[0317] The helicase of the present invention preferably includes a variant of Sequence ID No. 118, which further comprises (a) E94C / A360C / W378A or (b) E94C / A360C / C109A / C136A / W378A or (d) E94C / A360C / C109A / C136A / W378A, followed by (ΔM1)G1G2 (i.e., deletion of M1, followed by addition of G1 and G2).

[0318] A preferred variant of any one of Sequence IDs 118-133 is (in addition to the modifications of the present invention) in which the N-terminal methionine (M) is replaced with a single glycine residue (G). In the examples, this is shown as (ΔM1)G1. This may also be called M1G. Any of the above variants may further include M1G.

[0319] The most preferred helicase of the present invention includes variants of Sequence ID No. 118, further comprising (a) E94C / F98W / A360C / C109A / C136A / K194L, (b) M1G / E94C / F98W / A360C / C109A / C136A / K194L; (c) E94C / F98W / A360C / C109A / C136A / K199L; or (d) M1G / E94C / F98W / A360C / C109A / C136A / K199L.

[0320] Further modification / replacement The helicase of the present invention may further be modified or substituted at one or more of the following amino acid positions in Dda 1993: 86, 90, 92, 97, 101, 102, 273, 293, 300, 301, 303, 305, 308, 310, 312, 317, 323, 328, 332, 334, 335, 336, 337, 339, 351, 354, 359, 361, 364, 366, 368, 371, 374, 376, 377, 379, and 388. The helicase of the present invention may further be modified or substituted at one or more of the following amino acid positions in Dda 1993: 351, 354, and 361. Any number and combination of these modifications / substitutions can be made, including 351, 354, 361, 351 and 354, 351 and 361, 354 and 361, or 351, 354 and 361. These positions may be modified or substituted in combination with any of the above modifications or substitutions of the present invention.

[0321] The helicase of the present invention preferably has the following substitutions: K86A, V90T, Y92A, Y92D, Y92F, Y92G, Y92H, Y92N, Y92Q, Y92S, Y92T, Y92V, Y92W, L97H, K101A, E102G, E273A, N293H, I200A, I300F, E301I, E303I, Y305L, F308I, F308L, K310A, K310I, K310L, R312I, R312L, R312M, E317I, E317Y, W323H, E328I, D332A, D332L, E334A, E334I , further including a variant of sequence number 118 which includes one or more of E334Y, Y335A, Y335I, Y335L, Y336L, R337I, R337L, R337M, K339A, K339I, K339L, K351I, K351Q, L354Q, L354A, T359L, E361T, E361I, E361Q, K364A, K364R, W366L, K368A, K368I, K368L, K371I, K371L, K371M, W374A, W374L, D376S, F377A, D379A, D379L, or K388R. The helicase of the present invention preferably comprises a variant of Sequence ID No. 118 further comprising one or more of the following substitutions: (a) K351I or K351Q, (b) L354A or L354Q, and (c) E361I or E361Q. The variant may include (a), (b), (c), (a) and (b), (a) and (c), (b) and (c), or (a), (b) and (c). These substitutions can be made in combination with any of the above modifications or substitutions of the present invention.

[0322] variant Helicase variants are enzymes that have a different amino acid sequence from wild-type helicase and possess polynucleotide binding activity. In particular, any of the variants of SEQ ID NOs. 118 to 133 have a different amino acid sequence from any of the amino acid sequences of SEQ ID NOs. 118 to 133 and possess polynucleotide binding activity. Polynucleotide binding activity can be determined using methods known in the art. Suitable methods include, but are not limited to, fluorescence anisotropy, tryptophan fluorescence, and electrophoretic mobility shift assays (EMSA). For example, the ability of a variant to bind single-stranded polynucleotides can be determined as described in the examples.

[0323] The variant possesses helicase activity, which can be measured by various methods. For example, the ability of a variant to rearrange along a polynucleotide can be measured using electrophysiology, fluorescence assays, or ATP hydrolysis.

[0324] The variants may include modifications that facilitate the handling of the polynucleotide encoding the helicase and / or facilitate its activity at high salt concentrations and / or room temperature.

[0325] The variant is preferably at least 20% homologous to any one of the amino acid sequences of SEQ ID NOs. 118-133 across its entire length, based on amino acid similarity or identity. More preferably, the variant polypeptide may be at least 30%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, more preferably at least 95%, 97%, or 99% homologous to any one of the amino acid sequences of SEQ ID NOs. 118-133 across its entire sequence, based on amino acid identity. More preferably, the variant polypeptide may be at least 30%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, more preferably at least 95%, 97%, or 99% identical across the entire sequence to any one amino acid sequence of SEQ ID NOs. There may be at least 70%, for example at least 80%, at least 85%, at least 90%, or at least 95% amino acid identity across stretches of 100 or more consecutive amino acids, e.g., 150, 200, 300, 400, or 500 or more ("hard homology"). In particular, in addition to the specific modifications discussed above, any one variant of SEQ ID NOs. 118-133 may include one or more substitutions, one or more deletions, and / or one or more additions, as discussed below.

[0326] Standard methods in the art can be used to determine homology. For example, the UWGCG package provides the BESTFIT program, which can be used to calculate homology, for example, with its default settings (Devereux et al (1984) Nucleic Acids Research 12, pp. 387-395). For example, homologous sequences or sequence alignments (e.g., identifying equivalent residues or corresponding sequences (typically with their default settings)) can be calculated using the PILEUP and BLAST algorithms, as described in Altschul SF (1993) J Mol Evol 36:290-300 (Altschul, SF et al (1990) J Mol Biol 215:403-10). Software for performing BLAST analysis is publicly available from the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ).

[0327] Any one preferred variant of SEQ ID NOs. 118-133 has a non-natural amino acid such as faz at the amino(N-) terminus and / or carboxy(C-) terminus. Any one preferred variant of SEQ ID NOs. 118-133 has a cysteine ​​residue at the amino(N-) terminus and / or carboxy(C-) terminus. Any one preferred variant of SEQ ID NOs. 118-133 has a cysteine ​​residue at the amino(N-) terminus and a non-natural amino acid such as faz at the carboxy(C-) terminus, or vice versa.

[0328] Preferred variants of Sequence ID No. 118 include one or more of the following modifications E54G, D151E, I196N, and G357A, for example, all of them.

[0329] No connection In one preferred embodiment, neither the introduced cysteine ​​and / or unnatural amino acids in the modified helicase of the present invention are linked to each other.

[0330] Linkage of two or more introduced cysteine ​​and / or non-natural amino acids In another preferred embodiment, two or more introduced cysteine ​​and / or non-natural amino acids in the modified helicase of the present invention are linked to each other. This typically reduces the ability of the helicase of the present invention to debond from polynucleotides.

[0331] Any number of introduced cysteine ​​and / or non-natural amino acids, and any combination of two or more, may be linked together. For example, three, four, five, six, seven, eight or more cysteine ​​and / or non-natural amino acids may be linked together. One or more cysteine ​​may be linked to one or more other cysteine. One or more cysteine ​​may be linked to one or more other non-natural amino acids, such as faz. One or more other non-natural amino acids, such as faz, may be linked to one or more other non-natural amino acids, such as faz.

[0332] Two or more cysteine ​​and / or non-natural amino acids may be linked in any way. The linking may be transient, for example, non-covalent. Even transient linking reduces the debonding of polynucleotides from helicase.

[0333] Two or more cysteine ​​and / or non-natural amino acids are preferably linked by affinity molecules. Suitable affinity molecules are known in the art. Affinity molecules are preferably (a) complementary polynucleotides (International Publication No. 2010 / 086602, the whole of which is incorporated herein by reference), (b) antibodies or fragments thereof and complementary epitopes (Biochemistry 6th Ed, WH Freeman and co (2007) pp953-954), (c) peptide zippers (O'Shea et al., Science 254(5031):539-544), (d) molecules that can interact by β-sheet enhancement (Remaut and Waksman Trends Biochem. Sci. (2006) 31 436-444), (e) molecules that can form hydrogen bonds, π-stacking or salt crosslinks, (f) rotaxanes (Xiang Ma and He Tian Chem. Soc. Rev., 2010, 39, 70-80), and (g) aptamers and complementary proteins (James, W. in Encyclopedia of (Analytical Chemistry, RAMeyers (Ed.) pp. 4848-4871 John Wiley & Sons Ltd, Chichester, 2000) or (h) half-chelating agents (Hammerstein et al. J Biol Chem. 2011 April 22;286(16):14324-14334). (e) In this case, a hydrogen bond occurs between a proton bonded to an electronegative atom and another electronegative atom. π-stacking requires two aromatic rings that can be stacked together if the planes of the rings are parallel. Salt bridges are between groups that can delocalize their electrons across several atoms. g. Between aspartic acid and arginine

[0334] Two or more parts may be transiently concatenated by a hexa-his tag or Ni-NTA.

[0335] Two or more cysteine ​​and / or non-natural amino acids are preferably permanently linked. In the context of the present invention, the linkage is permanent if it is not cleaved while the helicase is being used, or if it cannot be cleaved without user intervention, such as by using reduction to open the disulfide bond.

[0336] Two or more cysteine ​​and / or non-natural amino acids are preferably covalently bonded. The two or more cysteine ​​and / or non-natural amino acids may be covalently bonded using any method known in the art.

[0337] Two or more cysteine ​​and / or non-natural amino acids may be covalently linked via naturally occurring amino acids such as cysteine, threonine, serine, aspartic acid, asparagine, glutamic acid, and glutamine. Naturally occurring amino acids may be modified to promote adhesion. For example, naturally occurring amino acids may be modified by acylation, phosphorylation, glycosylation, or farnesylation. Other suitable modifications are known in the art. Modifications to naturally occurring amino acids may be post-translational modifications. Two or more cysteine ​​and / or non-natural amino acids may be linked via amino acids introduced into their sequences. Such amino acids are preferably introduced by substitution. The introduced amino acids may be cysteine ​​or non-natural amino acids that promote bonding. Suitable non-natural amino acids include, but are not limited to, 4-azido-L-phenylalanine (Faz), one of the amino acids numbered 1-71 in Figure 1 of Liu CC and Schultz PG, Annu. Rev. Biochem., 2010, 79, 413-444, or one of the amino acids listed below. The introduced amino acids may be modified as described above.

[0338] In preferred embodiments, two or more cysteine ​​and / or non-natural amino acids are linked using linkers. Linker molecules are discussed in more detail below. One preferred method of linking is cysteine ​​linking, which is described in more detail below. Two or more cysteine ​​and / or non-natural amino acids are preferably linked using one or more, for example, two or three linkers. One or more linkers may be designed to reduce the size of the opening or to close the opening as described above. If one or more linkers are used to close the opening as described above, at least a portion of one or more linkers are preferably oriented so as not parallel to the polynucleotide when linked by helicase. More preferably, all linkers are oriented in this manner. If one or more linkers are used to close the opening as described above, at least a portion of one or more linkers are preferably oriented so as not parallel to the polynucleotide when linked by helicase. More preferably, all linkers are oriented so than. In these embodiments, at least a portion of one or more linkers may be perpendicular to the polynucleotide. Such orientation effectively closes the opening, preventing the polynucleotide from being detached from the helicase through the opening.

[0339] Each linker may have two or more functional ends, for example, two, three, or four functional ends. Appropriate configurations of ends in a linker are well known in the art.

[0340] Preferably, one or more ends of one or more linkers are covalently bonded to a helicase. If one or more ends are covalently bonded, one or more linkers can transiently link two or more cysteine ​​and / or non-natural amino acids as described above. If both or all ends are covalently bonded, one or more linkers permanently link two or more cysteine ​​and / or non-natural amino acids.

[0341] One or more linkers are preferably amino acid sequences and / or chemical crosslinking agents.

[0342] Suitable amino acid linkers such as peptide linkers are known in the art. The length, flexibility and hydrophilicity of the amino acid or peptide linker are typically designed to reduce the size of the opening but not interfere with the function of the helicase. Preferred flexible peptide linkers are stretches of 2 to 20, for example 4, 6, 8, 10 or 16 serine and / or glycine amino acids. More preferred flexible linkers include (SG)1, (SG)2, (SG)3, (SG)4, (SG)5, (SG)8, (SG) 10 , (SG) 15 or (SG) 20 (wherein S is serine and G is glycine). Preferred rigid linkers are stretches of 2 to 30, for example 4, 6, 8, 16 or 24 proline amino acids. More preferred rigid linkers include (P) 12 wherein P is proline. The amino acid sequence of the linker preferably comprises a polynucleotide binding moiety. Such moieties and the advantages associated with their use are discussed below.

[0343] Suitable chemical crosslinking agents are well known in the art. Suitable chemical crosslinking agents include, but are not limited to, those comprising the following functional groups: maleimide, active esters, succinimide, azide, alkyne (e.g., dibenzocyclooctynol (DIBO or DBCO), difluorocycloalkyne and linear alkyne), phosphine (e.g., those used in traceless and non-traceless Staudinger ligation), haloacetyl (e.g., iodoacetamide), phosgene-type reagents, sulfonyl chloride reagents, isothiocyanates, acyl halides, hydrazines, disulfides, vinyl sulfones, aziridines and photoreactive reagents (e.g., aryl azides, diaziridines).

[0344] The reaction between the amino acid and the functional group may be spontaneous, such as cysteine / maleimide, or may require an external reagent such as Cu(I) for linking the azide and the linear alkyne.

[0345] The linker can contain any molecule that extends over the required distance. Linkers can vary in length from one carbon (phosgene-type linker) to many angstroms. Examples of linear molecules include, but are not limited to, polyethylene glycol (PEG), polypeptides, polysaccharides, deoxyribonucleic acid (DNA), peptide nucleic acid (PNA), threose nucleic acid (TNA), glycerol nucleic acid (GNA), saturated and unsaturated hydrocarbons, and polyamides. These linkers may be inert or reactive, and in particular may be chemically cleavable at a predetermined position, or may be modified with fluorophores or ligands. The linker is preferably resistant to dithiothreitol (DTT).

[0346] Preferred crosslinking agents include 2,5-dioxopyrrolidine-1-yl3-(pyridine-2-yldisulfanyl)propanoate, 2,5-dioxopyrrolidine-1-yl4-(pyridine-2-yldisulfanyl)butanoate, and 2,5-dioxopyrrolidine-1-yl8-(pyridine-2-yldisulfanyl)octanoate, dimaleimide PEG1k, dimaleimide PEG3.4k, and dimaleimide PEG 5k, di-maleimide PEG10k, bis(maleimide)ethane (BMOE), bis-maleimidehexane (BMH), 1,4-bis-maleimidobutane (BMB), 1,4-bis-maleimido-2,3-dihydroxybutane (BMDB), BM[PEO]2 (1,8-bis-maleimidediethylene glycol), BM[PEO]3 (1,11-bis-maleimidetriethylene glycol), tris[2-maleimidoethyl]amine (TMEA), DTME dithiobismaleimideethane, bis-maleimide PEG3, bis-maleimide PEG11, DBCO-maleimide, DBCO-PEG4-maleimide, DBCO-PEG4-NH2, DBCO-PEG4-NHS, DBCO-NHS, DBCO-PEG-DBCO 2.8kDa, DBCO-PEG-DBCO Examples include 4.0kDa, DBCO-15 atom-DBCO, DBCO-26 atom-DBCO, DBCO-35 atom-DBCO, DBCO-PEG4-S-PEG3-biotin, DBCO-S-PEG3-biotin, DBCO-SS-PEG3-biotin, DBCO-SS-PEG11-biotin, (succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and maleimide-PEG(2kDa)-maleimide (α,ω-bis-maleimide poly(ethylene glycol)). The most preferred crosslinking agent is maleimide-propyl-SRDFWRS-(1,2-diaminoethane)-propyl-maleimide.

[0347] One or more linkers may be cleavable. This will be explained in more detail below.

[0348] Two or more cysteine ​​and / or non-natural amino acids may be linked using two distinct linkers specific to each other. One linker is attached to one part, and the other linker is attached to the other part. The linkers are to react to form the modified helicase of the present invention. Two or more cysteine ​​and / or non-natural amino acids may be linked using hybridization linkers described in International Publication 2010 / 086602 (which is incorporated herein by reference in its entirety). In particular, two or more cysteine ​​and / or non-natural amino acids may be linked using two or more linkers, each containing a hybridizable region and a group capable of forming a covalent bond. The hybridizable region in the linker hybridizes and links the two or more cysteine ​​and / or non-natural amino acids. The linked cysteine ​​and / or non-natural amino acids are then linked through the formation of covalent bonds between the groups. Any of the specific linkers disclosed in International Publication 2010 / 086602 (which is incorporated herein by reference in its entirety) may be used in accordance with the present invention.

[0349] Two or more cysteine ​​and / or non-natural amino acids can be modified and then linked together using a chemical crosslinking agent specific to the two modifications. Any of the crosslinking agents described above may be used.

[0350] The linker may be labeled. Suitable labels include fluorescent molecules (such as Cy3 or AlexaFluor® 555), radioisotopes, etc. 125 I, 35 Ligands include, but are not limited to, S, enzymes, antibodies, antigens, polynucleotides, and biotin. Such labels allow for the quantification of linker amounts. The labels may also be cleavable purified tags such as biotin, or specific sequences that appear in identification methods, such as peptides that are not present in the protein itself but are released by trypsin digestion.

[0351] A preferred method for linking two or more cysteines is via cysteine ​​bonds. This can be mediated by a bifunctional chemical crosslinking agent or an amino acid linker having a cysteine ​​residue at its terminus.

[0352] The length, reactivity, specificity, rigidity, and solubility of any bifunctional linker can be designed to ensure that the opening size is sufficiently reduced and the function of the helicase is preserved. Suitable linkers include bismaleimide crosslinkers, e.g., 1,4-bis(maleimide)butane (BMB) or bis(maleimide)hexane. One drawback of bifunctional linkers is that the binding of the bifunctional linker to surface-accessible cysteine ​​residues can be difficult to control and may affect substrate binding or activity; therefore, if binding at a specific site is preferred, it is necessary that the helicase does not contain any further surface-accessible cysteine ​​residues. If the helicase contains several accessible cysteine ​​residues, modification of the helicase may be necessary to remove them while ensuring that the modification of the helicase does not affect the folding or activity of the helicase. This is discussed in International Publication 2010 / 086603 (which is incorporated herein by reference in its entirety). The reactivity of cysteine ​​residues can be enhanced, for example, by modifying adjacent residues on the peptide linker. For instance, the basic group of an adjacent arginine, histidine, or lysine residue can increase the pKa of the cysteine ​​thiol group to a more reactive S. - The pKa of the group is changed. The reactivity of cysteine ​​residues can be protected by thiol protecting groups such as 5,5'-dithiobis-(2-nitrobenzoic acid) (dTNB). These can react with one or more cysteine ​​residues of the helicase before linker binding. Selective deprotection of surface-accessible cysteine ​​may be possible using a reducing agent immobilized on beads (e.g., immobilized tris(2-carboxyethyl)phosphine, TCEP). Cysteine ​​binding is discussed in more detail below.

[0353] Another preferred method of linkage via Faz linkage. This can be mediated by a bifunctional chemical linker or by a polypeptide linker in which a Faz residue is presented at the terminus.

[0354] Other modifications The helicase of the present invention may also be modified to increase the attractive force between (i) the tower domain and (ii) the pin domain and / or the 1A domain. Any known chemical modifications can be made in accordance with the present invention. These types of modifications are disclosed in International Publication No. 2015 / 055981, which is incorporated herein by reference in its entirety.

[0355] In particular, the present invention provides a helicase of the present invention having the ability to control the movement of polynucleotides, wherein at least one charged amino acid is further introduced into (i) the tower domain and / or (ii) the pin domain and / or (iii) the 1A (RecA-like motor) domain. The ability of a helicase to control the movement of polynucleotides can be measured as described above. Preferably, the present invention provides a helicase of the present invention having at least one charged amino acid further introduced into (i) the tower domain and (ii) the pin domain and / or the 1A domain.

[0356] At least one charged amino acid may be negatively charged or positively charged. Preferably, the at least one charged amino acid is charged opposite to any amino acid interacting with it in the helicase. For example, at least one positively charged amino acid may be introduced into the tower domain at a position that interacts with a negatively charged amino acid in the pin domain. At least one charged amino acid is typically introduced at an uncharged position in the wild-type (i.e., unmodified) helicase. At least one charged amino acid may be used to substitute at least one oppositely charged amino acid in the helicase. For example, a positively charged amino acid may be used to replace a negatively charged amino acid.

[0357] Suitable charged amino acids are discussed above. At least one charged amino acid may be naturally occurring, such as arginine (R), histidine (H), lysine (K), aspartic acid (D), or glutamic acid (D). Alternatively, at least one charged amino acid may be artificial or non-natural. Any number of charged amino acids can be introduced into each domain. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more charged amino acids can be introduced into each domain.

[0358] The helicase preferably includes a variant of SEQ ID NO: 118 containing one or more positively charged amino acids at the following positions: (i)93; (ii)354; (iii)360; (iv)361; (v)94; (vi)97; (vii)155; (viii)357; (ix)100; and (x)127. The helicase preferably includes a variant of SEQ ID NO: 118 containing one or more negatively charged amino acids at the following positions: (i)354; (ii)358; (iii)360; (iv)364; (v)97; (vi)123; (vii)155; (viii);357; (ix)100; and (x)127. The helicase preferably contains one variant of SEQ ID NO: 118 to 133 that includes an amino acid having a positive or negative charge at the position corresponding to the amino acid of SEQ ID NO: 119 as defined by any of (i) to (x). The position of any one of SEQ ID NOs: 119 to 133 corresponding to SEQ ID NO: 118 can be identified using the following alignment of SEQ ID NOs: 118 to 133.

[0359] The helicase is preferably located at the following positions: (i) 93 and 354; (ii) 93 and 358; (iii) 93 and 360; (iv) 93, 361; (v) 93 and 364; (vi) 94, 354; (vii) 94 and 358; (viii) 94, 360; (ix) 94 and 361; (x) 94, 364; (xi) 97, 354; (xii) 97, 358; (xiii) 97, 360; (xiv) 97, 361; (xv) 97, 364; The helicase of the present invention includes variants of SEQ ID NO: 118 modified by introducing at least one charged amino acid to include a reverse-charged amino acid in (xvi)123, 354; (xvii)123, 358; (xviii)123, 360; (xix)123, 361; (xx)123, 364; (xxi)155, 354; (xxii)155 and 358; (xxiii)155 and 360; (xxiv)155, 361; and (xxv)155 and 364. Preferably, the helicase of the present invention includes any one variant of SEQ ID NO: 118 to 133, further including a reverse-charged amino acid in the position corresponding to that in SEQ ID NO: 119 as defined in any of (i) to (xxv).

[0360] The helicase of the present invention may further (i) have at least one charged amino acid introduced into the tower domain, and (ii) have at least one anticharged amino acid introduced into the pin domain and / or the 1A (RecA-like motor) domain, thereby having the ability to control the movement of polynucleotides. At least one charged amino acid may be negatively charged, and at least one anticharged amino acid may be positively charged, or vice versa. Suitable charged amino acids are discussed above. Any number of charged amino acids and any number of anticharged amino acids can be introduced. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more charged amino acids may be introduced, and / or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more anticharged amino acids may be introduced.

[0361] Charged amino acids are typically introduced to uncharged positions in wild-type helicases. One or both charged amino acids can be used to substitute for charged amino acids in the helicase. For example, a positively charged amino acid may be used to substitute for a negatively charged amino acid. Charged amino acids can be introduced to any position in the (i) tower domain and (ii) pin domain and / or 1A domain described above. Conversely charged amino acids are typically introduced to interact in the resulting helicase. The helicase preferably includes a variant of SEQ ID NO: 118 in which the conversely charged amino acids are introduced to the following positions: (i) 97 and 354; (ii) 97 and 360; (iii) 155 and 354; or (iv) 155 and 360. The helicase of the present invention preferably includes a variant of any one of SEQ ID NOs: 119 to 133, further including a reverse-charged amino acid in the position corresponding to that of SEQ ID NO: 118 as defined in any of (i) to (iv).

[0362] construct The present invention also provides a construct comprising a modified helicase and a further polynucleotide binding moiety, wherein the helicase is bound to the polynucleotide binding moiety, and the construct has the ability to control the movement of polynucleotides. The construct is artificial or non-natural.

[0363] The constructs of the present invention are useful tools for controlling the movement of polynucleotides during chain sequencing. The constructs of the present invention have an even lower probability of detaching from the sequenced polynucleotide than the modified helicases of the present invention. Because the constructs control the rearrangement of polynucleotides through nanopores, they can provide longer read lengths for polynucleotides.

[0364] Targeted constructs that bind to specific polynucleotide sequences can also be designed. As will be discussed in more detail below, the polynucleotide binding moiety can bind to a specific polynucleotide sequence, thereby targeting the helicase moiety of the construct to a specific sequence.

[0365] The construct has the ability to control the movement of polynucleotides. This can be determined as described above.

[0366] The constructs of the present invention may be isolated, substantially isolated, purified, or substantially purified. A construct is isolated or purified if it does not contain any other components such as lipids, polynucleotides, or pore monomers. A construct is substantially isolated if it is mixed with a carrier or diluent that does not interfere with its intended use. For example, a construct is substantially isolated or substantially purified if it exists in a form containing less than 10%, less than 5%, less than 2%, or less than 1% of other components such as lipids, polynucleotides, or pore monomers.

[0367] The helicase may be any of the helicases of the present invention described above.

[0368] The helicase is preferably covalently bonded to the additional polynucleotide binding site. The helicase may be bonded to the site at two or more points, such as two or three points.

[0369] Helicases can be covalently bonded in part using any method known in the art. Suitable methods for bonding two or more parts are described above.

[0370] The helicase and the moiety may be produced separately and then joined together. The two components can be attached in any configuration. For example, they may be joined via their terminal (i.e., amino-terminal or carboxy-terminal) amino acids. Suitable configurations include, but are not limited to, the amino-terminal of the moiety being joined to the carboxy-terminal of the helicase and vice versa. Alternatively, the two components may be joined via amino acids in their sequences. For example, the moiety may be joined to one or more amino acids in the loop region of the helicase. In a preferred embodiment, the terminal amino acid of the moiety is joined to one or more amino acids in the loop region of the helicase.

[0371] In a preferred embodiment, the helicase is chemically bound to the portion, for example, via one or more linker molecules as described above. In another preferred embodiment, the helicase is genetically fused to the portion. The helicase is genetically fused to a portion if the entire construct is expressed from a single polynucleotide sequence. The coding sequences of the helicase and the portion can be combined in any way to form a single polynucleotide sequence that encodes the construct. Genetic fusion of pores to nucleic acid-binding proteins is discussed in International Publication 2010 / 004265 (which is incorporated herein by reference in its entirety).

[0372] Helicases and moieties can be genetically fused in any configuration. Helicases and moieties can be fused via their terminal amino acids. For example, the amino terminus of a moiety may be fused to the carboxy terminus of a helicase, and vice versa. The amino acid sequence of a moiety is preferably added in frame to the amino acid sequence of a helicase. In other words, the moiety is preferably inserted into the sequence of a helicase. In such embodiments, the helicase and moiety are typically linked at two points, namely via the amino and carboxy terminal amino acids of the moiety. When a moiety is inserted into the sequence of a helicase, the amino and carboxy terminal amino acids of the moiety are preferably in close proximity and linked to adjacent amino acids in the sequence of the helicase or its variant, respectively. In preferred embodiments, the moiety is inserted into the loop region of a helicase.

[0373] The helicase may be directly bound to the part. Preferably, the helicase is bound to the part using one or more linkers, for example, two or three, as described above. One or more linkers may be designed to restrict the mobility of the part. The helicase and / or part may be modified to facilitate the binding of one or more linkers as described above.

[0374] A cleavable linker can be used to aid in the separation of a construct from unbound components and to further control the synthetic reaction. For example, a heterobifunctional linker can react with a helicase but not with its moiety. If the helicase protein can be bound to the surface using the free end of the linker, unreacted helicase can be removed from the mixture from the first reaction. The linker can then be cleaved to expose the group that reacts with its moiety. Furthermore, by following this series of linking reactions, the conditions can be optimized for the reaction with the helicase first, and then with the moiety after the linker has been cleaved. The second reaction is also much more directed to the correct reaction site with the moiety, since it is limited to the region where the linker is already bound.

[0375] The helicase may be covalently bonded to the bifunctional crosslinker before the helicase / crosslinker complex is covalently bonded to the partial. Alternatively, the partial may be covalently bonded to the bifunctional crosslinker before the bifunctional crosslinker / partial complex is bonded to the helicase. The helicase and the partial may be covalently bonded to the chemical crosslinker simultaneously.

[0376] Preferred methods for attaching the helicase to the moiety are the cysteine ​​bond and the Faz bond described above. In a preferred embodiment, the reactive cysteine ​​is presented on a peptide linker that is genetically bound to the moiety. This means that additional modifications are not necessarily required to remove other accessible cysteine ​​residues from the moiety.

[0377] Crosslinking of helicases or parts to themselves can be prevented by maintaining a large excess of the linker concentration for the helicases and / or parts. Alternatively, a "lock-and-key" configuration in which two linkers are used may be employed. Only one end of each linker may react together, for example, they may be linked via their terminal (i.e., amino-terminus or carboxy-terminus) amino acids. Longer linkers may be formed, with the other end of each linker reacting with a different part of the construct (i.e., a helicase or part). This will be discussed in more detail below.

[0378] The binding site is selected such that, upon contact between the construct and the polynucleotide, both the helicase and the subunit can bind to the polynucleotide and control its movement.

[0379] The present invention also provides a method for producing a construct of the present invention, comprising attaching the helicase of the present invention to a further polynucleotide binding site, thereby producing a construct. This method preferably further includes determining whether the resulting construct can control the movement of polynucleotides. All of the above embodiments of the construct are equally applicable to this method.

[0380] Pores and pore composites for use in the present invention The present invention provides various methods and products in which a modified Dda helicase or construct of the present invention is combined with / used in a transmembrane pore. The transmembrane pore can be used as a solid-state pore. The transmembrane pore can be a transmembrane protein pore. Transmembrane protein pores include hemolysins, such as α-hemolysin or γ-hemolysin, leucocidine, Mycobacterium smegmatis porin A (MspA), MspB, MspC, MspD, PorARr, PorBRr, PorARc, lysenin, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A, Neisseria autotransporter lipoprotein (NalP), and WZA, CsgG, CsgG / CsgF, ClyA, Sp1, hemolytic protein fragase toxin C (FraC), iotatoxin, anthrax protective antigen, and Vibrio cholera (Vibrio (Cholerae) Cytolysine, Cytotoxin K (CytolysK), CELIII, Aerolidine, InvG, GspD, PilQ, Necrotizing enterocolitis B-like toxin (NetB), Portal vein proteins, e.g., G20c, P23_45, T4, SPP1, P22 and Phi29, Monalidine, Clostridium perfringens beta toxin, Parasporin-2, Epsilon toxin, Lectins derived from the parasitic fungus Laetiporus sulphureus (LSL), Volvatoxin, Cry toxin, Cyte 1Aa or Cyte 2Aa may be derived from these.

[0381] The transmembrane protein pore preferably comprises a CsgG pore or its homolog or variant, or an isolated pore complex comprising a CsgG pore or its homolog or variant and a modified CsgF peptide or its homolog or variant. The isolated pore complex comprising a CsgG pore or its homolog or variant, or a CsgG pore or its homolog or variant and a modified CsgF peptide or its homolog or variant, preferably comprises at least one variant monomer.

[0382] A variant monomer is a monomer whose sequence differs from that of the wild-type CsgG monomer and which retains the ability to form pores. Variant monomers may also be referred to as variants herein. Methods for confirming the ability of a variant monomer to form pores are well known in the art and will be discussed in more detail below. At least one variant monomer or variant may have either homology / sequence identity % with SEQ ID NO: 117 or SEQ ID NO: 3 shown below. At least one variant monomer may include any of the modifications, mutations, or substitutions described below, including the types of modifications and substitutions described with reference to the Dda helicase of the present invention. At least one variant monomer may contain any of the further modifications, mutations, or substitutions described in International Publication Nos. 2016 / 034591, 2017 / 149316, 2017 / 149317, 2017 / 149318, 2018 / 211241, and 2019 / 002893 (all of which are incorporated herein by reference in their entirety).

[0383] Methods for characterizing analytes The present invention provides a method for determining the presence or absence or one or more properties of a target analyte. This method involves contacting the target analyte with a transmembrane pore and a helicase or construct of the present invention, controlling the movement of the target analyte to or through the pore by the helicase or construct, obtaining one or more measurements as the analyte moves toward the pore, thereby determining the presence or absence or one or more properties of the analyte. The target analyte may also be called a template analyte or analyte of interest. The transmembrane pore may be any of the above pores or complexes. The transmembrane pore typically contains at least 7, at least 8, at least 9, or at least 10 monomers, e.g., 7, 8, 9, or 10 CsgG monomers. The transmembrane pore preferably contains 8 or 9 identical CsgG monomers. One or more of the CsgG monomers, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10, are preferably chemically modified, or the CsgF peptide is chemically modified. Monomers such as CsgG monomer, or their homologs or variants, and modified CsgF monomer, or its homologs or variants, may be derived from any organism. The analyte can pass through the CsgG constriction and then the CsgF constriction. In an alternative embodiment, the analyte can pass through the CsgF constriction and then the CsgG constriction, depending on the orientation of the CsgG / CsgF complex in the membrane.

[0384] This method is for determining the presence or absence of a target analyte or one or more properties. This method may be for determining the presence or absence of at least one analyte or one or more properties. This method may relate to determining the presence or absence of two or more analytes or one or more properties. This method may include determining the presence, absence or one or more properties of any number of analytes, e.g., 2, 5, 10, 15, 20, 30, 40, 50, 100 or more analytes. Any number of properties of one or more analytes, e.g., 1, 2, 3, 4, 5, 10 or more properties can be determined.

[0385] The binding of molecules within the channel of a pore complex, or near any opening of the channel, affects the open-channel ion flow through the pore, which is the essence of pore channel "molecular sensing." Similar to nucleic acid sequencing applications, fluctuations in open-channel ion flow can be measured using appropriate measurement techniques based on changes in current (e.g., International Publication 2000 / 28312 and D. Stoddart et al., Proc. Natl. Acad. Sci., 2010, 106, 7702-7 or International Publication 2009 / 077734; the entirety of which is incorporated herein by reference). The degree of decrease in ion flow, measured by a decrease in current, is related to the magnitude of the blockage within or near the pore. Thus, the binding of the target molecule, also called the "analyte," within or near the pore provides a detectable and measurable event, thereby forming the basis for a "biological sensor." Molecules suitable for nanopore sensing include nucleic acids; proteins; peptides; polysaccharides; and small molecules (referring to organic or inorganic compounds with low molecular weight (e.g., <900 Da or <500 Da)), such as pharmaceuticals, toxins, cytokines, and contaminants. Detecting the presence of biological molecules has applications in personalized drug development, medicine, diagnostics, life science research, environmental monitoring, and the security and / or defense industries.

[0386] Transmembrane pores can function as molecular or biological sensors. In some embodiments, transmembrane pores can be derived from or isolated from bacterial proteins (e.g., Escherichia coli, Salmonella typhimurium). In some embodiments, transmembrane pores can be recombinantly produced. Procedures for analyte detection are described in Howa et al. Nature Biotechnology (2012) Jun 7;30(6):506-7. The analyte molecule to be detected may bind either to the surface of the channel or within the lumen of the channel itself. The location of binding may be determined by the size of the molecule being sensed.

[0387] One or more properties of the target analyte are preferably measured by electrical and / or optical measurements. Electrical measurements are preferably current measurements, impedance measurements, tunneling measurements, or field-effect transistor (FET) measurements. The method preferably further includes the step of applying a voltage across the pore to form a composite between the pore and the helicase or construct.

[0388] The target analytes are preferably metal ions, inorganic salts, polymers, amino acids, peptides, polypeptides, proteins, nucleotides, oligonucleotides, polynucleotides, monosaccharides, oligosaccharides, polysaccharides, dyes, bleaching agents, pharmaceuticals, diagnostic agents, recreational drugs, explosives, toxic compounds, or environmental pollutants. The target analyte is preferably a target polynucleotide. This method may relate to determining the presence, absence, or one or more characteristics of two or more analytes of the same type, such as two or more proteins, two or more nucleotides, or two or more pharmaceuticals. Alternatively, this method may relate to determining the presence, absence, or one or more characteristics of two or more analytes of different types, such as one or more proteins, one or more nucleotides, and one or more pharmaceuticals.

[0389] The target analyte, preferably the target polynucleotide, may be modified by methylation, oxidation, damage, with one or more proteins, or with one or more labels, tags, or spacers.

[0390] The target analyte may be secreted from a cell. Alternatively, the target analyte may be an analyte present inside a cell, such that it must be extracted from the cell before the method can be performed.

[0391] In one embodiment, the target analyte is an amino acid, peptide, polypeptide, or protein. The amino acid, peptide, polypeptide, or protein may be naturally occurring or not. The polypeptide or protein may contain synthetic or modified amino acids. Several different types of modifications of amino acids are known in the art. Suitable amino acids and their modifications are as described above. It should be understood that the target analyte can be modified by any method available in the art.

[0392] In another embodiment, the target analyte is a polynucleotide, such as a nucleic acid, defined as a macromolecule containing two or more nucleotides. Nucleic acids are particularly suitable for nanopore sequencing. Naturally occurring nucleic acid bases in DNA and RNA can be distinguished by their physical size. As nucleic acid molecules or individual bases pass through the nanopore channel, the size differences between the bases cause a directly correlated decrease in the ion flow through the channel. The variation in ion flow can be recorded. Appropriate electrical measurement techniques for recording the variation in ion flow are discussed above. With appropriate calibration, the characteristic decrease in ion flow can be used to identify specific nucleotides and associated bases traversing the channel in real time. In typical nanopore nucleic acid sequencing, due to partial occlusion of the channel by nucleotides, the open-channel ion flow decreases as individual nucleotides of the nucleic acid sequence of interest sequentially pass through the nanopore channel. It is this decrease in ion flow that is measured using the appropriate recording techniques described above. The reduction in ion flow may be calibrated to the measured reduction in ion flow of known nucleotides passing through the channel, thereby providing a means to determine which nucleotides are passing through the channel, and thus, if performed sequentially, a method for determining the nucleotide sequence of nucleic acids passing through the nanopore. For accurate determination of individual nucleotides, it was typically necessary that the reduction in ion flow through the channel directly correlated with the size of the individual nucleotides passing through the constriction (or "reading head"). It will be understood that sequencing may be performed, for example, on intact nucleic acid polymers "passed" through the pore via the action of the relevant polymerase. Alternatively, the sequence may be determined by the passage of nucleotide triphosphates sequentially removed from a target nucleic acid adjacent to the pore (see, for example, International Publication 2014 / 187924, which is incorporated in whole herein by reference).

[0393] Polynucleotides can be single-stranded or double-stranded. At least a portion of a polynucleotide is preferably double-stranded. Most preferably, the polynucleotide is ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). In particular, the method using a polynucleotide as an analyte alternatively includes determining one or more features selected from (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide, and (v) whether or not the polynucleotide has been modified.

[0394] A polynucleotide can be of any length (i). For example, a polynucleotide can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, or at least 500 nucleotides or nucleotide pairs in length. A polynucleotide can be at a length of 1000 or more nucleotides or nucleotide pairs, 5000 or more nucleotides or nucleotide pairs, or 100,000 or more nucleotides or nucleotide pairs. Any number of polynucleotides can be examined. For example, this method may relate to characterizing 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100, or more polynucleotides. If two or more polynucleotides are characterized, they may be different polynucleotides or two examples of the same polynucleotide. Polynucleotides may be naturally occurring or artificial. For example, this method may be used to verify the sequence of a manufactured oligonucleotide. This method is typically performed in vitro.

[0395] Embodiments of the present invention including modified helicases and structures This invention provides polynucleotides, vectors, and host cells, which are described above.

[0396] The present invention provides various methods using the Dda helicase of the present invention, particularly for controlling the migration of analytes and characterizing target analytes. Such methods are described above and in International Publications 2016 / 034591, 2017 / 149316, 2017 / 149317, 2017 / 149318, 2018 / 211241, 2019 / 002893, 2015 / 055981, 2015 / 166276 and 2016 / 055777 (all incorporated herein by reference).

[0397] Modified Dda helicases and constructs of the present invention can be used to form sensors for characterizing target analytes. These sensors can be formed by bringing a pore into contact with a helicase or construct in the presence of a target analyte and applying a potential across the pore. The potential may be a potential difference or a chemical potential. The helicase or construct may be covalently bonded to the pore, for example, as described above.

[0398] In these methods and sensors, the modified Dda helicases and constructs of the present invention may be used in combination with a solid pore or a transmembrane protein pore. The transmembrane protein pore may be any of the above.

[0399] kit The present invention also provides a kit for characterizing a target analyte comprising (a) a pore and a helicase or construct of the present invention, or (b) a helicase or construct of the present invention and one or more loading portions. The pore may be any of those described above. Preferred combinations of pore and helicase will be discussed in more detail below.

[0400] The kit preferably further comprises membrane components. The kit may comprise any type of membrane component, such as an amphiphilic layer or a triblock copolymer membrane. The kit may further comprise one or more anchors, such as cholesterol, for binding the target analyte to the membrane. The kit may further comprise one or more polynucleotide adapters, which can be attached to the target polynucleotide to facilitate the characterization of the polynucleotide. In one embodiment, the anchor, such as cholesterol, is bound to the polynucleotide adapter.

[0401] The kit may further include one or more other reagents or instruments that enable the implementation of any of the embodiments described above. Such reagents or instruments include one or more of the following: a suitable buffer (aqueous solution), means for obtaining a sample from a subject (such as an instrument including a blood vessel or needle), and means for amplifying and / or expressing polynucleotides or voltage or patch-clamp devices. The reagents may be present in the kit in a dry state so that the liquid sample resuspends the reagent. The kit may also include instructions or details regarding which organisms the method may be used for, to enable the kit to be used in the method of the present invention, as necessary. Finally, the kit may also include additional components useful for characterizing the analyte.

[0402] Polynucleotide-binding proteins and partial Preferred polynucleotide-binding proteins are topoisomerases such as polymerases, exonucleases, helicases, and gyrales. The preferred polynucleotide-binding moiety is a topoisomerase such as a polymerase, exonuclease, helicase, and gyrales, or derived therefrom. Suitable enzymes include, but are not limited to, exonuclease I from E. coli, exonuclease III from E. coli, RecJ and bacteriophage lambda exonuclease from T. thermophilus, TatD exonuclease, and their variants. Three subunits containing the RecJ sequence or its variant from T. thermophilus interact to form a trimer exonuclease. The polymerase may be PyroPhage® 3173 DNA Polymerase (commercially available from Lucigen® Corporation), SD Polymerase (commercially available from Bioron®), or a variant thereof. The enzyme may be Phi29 DNA polymerase (SEQ ID NO: 7) or a variant thereof. The topoisomerase is preferably a member of either subclassification (EC) group 5.99.1.2 or 5.99.1.3.

[0403] The enzyme is most preferably derived from a helicase, such as Hel308 Mbu, Hel308 Csy, Hel308 Tga, Hel308 Mhu, TraI Eco, XPD Mbu, or a variant thereof. Any helicase can be used in the present invention. The helicase may be or derived from Hel308 helicase, RecD helicase, such as TraI helicase or TrwC helicase, XPD helicase or Dda helicase. The helicase may be any of the helicases, modified helicases, or helicase constructs disclosed in International Publication Nos. 2013 / 057495; 2013 / 098562; 2013098561; 2014 / 013260; 2014 / 013259; 2014 / 013262 and 2015 / 055981. All of these are incorporated in whole by reference.

[0404] Device The present invention also provides an apparatus for characterizing a target analyte in a sample, comprising (a) a plurality of pores and (b) a plurality of helicase constructs of the present invention. The plurality of pores may be any of those described above. Preferred combinations of pores and helicases will be discussed in more detail below.

[0405] In particular, any of the specific embodiments described above with respect to the pores, pore complexes, helicases, and constructs of the present invention are equally applicable to the apparatus of the present invention.

[0406] array The present invention can be used with an array comprising multiple membranes. Any of the embodiments described above with respect to membranes is equally applicable to the array of the present invention. The array may be configured to perform any of the methods described above.

[0407] In a preferred embodiment, each membrane in the array contains one pore. Depending on how the array is formed, for example, the array may contain one or more membranes that do not contain pores, and / or one or more membranes that contain two or more pores. The array may contain about 2 to about 1000 membranes, for example, about 10 to about 800, about 20 to about 600, or about 30 to about 500.

[0408] system The present invention may utilize a system comprising (a) a film or array, (b) means for applying a potential across the film, and (c) means for detecting an electrical or optical signal across the film.

[0409] The pore and membrane may be any of the above or below.

[0410] In one embodiment, the system further comprises a first chamber and a second chamber, separated by a membrane. When used to characterize a target analyte, the system may further include a target analyte, which is transiently placed in a continuous channel, with one end of the target analyte in the first chamber and the other end in the second chamber. The target analyte is preferably a target polypeptide or a target polynucleotide.

[0411] In one embodiment, the system further includes a conductive solution in contact with one or more pores, electrodes providing a potential across one or more films, and a measuring system for measuring the current passing through one or more pores. In one embodiment, the voltage applied to the films and pores is +5V to -5V, for example, -600mV to +600mV or -400mV to +400mV. The voltage used is preferably in the range of 100mV to 240mV, more preferably in the range of 120mV to 220mV. Increasing the applied potential can enhance the discriminability of different amino acids or nucleotides by the pores. Any suitable conductive solution can be used. For example, the solution may contain charge carriers such as metal salts, such as alkali metal salts, halide salts, and chloride salts such as alkali metal chloride salts. The charge carriers may include ionic liquids or organic salts, such as tetramethylammonium chloride, trimethylphenylammonium chloride, phenyltrimethylammonium chloride, or 1-ethyl-3-methylimidazolium chloride. In an exemplary system, the salt is present in an aqueous solution within the chamber. Potassium chloride (KCl), sodium chloride (NaCl), cesium chloride (CsCl), or a mixture of potassium ferrocyanide and potassium ferricyanide are typically used. KCl, NaCl, and mixtures of potassium ferrocyanide and potassium ferricyanide are preferred. The charge carrier may be asymmetric across the membrane. For example, the type and / or concentration of the charge carrier may differ on both sides of the membrane, e.g., in each chamber.

[0412] The salt concentration may be saturated. The salt concentration may be 3M or less, and is typically 0.1–2.5M, 0.3–1.9M, 0.5–1.8M, 0.7–1.7M, 0.9–1.6M, or 1M–1.4M. The salt concentration is preferably 150mM–1M. The method is preferably carried out using a salt concentration of at least 0.3M, for example, at least 0.4M, at least 0.5M, at least 0.6M, at least 0.8M, at least 1.0M, at least 1.5M, at least 2.0M, at least 2.5M, or at least 3.0M. Higher salt concentrations provide a high signal-to-noise ratio, allowing currents indicating the presence of amino acids or nucleotides to be distinguished against a background of normal current fluctuations.

[0413] A buffer may be present in the conductive solution. Typically, the buffer is a phosphate buffer. Other suitable buffers are HEPES and Tris-HCl buffers. The pH of the conductive solution may be 4.0–12.0, 4.5–10.0, 5.0–9.0, 5.5–8.8, 6.0–8.7, or 7.0–8.8 or 7.5–8.5. The pH used is preferably about 7.5.

[0414] The system may be included in the apparatus. The apparatus may be any conventional apparatus for analyte analysis, such as an array or tip. The apparatus is preferably configured to perform the disclosed method. For example, the apparatus may comprise a chamber containing an aqueous solution and a barrier separating the chamber into two parts. The barrier typically has openings on which a membrane containing pores is formed. Alternatively, the barrier forms a membrane in which pores are present.

[0415] The apparatus may also include an electrical circuit capable of applying an electric potential and measuring electrical signals across the film and pores.

[0416] The apparatus may be any of the apparatus described in International Publication No. 2008 / 102120, International Publication No. 2009 / 077734, International Publication No. 2010 / 122293, International Publication No. 2011 / 067559, or International Publication No. 00 / 28312 (all of which are incorporated herein by reference in their entirety).

[0417] film In the present invention, any suitable film can be used. The film is preferably an amphiphilic layer. The amphiphilic layer is a layer formed from amphiphilic molecules, such as phospholipids, that have both hydrophilic and lipophilic properties. Amphiphilic molecules can be synthetic or naturally occurring. Amphiphilic substances that do not exist naturally and form monolayers are known in the art, for example, block copolymers (Gonzalez-Perez et al., Langmuir, 2009, 25, 10447-10450). Block copolymers are polymer materials in which two or more monomer subunits polymerize together to produce a single polymer chain. Block copolymers typically have properties to which each monomer subunit contributes. However, block copolymers may have unique properties that polymers formed from individual subunits do not have. Block copolymers can be manipulated so that one monomer subunit is hydrophobic (i.e., lipophilic) while the other subunits are hydrophilic in an aqueous medium. In this case, the block copolymer may be amphiphilic and can form structures that mimic biological membranes. The block copolymer may be a diblock (consisting of two monomer subunits), but may be constructed from three or more monomer subunits to form more complex arrangements that behave as amphiphilic materials. The copolymer may be a triblock, tetrablock, or pentablock copolymer. The membrane is preferably a triblock copolymer membrane.

[0418] The film is most preferably one of the films disclosed in International Publication No. 2014 / 064443 or International Publication No. 2014 / 064444.

[0419] Amphiphilic molecules can be chemically modified or functionalized to facilitate the coupling of polynucleotides. The amphiphilic layer may be a monolayer or a bilayer. The amphiphilic layer is typically planar. The amphiphilic layer may be curved. The amphiphilic layer may be supported.

[0420] Amphiphilic membranes are typically naturally mobile and essentially about 10 -8 cm s -1 It acts as a two-dimensional fluid with a lipid diffusion rate. This means that pores and coupled polynucleotides can typically move within an amphiphilic membrane.

[0421] The membrane may be a lipid bilayer. Lipid bilayers serve as a model of cell membranes and are excellent platforms for various experimental studies. For example, lipid bilayers can be used for in vitro investigations of membrane proteins using single-channel recording. Alternatively, lipid bilayers can be used as biosensors to detect the presence of a range of substances. The lipid bilayer can be any lipid bilayer. Suitable lipid bilayers include, but are not limited to, planar lipid bilayers, supported bilayers, or liposomes. The lipid bilayer is preferably a planar lipid bilayer. Suitable lipid bilayers are disclosed in International Publication Nos. 2008 / 102121, International Publication Nos. 2009 / 077734, and International Publication Nos. 2006 / 100484 (all incorporated herein by reference in their entirety).

[0422] In another preferred embodiment, the film includes a solid layer. The solid layer may be, but is not limited to, a microelectronic material, Si3N4, A12O 3、The film can be formed from both organic and inorganic materials, including insulating materials such as SiO, organic and inorganic polymers such as polyamide, plastics such as Teflon®, or elastomers such as two-component addition-cured silicone rubber, and glass. The solid layer may be formed from graphene. A suitable graphene layer is disclosed in International Publication 2009 / 035647 (which is incorporated herein by reference in its entirety). When the film includes a solid layer, pores are typically located within amphiphilic films or layers contained within the solid layer, such as holes, wells, gaps, channels, trenches, or slits within the solid layer. Those skilled in the art can prepare a suitable solid / amphiphilic hybrid system. Suitable systems are disclosed in International Publication 2009 / 020682 and International Publication 2012 / 005857 (both which are incorporated herein by reference in their entirety). Any of the above amphiphilic films or layers may be used.

[0423] This method is typically carried out using (i) an artificial amphiphilic layer containing pores, (ii) an isolated, naturally occurring lipid bilayer containing pores, or (iii) cells into which pores have been inserted. This method is typically carried out using an artificial amphiphilic layer, such as an artificial triblock copolymer layer. The layer may contain other transmembrane proteins and / or intramembrane proteins and other molecules in addition to pores. Suitable apparatus and conditions are described below. The method of the present invention is typically carried out in vitro.

[0424] A preferred combination of pore and helicase In some of the embodiments described above, the modified helicase of the present invention can be used in conjunction with a pore or a transmembrane pore.

[0425] The modified helicases of the present invention may be used in combination with any of the pores described in International Publication No. 2016 / 034591, International Publication No. 2017 / 149316, International Publication No. 2017 / 149317, International Publication No. 2017 / 149318, International Publication No. 2018 / 211241, International Publication No. 2019 / 002893 and PCT / EP2023 / 059821 (all incorporated herein by reference in their entirety). The modified helicases of the present invention may preferably be used with a CsgG pore as described in International Publication No. 2016 / 034591 (incorporated herein by reference), as in Example 2, or with a CsgG:CsgF pore complex as described in International Publication No. 2019 / 002893 (incorporated herein by reference).

[0426] The helicase of the present invention is preferably used in conjunction with the above-mentioned CsgG pore or CsgG:CsgF pore complex, and vice versa. The CsgG pore or CsgG:CsgF pore complex of the present invention preferably comprises Q100A and / or N102A or N102S, and the helicase preferably comprises one of the substitutions of PCT / EP2023 / 059821, preferably Y350I and / or K358I.

[0427] While specific embodiments, configurations, and materials and / or molecules of the manipulated cells and methods according to the present invention are discussed herein, it should be understood that various changes or modifications in form and detail may be made without departing from the scope and spirit of the invention. The following examples are provided to better illustrate specific embodiments and should not be considered as limiting this application. This application is limited only by the claims.

[0428] array Sequence ID 1 shows the polynucleotide sequence of wild-type Escherichia coli (E. coli) CsgG from strain K12, including the signal sequence (gene ID: 945619).

[0429] Sequence ID 2 shows the amino acid sequence of wild-type Escherichia coli (E. coli) CsgG, including the signal sequence (Uniprot accession number P0AEA2).

[0430] Sequence ID 3 shows the amino acid sequence (Uniprot accession number P0AEA2) of wild-type Escherichia coli (E. coli) CsgG as a mature protein.

[0431] Sequence ID 4 shows the polynucleotide sequence of wild-type Escherichia coli (E. coli) CsgF from strain K12, including the signal sequence (gene ID: 945622).

[0432] Sequence ID 5 shows the amino acid sequence of wild-type E. coli CsgF, including the signal sequence (Uniprot accession number P0AE98).

[0433] Sequence ID 6 shows the amino acid sequence of wild-type Escherichia coli (E. coli) CsgF as a mature protein (Uniprot accession number P0AE98).

[0434] Sequence ID 7 shows the polynucleotide sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF encoding amino acids 1-27 and the C-terminal 6 His tag.

[0435] Sequence ID 8 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, including amino acids 1-27 and the C-terminal 6 His tag.

[0436] Sequence ID 9 shows the polynucleotide sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF encoding amino acids 1-38 and the C-terminal 6 His tag.

[0437] Sequence ID 10 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, including amino acids 1-38 and the C-terminal 6 His tag.

[0438] Sequence ID 11 shows the polynucleotide sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF encoding amino acids 1-48 and the C-terminal 6 His tag.

[0439] Sequence ID 12 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, including amino acids 1-48 and the C-terminal 6 His tag.

[0440] Sequence ID 13 shows the polynucleotide sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF encoding amino acids 1-64 and the C-terminal 6 His tag.

[0441] Sequence ID 14 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, including amino acids 1-664 and the C-terminal 6 His tag.

[0442] Sequence ID 15 shows the amino acid sequence of the peptide corresponding to residues 20-53 of Escherichia coli (E. coli) CsgF.

[0443] Sequence ID 16 shows the amino acid sequence of a peptide corresponding to residues 20-42 of Escherichia coli (E. coli) CsgF, which has a KD at its C-terminus.

[0444] Sequence ID 17 shows the amino acid sequence of the peptide corresponding to residues 23-55 of the CsgF homolog Q88H88.

[0445] Sequence ID 18 shows the amino acid sequence of the peptide corresponding to residues 25-57 of the CsgF homolog A0A143HJA0.

[0446] Sequence ID 19 shows the amino acid sequence of the peptide corresponding to residues 21-53 of the CsgF homolog Q5E245.

[0447] Sequence ID 20 shows the amino acid sequence of the peptide corresponding to residues 19-51 of the CsgF homolog Q084E5.

[0448] Sequence ID 21 shows the amino acid sequence of the peptide corresponding to residues 15-47 of the CsgF homolog F0LZU2.

[0449] Sequence ID 22 shows the amino acid sequence of the peptide corresponding to residues 26-58 of the CsgF homolog A0A136HQR0.

[0450] Sequence ID 23 shows the amino acid sequence of the peptide corresponding to residues 21-53 of the CsgF homolog A0A0W1SRL3.

[0451] Sequence ID 24 shows the amino acid sequence of the peptide corresponding to residues 26-59 of the CsgF homolog B0UH01.

[0452] Sequence ID 25 shows the amino acid sequence of the peptide corresponding to residues 22-53 of the CsgF homolog Q6NAU5.

[0453] Sequence ID 26 shows the amino acid sequence of the peptide corresponding to residues 7-38 of the CsgF homolog G8PUY5.

[0454] Sequence ID 27 shows the amino acid sequence of the peptide corresponding to residues 25-57 of the CsgF homolog A0A0S2ETP7.

[0455] Sequence ID 28 shows the amino acid sequence of the peptide corresponding to residues 19-51 of the CsgF homolog E3I1Z1.

[0456] Sequence ID 29 shows the amino acid sequence of the peptide corresponding to residues 24-55 of the CsgF homolog F3Z094.

[0457] Sequence ID 30 shows the amino acid sequence of the peptide corresponding to residues 21-53 of the CsgF homolog A0A176T7M2.

[0458] Sequence ID 31 shows the amino acid sequence of the peptide corresponding to residues 14-45 of the CsgF homolog D2QPP8.

[0459] Sequence ID 32 shows the amino acid sequence of the peptide corresponding to residues 28-58 of the CsgF homolog N2IYT1.

[0460] Sequence ID 33 shows the amino acid sequence of the peptide corresponding to residues 26-58 of the CsgF homolog W7QHV5.

[0461] Sequence ID 34 shows the amino acid sequence of the peptide corresponding to residues 23-55 of the CsgF homolog D4ZLW2.

[0462] Sequence ID 35 shows the amino acid sequence of the peptide corresponding to residues 21-53 of the CsgF homolog D2QT92.

[0463] Sequence ID 36 shows the amino acid sequence of the peptide corresponding to residues 20-51 of the CsgF homolog A0A167UJA2.

[0464] Sequence ID 37 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF containing amino acids 20-27.

[0465] Sequence ID 38 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, encompassing amino acids 20-38.

[0466] Sequence ID 39 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, encompassing amino acids 20-48.

[0467] Sequence ID 40 shows the amino acid sequence of a fragment of wild-type Escherichia coli (E. coli) CsgF, encompassing amino acids 20-64.

[0468] Sequence ID 41 shows the nucleotide sequence of primer CsgF_d27_end.

[0469] Sequence ID 42 shows the nucleotide sequence of primer CsgF_d38_end.

[0470] Sequence ID 43 shows the nucleotide sequence of primer CsgF_d48_end.

[0471] Sequence ID 44 shows the nucleotide sequence of primer CsgF_d64_end.

[0472] Sequence ID 45 shows the nucleotide sequence of the primer pNa62_CsgF_histag_Fw.

[0473] Sequence ID 46 shows the nucleotide sequence of the primer CsgF-His_pET22b_FW.

[0474] Sequence ID 47 shows the nucleotide sequence of the primer CsgF-His_pET22b_Rev.

[0475] Sequence ID 48 shows the nucleotide sequence of the primer csgEFG_pDONR221_FW.

[0476] Sequence ID 49 shows the nucleotide sequence of the primer csgEFG_pDONR221_Rev.

[0477] Sequence ID 50 shows the nucleotide sequence of the primer Mut_csgF_His_FW.

[0478] Sequence ID 51 shows the nucleotide sequence of the primer Mut_csgF_His_Rev.

[0479] Sequence ID 52 shows the nucleotide sequence of the primer DelCsgE_Rev.

[0480] Sequence ID 53 is the nucleotide sequence of primer DelCsgE FW.

[0481] Sequence ID 54 shows the amino acid sequence of residues 1-30 of mature Escherichia coli (E. coli) CsgF.

[0482] Sequence ID 55 shows the amino acid sequence of residues 1-35 of mature Escherichia coli (E. coli) CsgF.

[0483] Sequence ID 56 shows the amino acid sequence of the signal sequence-containing mutant (T4C / N17S) CsgF sequence and the TEV protease cleavage site (ENLYFQS) inserted between residues 35 and 36 of the mature protein sequence.

[0484] Sequence ID 57 shows the amino acid sequence of the mutant (N17S-Del) CsgF sequence with a signal sequence, and the TEV protease cleavage site (ENLYFQS) inserted between residues 35 and 36 of the mature protein sequence.

[0485] Sequence ID 58 shows the amino acid sequence of the signal sequence-containing mutant (G1C / N17S) CsgF sequence and the TEV protease cleavage site (ENLYFQS) inserted between residues 35 and 36 of the mature protein sequence.

[0486] Sequence ID 59 shows the amino acid sequence of the mutant (G1C) CsgF sequence with a signal sequence and the TEV protease cleavage site (ENLYFQS) inserted between residues 35 and 36 of the mature protein sequence.

[0487] Sequence ID 60 has a TEV protease cleavage site (ENLYFQS) inserted between residues 45 and 46 of the signal sequence and the mature protein sequence, with the C-terminus being His 10 The amino acid sequence of the tag, CsgF, is shown.

[0488] Sequence ID 61 has a TEV protease cleavage site (ENLYFQS) inserted between residues 35 and 36 of the signal sequence and the mature protein sequence, with the C-terminus being His 10 The amino acid sequence of the tag, CsgF, is shown.

[0489] Sequence ID 62 has a TEV protease cleavage site (ENLYFQS) inserted between residues 30 and 31 of the signal sequence and the mature protein sequence, with the C-terminus being His 10 The amino acid sequence of the tag, CsgF, is shown.

[0490] Sequence ID 63 has a TEV protease cleavage site (ENLYFQS) inserted between residues 45-51 of the signal sequence and the mature protein sequence, with the C-terminus being His 10 The amino acid sequence of the tag, CsgF, is shown.

[0491] Sequence ID 64 has a TEV protease cleavage site (ENLYFQS) inserted between residues 30-37 of the signal sequence and the mature protein sequence, with the C-terminus being His 10 The amino acid sequence of the tag, CsgF, is shown.

[0492] Sequence ID 65 contains the signal sequence, the HCV C3 protease cleavage site (LEVLFQGP) inserted at residues 34-36 of the mature protein sequence, and the C-terminal His 10 The amino acid sequence of the tagged CsgF sequence is shown.

[0493] Sequence ID 66 contains a signal sequence, an HCV C3 protease cleavage site (LEVLFQGP) inserted between residues 42-43 of the mature protein sequence, and the C-terminal His 10 The amino acid sequence of the tagged CsgF sequence is shown.

[0494] Sequence ID 67 contains the signal sequence, the HCV C3 protease cleavage site (LEVLFQGP) inserted between residues 38-47 of the mature protein sequence, and the C-terminal His 10 The amino acid sequence of the tagged CsgF sequence is shown.

[0495] Sequence ID 68 shows the amino acid sequence YP_001453594.1:1-248 of the hypothetical protein CKO_02032 [Citrobacter koseri ATCC BAA-895], which is 99% identical to Sequence ID 3.

[0496] Sequence ID 69 shows the amino acid sequence of WP_001787128.1:16-238 of the CsgG portion [Salmonella enterica], which is 98% of Sequence ID 3.

[0497] Sequence ID 70 shows the amino acid sequence of KEY44978.1|:16-277 of the Kari production / assembly / transport protein CsgG [Citrobacter amalonaticus], which is 98% identical to Sequence ID 3.

[0498] Sequence ID 71 shows the amino acid sequence YP_003364699.1:16-277 of the Kari production / assembly / transport component [Citrobacter rodentium ICC168], which is 97% identical to Sequence ID 3.

[0499] Sequence ID 72 shows the amino acid sequence YP_004828099.1:16-277 of the kari-producing / assembling / transporting component CsgG [Enterobacter asburiae LF7a], which is 94% identical to Sequence ID 3.

[0500] Sequence ID 73 shows the amino acid sequence of WP_006819418.1:19-280 of the transporter [Yokenella regensburgei], which is 91% identical to Sequence ID 3.

[0501] Sequence ID 74 shows the amino acid sequence of WP_024556654.1:16-277 of the Kari-producing / assembling / transport protein CsgG [Cronobacter pulveris], which is 89% identical to Sequence ID 3.

[0502] Sequence ID 75 is the amino acid sequence YP_005400916.1:16-277 of the Kari production / assembly / transport protein CsgG [Rahnella aquatilis HX2], which is 84% ​​identical to Sequence ID 3.

[0503] Sequence ID 76 shows the amino acid sequence of KFC99297.1:20-278 of the CsgG family kari production / assembly / transport component [Kluyvera ascorbata ATCC 33433], which is 82% identical to Sequence ID 3.

[0504] Sequence ID 77 shows the amino acid sequence of KFC86716.1|:16-274 of the CsgG family kari production / assembly / transport component [Hafnia alvei ATCC 13337], which is 81% identical to Sequence ID 3.

[0505] Sequence ID 78 shows the amino acid sequence YP_007340845.1|:16-270 of an uncharacterized protein involved in the formation of the curly polymer [Enterobacteriaceae bacterium FGI 57 strain], which is 76% identical to Sequence ID 3.

[0506] Sequence ID 79 shows the amino acid sequence of WP_010861740.1:17-274 of the Kari-producing and transporting protein CsgG [Plesiomonas shigelloides], which is 70% identical to Sequence ID 3.

[0507] Sequence ID 80 shows the amino acid sequence YP_205788.1:23-270 of CsgG [Vibrio fischeri ES114], a component of the outer membrane lipoprotein that produces, aggregates, and transports Kari, which is 60% identical to Sequence ID 3.

[0508] Sequence ID 81 shows the amino acid sequence of WP_017023479.1:23-270 of the Kari-producing and assembling protein CsgG [Aliivibrio logei], which is 59% identical to Sequence ID 3.

[0509] Sequence ID 82 shows the amino acid sequence of WP_007470398.1:22-275 of the Kari production / assembly / transport component CsgG [Photobacterium genus AK15], which is 57% identical to Sequence ID 3.

[0510] Sequence ID 83 shows the amino acid sequence of WP_021231638.1:17-277 of the Kari-producing and assembling protein CsgG [Aeromonas veronii], which is 56% identical to Sequence ID 3.

[0511] Sequence ID 84 shows the amino acid sequence of WP_033538267.1:27-265 of the Kari production / assembly / transport protein CsgG [Shewanella genus ECSMB14101], which is 56% identical to Sequence ID 3.

[0512] Sequence ID 85 shows the amino acid sequence of WP_03247972.1:30-262 of the Kari-producing and assembling protein CsgG [Pseudomonas putida], which is 54% identical to Sequence ID 3.

[0513] Sequence ID 86 shows the amino acid sequence YP_003557438.1:1-234 of the kari production / assembly / transport component CsgG [Shewanella violacea DSS12], which is 53% identical to Sequence ID 3.

[0514] Sequence ID 87 shows the amino acid sequence of WP_027859066.1:36-280 of the Kari production / assembly / transport protein CsgG [Marinobacterium jannaschii], which is 53% identical to Sequence ID 3.

[0515] Sequence ID 88 shows the amino acid sequence of CEJ70222.1:29-262 of the kari-producing, aggregation / transport component CsgG [Chryseobacterium oranimense G311], which is 50% identical to Sequence ID 3.

[0516] Sequence numbers 89-104 show the sequences in Table 1.

[0517] Sequence ID 1 (>p0aea2; code sequence of wt csgg derived from E. coli K12) ATGCAGCGCTTATTTCTTTTGGTTGCCGTCATGTTACTGAGCGGATGCTTAACCGCCCCGCCTAAAGAAGCCGCCAGACCGACATTAATGCCTCGTGCTCAGAGCTACAAAGATTTGACCCATCTGCCAGCGCCGACGGGTAAAATCTTTGTTTCGGTATACAACATTCAGGACGAAACCGGGCAATTTAAACCCTACCCGGCAAGTAACTTCTCCACTGCTGTTCCGCAAAGCGCCACGGCAATGCTGGTCACGGCACTGAAAGATTCTCGCTGGTTTATACCGCTGGAGCGCCAGGGCTTACAAAACCTGCTTAACGAGCGCAAGATTATTCGTGCGGCACAAGAAAACGGCACGGTTGCCATTAATAACCGAATCCCGCTGCAATCTTTAACGGCGGCAAATATCATGGTTGAAGGTTCGATTATCGGTTATGAAAGCAACGTCAAATCTGGCGGGGTTGGGGCAAGATATTTTGGCATCGGTGCCGACACGCAATACCAGCTCGATCAGATTGCCGTGAACCTGCGCGTCGTCAATGTGAGTACCGGCGAGATCCTTTCTTCGGTGAACACCAGTAAGACGATACTTTCCTATGAAGTTCAGGCCGGGGTTTTCCGCTTTATTGACTACCAGCGCTTGCTTGAAGGGGAAGTGGGTTACACCTCGAACGAACCTGTTATGCTGTGCCTGATGTCGGCTATCGAAACAGGGGTCATTTTCCTGATTAATGATGGTATCGACCGTGGTCTGTGGGATTTGCAAAATAAAGCAGAACGGCAGAATGACATTCTGGTGAAATACCGCCATATGTCGGTTCCACCGGAATCCTGA

[0518] SEQ ID NO: 2 (>P0AEA2(1:277); WT prepro-CsgG derived from Escherichia coli (E. coli) K12) MQRLFLVAVMLLSGCLTAPPKEAARPTLMPRAQSYKDLTHLPAPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFIPLERQGLQNLLNERKIIRAAQENGTVAINNRIPLQSLTAANIMV EGSIIGYESNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEVGYTSNEPVMLCLMSAIETGVIFLINDGIDRGLWDLQNKAERQNDILVKYRHMSVPPES

[0519] Sequence ID 3 (>p0aea2(16:277); mature csgg derived from Escherichia coli (e. coli) k12) CLTAPPKEAARPTLMPRAQSYKDLTHLPAPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFIPLERQGLQNLLNERKIIRAAQENGTVAINNRIPLQSLTAANIMVEGSIIGYE SNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEVGYTSNEPVMLCLMSAIETGVIFLINDGIDRGLWDLQNKAERQNDILVKYRHMSVPPES

[0520] Sequence ID 4 (>P0AE98; coding sequence for WT CsgF derived from Escherichia coli (E. coli) K12) ATGCGTGTCAAACATGCAGTAGTTCTACTCATGCTTATTTCGCCATTAAGTTGGGCTGGAACCATGACTTTCCAGTTCCGTAATCCAAACTTTGGTGGTAACCCAAATAATGGCGCTTTTTTAAATAGCGCTCAGGCCCAAAACTCTTATAAAAGATCCGAGCTATAACGATGACTTTGGTATTGAAACACCCTCAGCGTTAGAT AACTTTACTCAGGCCATCCAGTCACAAATTTTAGGTGGCTACTGTCGAATATTAATACCGGTAAACCGGGCCGCATGGTGACCAACGATTATATTGTCGATATTGCCAACCGCGATGGTCAATTGCAGTTGAACGTGACAGATCGTAAAACCGGACAAACCTCGACCATCCAGGTTTCGGGTTTACAAAATAACTCAACCGATTTT

[0521] Sequence ID 5 (>P0AE98(1:138); WT pre CsgF derived from Escherichia coli (E. coli) K12) MRVKHAVVLLMLISPLSWAGTMTFQFRNPNFGGNPNNNGAFLLNSAQAQNSYKDPSYNDDFGIETPSALDNFTQAIQSQILGGLLSNINTGKPGRMVTNDYIVDIANRDGQLQLNVTDRKTGQTSTIQVSGLQNNSTDF

[0522] Sequence ID 6 (>p0ae98(20:138); WT mature CSGF from Escherichia coli (e. coli) K12) GTMTFQFRNPNFGGNPNNNGAFLLNSAQAQNSYKDPSYNDDFGIETPSALDNFTQAIQSQILGGLLSNINTGKPGRMVTNDYIVDIANRDGQLQLNVTDRKTGQTSTIQVSGLQNNSTDF

[0523] Sequence ID 7 (>P0AE98;CsgF 1:27_6His code sequence) ATGCGTGTCAAACATGCAGTAGTTCTACTCATGCTTATTTCGCCATTAAGTTGGGCTGGAACCATGACTTTCCAGTTCCGTCATCACCATCACCATCACTAAGCCC

[0524] Sequence ID 8 (>p0ae98(1:28); preprotein of csgf 20:27_6his) MRVKHAVVLLMLISPLSWA GTMTFQFR HHHHHH

[0525] Sequence ID 9 (>P0AE98;CsgF 1:38_6His code sequence) ATGCGTGTCAAACATGCAGTAGTTCTACTCATGCTTATTTCGCCATTAAGTTGGGCTGGAACCATGACTTTCCAGTTCCGTAATCCAAACTTTGGTGGTAACCCAAATAATGGCCATCACCATCACCATCACTAAGCCC

[0526] Sequence ID 10 (>P0AE98(1:39); CsgF 20:38_6His preprotein) MRVKHAVVLLMLISPLSWAGTMTFQFRNPNFGGNPNNG HHHHHH

[0527] Sequence ID 11 (>P0AE98;CsgF 1:48_6His code sequence) ATGCGTGTCAAACATGCAGTAGTTCTACTCATGCTTATTTCGCCATTAAGTTGGGCTGGAACCATGACTTTCCAGTTCCGTAATCCAAACTTTGGTGGTAACCCAAATAATGGCGCTTTTTTATTAAATAGCGCTCAGGCCCAACATCACCATCACCATCACTAAGCCC

[0528] Sequence ID 12 (>P0AE98(1:49); CsgF 20:48_6His preprotein) MRVKHAVVLLMLISPLSWAGTMTFQFRNPNFGGNPNNNGAFLLNSAQAQ HHHHHH

[0529] Sequence ID 13 (>P0AE98;CsgF 1:64_6His code sequence) ATGCGTGTCAAACATGCAGTAGTTCTACTCATGCTTATTTCGCCATTAAGTTGGGCTGGAACCATGACTTTCCAGTTCCGTAATCCAAACTTTGGTGGTAACCCAAATAATGGCGCTTTTTTAAATAGCGCTCAGGCCCAAAACTCTTATAAAAGATCCGAGCTATAACGATGACTTTGGTATTGAAACA CATCACCATCACCATCACTAAGCCC

[0530] Sequence ID 14 (>P0AE98(1:65); CsgF 20:64_6His preprotein) MRVKHAVVLLMLISPLSWAGTMTFQFRNPNFGGNPNNNGAFLLNSAQAQNSYKDPSYNDDFGIETHHHHHH

[0531] Sequence ID 15 (>P0AE98(20:53); Mature peptide of CsgF 20:53) GTMTFQFRNPNFGGNPNNNGAFLLNSAQAQNSYKD

[0532] Sequence ID 16 (>P0AE98(20:42); CsgF 20:42 + matured KD peptide) GTMTFQFRNPNFGGNPNNGAFLLKD

[0533] Sequence ID 17 (>Q88H88_PSEPK(23:55)) TELVYTPVNPAFGGNPLNGTWLLNNAQAQNDY

[0534] Sequence ID 18 (>A0A143HJA0_9GAMM(25:57)) TELIYEPVNPNFGGNPLNGSYLLNNAQAQDRH

[0535] Sequence ID 19 (>Q5E245_VIBF1(21:53)) SELVYTPVNPNFGGNPLNTSHLFGGANAINDY

[0536] Sequence ID 20 (>Q084E5_SHEFN(19:51)) TQLVYTPVNPAFGGSYLNGSYLLANASAQNEH

[0537] Sequence ID 21 (>F0LZU2_VIBFN(15:47)) SSLVYEPVNPTFGGNPLNTTHLFSRAEAINDY

[0538] Sequence ID 22 (>A0A136HQR0_9ALTE(26:58)) TELVYEPINPSFGGNPLNGSFLLSKANSQNAH

[0539] Sequence ID 23 (>A0A0W1SRL3_9GAMM(21:53)) TEIVYQPINPSFGGNPMNGSFLLQKAQSQNAH

[0540] Sequence ID 24 (>B0UH01_METS4(26:59)) SSLVYQPVNPAFGGPQLNGSWLQAEANAQNIPQ

[0541] Sequence ID 25 (>Q6NAU5_RHOPA(22:53)) GSLVYTPTNPAFGGSPLNGSWQMQQATAGNH

[0542] Sequence ID 26 (>G8PUY5_PSEUV(7:38)) QQLIYQPTNPSFGGYAANTTHLFATANAQKTA

[0543] Sequence ID 27 (>A0A0S2ETP7_9RHIZ(25:57)) GDLVYTPVNPSFGGGSPLNSAHLLSIAGAQKNA

[0544] Sequence ID 28 (>E3I1Z1_RHOVT(19:51)) AELGYTPVNPSFGGGSPLNGSTLLSEASAQKPN

[0545] Sequence ID 29 (>F3Z094_DESAF(24:55)) TELVFSFTNPSFFGGDPMIGNFLLNKADSQKR

[0546] Sequence ID 30 (>A0A176T7M2_9FLAO(21:53)) QQLVYKSINPFFGGGDSFAYQQLLASANAQND

[0547] Sequence ID 31 (>D2QPP8_SPILD(14:45)) QALVYHPNNPAFGGNTFNYQWMLSSAQAQDR

[0548] Sequence ID 32 (>N2IYT1_9PSED(26:58)) TELVYTPKNPAFGGGSPLNGSYLLGNAQAQNDY

[0549] Sequence ID 33 (>W7QHV5_9GAMM(26:58)) GQLIYQPINPSFGGDPLLGNHLLNKAQAQDTK

[0550] Sequence ID 34 (>D4ZLW2_SHEVD(23:55)) TQLIYTPVNPNFGGSYLNGSYLLANASVQNDH

[0551] Sequence ID 35 (>D2QT92_SPILD(21:53)) QAFVYHPNNPNFGGNTFNYSWMLSSAQAQDRT

[0552] Sequence ID 36 (>A0A167UJA2_9FLAO(20:51)) QGLIYKPKNPAFGGDTFNYQWLASSAESQNK

[0553] Sequence ID 37 (>P0AE98(20:28); mature peptide of CsgF 20:27) GTMTFQFR

[0554] Sequence ID 38 (>P0AE98(20:39); mature peptide of CsgF 20:38) GTMTFQFRNPNFGGNPNNG

[0555] Sequence ID 39 (>P0AE98(20:49); mature peptide of CsgF 20:48) GTMTFQFRNPNFGGNPNNGAFLLNSAQAQ

[0556] Sequence ID 40 (>P0AE98(20:65); mature peptide of CsgF 20:64) GTMTFQFRNPNFGGNPNNNGAFLLNSAQAQNSYKDPSYNDDFGIET

[0557] Sequence ID 41 (CsgF_d27_end) ACGGAACTGGAAAGTCATGGTTCC

[0558] Sequence ID 42 (CsgF_d38_end) GCCATTATTTGGGTTACCACCAAAGTTTGG

[0559] Sequence ID 43 (CsgF_d48_end) TTGGGCCTGAGCGCTATTTAATAAAAAAGC

[0560] Sequence ID 44 (CsgF_d64_end) TGTTTCAATACCAAAGTCATCGTTATAGCTCGG

[0561] Sequence ID 45 (pNa62_CsgF_histag_Fw) CATCACCATCACCATCACTAAGCCC

[0562] Sequence ID 46 (CsgF-His_pET22b_FW) cccccatatgGGAACCATGACTTTCCAGTTCC

[0563] Sequence ID 47: (CsgF-His_pET22b_Rev) ccccGAATTCCTAatggtgatggtgatggtgGTAAAATCGGTTGAGTTATTTTG

[0564] Sequence ID 48: (csgEFG_pDONR221_FW) GGGGACAAGTTTGTACAAAAAAGCAGGCTACCTCAGGCGATAAAGCCATGAAACGTTA

[0565] Sequence ID 49: (csgEFG_pDONR221_Rev)GGGGACCACTTTGTACAAGAAAGCTGGGTGTTTAAACTCATTTTTCGAACTGCGGGTGGCTCCAAGCGCTGG

[0566] SEQ ID NO: 50: (Mut_csgF_His_FW)CAAAATAACTCAACCGATTTTcatcaccatcaccatcacTAAGCCCCAGCTTCATAAGG

[0567] Sequence ID 51: (Mut_csgF_His_Rev)CCTTATGAAGCTGGGGCTTAgtgatggtgatggtgatgAAAATCGGTTGAGTTATTTTG

[0568] Sequence ID 52: (DelCsgE_Rev) AGCCTGCTTTTTTGTACAAAC

[0569] Sequence ID 53: (DelCsgE FW) ATAAAAAATTGTTCGGAGGCTGC

[0570] Sequence ID 54 (>P0AE98(20:50); mature peptide with CsgF 1:30) GTMTFQFRNPNFGGNPNNNGAFLLNSAQAQN

[0571] Sequence ID 55 (>P0AE98(20:54); mature peptide with CsgF 1:35) GTMTFQFRNPNFGGNPNNNGAFLLNSAQAQNSYKDP

[0572] Examples of CsgF sequences with protease cleavage sites created in proteins. Signal peptides are in bold, and TEV protease cleavage sites are shown. Bold and underlined And the HCV C3 protease cleavage site underline This is shown as follows: StrepII indicates the C-terminal Strep tag, H10 indicates the C-terminal 10xHistidine tag, and ** indicates the STOP codon.

[0573] SEQ ID NO: 56 Pro-CsgF-Eco-(WT-T4C / N17S / P35-TEV-S36)-StrepII [Table 9]

[0574] SEQ ID NO: 57 Pro-CsgF-Eco-(WT-N17S-Del(P35-[TEV]-S36)-StrepII [Table 10]

[0575] SEQ ID NO: 58 Pro-CsgF-Eco-(WT-G1C / N17S / P35-[TEV]-S36)-StrepII [Table 11]

[0576] Layout number 59 Pro-CsgF-Eco-(WT-G1C / P35-[TEV]-S36)-StrepII Table 12

[0577] Layout number 60 Pro-CsgF-Eco-(WT-T45-TEV-P46)-H10 Table 13

[0578] Layout number 61 Pro-CsgF-Eco-(WT-P35-TEV-S36)-H10 Table 14

[0579] Layout number 62 Pro-CsgF-Eco-(WT-N30-TEV-S31)-H10 Table 15

[0580] Configuration number 63 Pro-CsgF-Eco-(WT-T45-TEV-F51)-H10 Table 16

[0581] Layout number 64 Pro-CsgF-Eco-(WT-N30-TEV-Y37)-H10 Table 17

[0582] Configuration number 65 Pro-CsgF-Eco-(WT-D34-[C3]-S36) Table 18

[0583] Sequence ID 66: Pro-CsgF-Eco-(WT-I42-[C3]-E43) [Table 19]

[0584] Sequence ID 67 Pro-CsgF-Eco-(WT-N38-[C3]-S47) [Table 20]

[0585] Sequence ID 68 MPRAQSYKDLTHLPMPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFIPLERQGLQNLLNERKIIRAAQENGTVAINNRIPLQSLTAANIMVEGSIIGYESNVKSGG VGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEIGYTSNEPVMLCLMSAIETGVIFLINDGIDRGLWDLQNKAERQNDILVKYRHMSVPPES

[0586] Sequence ID 69 CLTAPPKQAAKPTLMPRAQSYKDLTHLPAPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFIPLERQGLQNLLNERKIIRAAQENGTVAMNNRIPLQSLTAANIMVEGSIIGYESNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEIGYTSNEPVMLCLMSAIETG

[0587] Sequence ID 70 CLTAPPKEAAKPTLMPRAQSYKDLTHLPIPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFVPLERQGLQNLLNERKIIRAAQENGTVAINNRIPLQSLTAANIMVEGSIIGYE SNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEIGYTSNEPVMLCLMSAIETGVIFLINDGIDRGLWDLQNKADRQNDILVKYRHMSVPPES

[0588] Sequence ID 71 CLTTPPKEAAKPTLMPRAQSYKDLTHLPVPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFIPLERQGLQNLLNERKIIRAAQENGTVAINNRIPLPSLTAANIMVEGSIIGYE SNVKSGGAGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEIGYTSNEPVMLCLMSAIETGVIFLINDGIDRGLWDLQNKADRQNDILVKYRQMSVPPES

[0589] Sequence ID 72 CLTAPPKEAAKPTLMPRAQSYRDLTHLPAPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSHWFIPLERQGLQNLLNERKIIRAAQENGTVANNNRMPLQSLAAANVMIEGSIIGYE SNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEVLSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEIGYTSNEPVMMCLMSAIETGVIFLINDGIDRGLWDLQNKADAQNPVLVKYRDMSVPPES

[0590] Sequence ID 73 CLTAPPKEAAKPTLMPRAQSYRDLTHLPLPSGKVFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFVPLERQGLQNLLNERKIIRAAQENGTVADNNRIPLQSLTAANVMIEEGSIIGYE SNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEVLSSVNTSKTILSYEVQAGVFRFVDYQRLLEGEIGYTSNEPVMLCLMSAIETGVIYLINDGIERGLWDLQQKADVDNPILARYRNMSAPPES

[0591] Sequence ID 74 CLTAPPKEAAKPTLMPRAQSYRDLTNLPDPKGKLFVSVYNIQDETGQFKPYPASNFSTAVPQSATSMLVTALKDSRWFIPLERQGLQNLLNERKIIRAAQENGTVAENNRMPLQSLVAANVMIEEGSIIGYE SNVKSGGVGARYFGIGGDTQYQLDQIAVNLRVVNVSTGEVLSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEIGYTANEPVMLCLMSAIETGVIHLINDGINRGLWELKNKGDAKNTILAKYRSMAVPPES

[0592] Sequence ID 75 CLTAAPKEAARPTLLPRAPSYTDLTHLPSPQGRIFVSVYNIQDETGQFKPYPACNFSTAVPQSATAMLVSALKDSKWFIPLERQGLQNLLNERKIIRAAQENGSVAINNQRPLSSLVAANILIEGSIIGYE SNVKSGGVGARYFGIGASTQYQLDQIAVNLRAVDVNTGEVLSSVNTSKTILSYEVQAGVFRFIDYQRLLEGELGYTTNEPVMLCLMSAIESGVIYLVNDGIERNLWQLQNPSEINSPILQRYKNNIVPAES

[0593] Sequence ID 76 CITSPPKQAAKPTLLPRSQSYQDLTHLPEPQGRLFVSVYNISDETGQFKPYPASNFSTSVPQSATAMLVSALKDSNWFIPLERQGLQNLLNERKIIRAAQENGTVAVNNRTQLPSLVAANILIEGSIIG YESNVKSGGAGARYFGIGASTQYQLDQIAVNLRVVNVSTGEVLSSVNTSKTILSYEFQAGVFRYIDYQRLLEGEVGYTVNEPVMLCLMSAIETGVIYLVNDGISRNLWQLKNASDINSPVLEKYKSIIVP

[0594] Sequence ID 77 CLTAPPKQAAKPTLMPRAQSYQDLTHLPEPAGKLFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVSALKDSGWFIPLERQGLQNLLNERKIIRAAQENGTAAVNNQHQLSSLVAANVLVEGSIIG YESNVKSGGAGARFFGIGASTQYQLDQIAVNLRVVDVNTGQVLSSVNTSKTILSYEVQAGVFRYIDYQRLLEGEIGYTTNEPVMLCVMSAIETGVIYLVNDGINRNLWTLKNPQDAKSSVLERYKSTIVP

[0595] Sequence ID 78 CITTPPQEAAKPTLLPRDATYKDLVSLPQPRGKIYVAVYNIQDETGQFQPYPASNFSTSVPQSATAMLVSSLKDSRWFVPLERQGLNNLLNERKIIRAAQQNGTVGDNNASPLPSLYSANVIVEGSI IGYASNVKTGGFGARYFGIGGSTQYQLDQVAVNLRIVNVHTGEVLSSVNTSKTILSYEIQAGVFRFIDYQRLLEGEAGFTTNEPVMTCLMSAIEEGVIHLINDGINKKLWALSNAADINSEVLTRYRK

[0596] Sequence ID 79 ITEVPKEAAKPTLMPRASTYKDLVALPKPNGKIIVSVYSVQDETGQFKPLPASNFSTAVPQSGNAMLTSALKDSGWFVPLEREGLQNLLNERKIIRAAQENGTVAANNQQPLPSLLSANVVIEGAIIGY DSDIKTGGAGARYFGIGADGKYRVDQVAVNLRAVDVRTGEVLLSVNTSKTILSSELSAGVFRFIEYQRLLELEAGYTTNEPVMMCMMSALEAGVAHLIVEGIRQNLWSLQNPSDINNPIIQRYMKEDVP

[0597] Sequence ID 80 PETSESPTLMQRGANYIDLISLPKPQGKIFVSVYDFRDQTGQYKPQPNSNFSTAVPQGGTALLTMALLDSEWFYPLERQGLQNLLTERKIIRAAQKKQESISNHGSTLPSLLSANVMIEGGIVA YDSNIKTGGAGARYLGIGGSGQYRADQVTVNIRAVDVRSGKILTSVTTSKTILSYEVSAGAFRFVDYKELLEVELGYTNNEPVNIALMSAIDSAVIHLIVKGVQQGLWRPANLDTRNNPIFKKY

[0598] Sequence ID 81 PDASESPTLMQRGATYLDLISLPKPQGKIYVSVYDFRDQTGQYKPQPNSNFSTAVPQGGTALLTMALLDSEWFYPLERQGLQNLLTERKIIRAAQKKQESISNHGSTLPSLLSANVMIEGGIVA YDSNIKTGGAGARYLGIGGSGQYRADQVTVNIRAVDVRSGKILTSVTTSKTILSYELSAGAFRFVDYKELLEVELGYTNNEPVNIALMSAIDSAVIHLIVKGIEEGLWRPENQNGKENPIFRKY

[0599] Sequence ID 82 PETSKEPTLMARGTAYQDLVSLPLPKGKVYVSVYDFRDQTGQYKPQPNSNFSTAVPQGGAALLTTALLDSRWFMPLEREGLQNLLTERKIIRAAQKKDEIPTNHGVHLPSLASANIMVEGGIVAYDT NIQTGGAGARYLGVGASGQYRTDQVTVNIRAVDVRTGRILLSVTTSKTILSKELQTGVFKFVDYKDLLEAELGYTTNEPVNLAVMSAIDAAVVHVIVDGIKTGLWEPLRGEDLQHPIIQEYMNRSKP

[0600] Sequence ID 83 CATHIGSPVADEKATLMPRSVSYKELISLPKPKGKIVAAVYDFRDQTGQYLPAPASNFSTAVTQGGVAMLSTALWDSQWFVPLEREGLQNLLTERKIVRAAQNKPNVPGNNANQLPSLVAANILIEGGIV AYDSNVRTGGAGAKYFGIGASGEYRVDQVTVNLRAVDIRSGRILNSVTTSKTVMSQQVQAGVFRFVEYKRLLEAEAGFSTNEPVQMCVMSAIESGVIRLIANGVRDNLWQLADQRDIDNPILQEYLQDNAP

[0601] Sequence ID 84 ASSSLMPKGESYYDLINLPAPQGVMLAAVYDFRDQTGQYKPIPSSNFSTAVPQSGTAFLAQALNDSSWFIPVEREGLQNLLTERKIVRAGLKGDANKLPQLNSAQILMEGGIVAYDTNV RTGGAGARYLGIGAATQFRVDTVTVNLRAVDIRTGRLLSSVTTTKSILSKEITAGVFKFIDAQELLESELGYTSNEPVSLCVASAIESAVVHMIADGIWKGAWNLADQASGLRSPVLQKY

[0602] Sequence ID 85 QDSETPTLTPRASTYYDLINMPRPKGRLMAVVYGFRDQTGQYKPTPASSFSTSVTQGAASMLMDALSASGWFVVLEREGLQNLLTERKIIRASQKKPDVAENIMGELPPLQAANLM LEGGIIAYDTNVRSGGEGARYLGIDISREYRVDQVTVNLRAVDVRTGQVLANVMTSKTIYSVGRSAGVFKFIEFKKLLEAEVGYTTNEPAQLCVLSAIESAVGHLLAQGIEQRLWQV

[0603] Sequence ID 86 MPKSDTYYDLIGLPHPQGSMLAAVYDFRDQTGQYKAIPSSNFSTAVPQSGTAFLAQALNDSSWFVPVEREGLQNLLTERKIVRAGLKGEANQLPQLSSAQILMEGGIVAYDTNIKTG GAGARYLGIGVNSKFRVDTVTVNLRAVDIRTGRLLSSVTTTKSILSKEVSAGVFKFIDAQDLLESELGYTSNEPVSLCVAQAIESAVVHMIADGIWKRAWNLADTASGLNNPVLQKY

[0604] Sequence ID 87 LTRRMSTYQDLIDMPAPRGKIVTAVYSFRDQSGQYKPAPSSSFSTAVTQGAAAMLVNVLNDSGWFIPLEREGLQNILTERKIIRAALKKDNVPVNNSAGLPSLLAANIMLEGGIVGYDSNIH TGGAGARYFGIGASEKYRVDEVTVNLRAIDIRTGRILHSVLTSKKILSREIRSDVYRFIEFKHLLEMEAGITTNNDPAQLCVLSAIESAVAHLIVDGVIKKSWSLADPNELNSPVIQAYQQQRI

[0605] Sequence ID 88 PSDPERSTMGELTPSTAELRNLPLPNEKIVIGVYKFRDQTGQYKPSENGNNWSTAVPQGTTTILIKALEDSRWFIPIERENIANLLNERQIIRSTRQEYMKDADKNSQSLPPLLYAG ILLEGGVISYDSNTMTGGFGARYFGIGASTQYRQDRITIYLRAVSTLNGEILKTVYTSKTILSTSVNGSFFRYIDTERLLEAEVGLTQNEPVQLAVTEAIEKAVRSLIIEGTRDKIW

[0606] Sequence IDs 89-116 are CsgF peptides that can be used in the present invention.

[0607] Sequence ID 117 is sequence ID 3, with W at position 97. CLTAPPKEAARPTLMPRAQSYKDLTHLPAPTGKIFVSVYNIQDETGQFKPYPASNFSTAVPQSATAMLVTALKDSRWFIPLERQGLQNLLNERKIIWAAQENGTVAINNRIPLQSLTAANIMVEGSIIGYE SNVKSGGVGARYFGIGADTQYQLDQIAVNLRVVNVSTGEILSSVNTSKTILSYEVQAGVFRFIDYQRLLEGEVGYTSNEPVMLCLMSAIETGVIFLINDGIDRGLWDLQNKAERQNDILVKYRHMSVPPES

[0608] Sequence ID 118 (>P32270; Enterobacteriaceae phage T4) MTFDDLTEGQKNAFNIVMKAIKEKKHHVTINGPAGTGKTTLTKFIIEALISTGGTGIILA APTHAAKKILSKLSGKEASTIHSILKINPVTYEENVLFEQKEVPDLAKCRVLICDEVSMY DRKLFKILLSTIPPWCTIIGIGDNKQIRPVEPGENTAYISPFFTHKDFYQCELTEVKRSN APIIDVATDVRNGKWNYDKVVDGHGVRGFTGDTALRDFMVNYFSIVKSLDDLFENRVMAF TNKSVDKLNSIIRKKIFETDKDFIVGEIIVMQEPLFKTYKIDGKPVSEIIFNNGQLVRII EAEYTSTFVKARGVPGEYLIRHWDLTVETYGDDEYYREKIKIISSDEELYKFNLFLAKTA ETYKNWNKGGKAPWSDFWDAKSQFSKVKALPASTFHKAQGMSVDRAFIYTPCIHYADVEL AQQLLYVGVTRGRYDVFYV

[0609] SEQ ID NO: 119 (>D0MKQ2; Rhodothermus marinus) MEELSNEQQRVLDHVLAWLERNDAPPIFILTGSAGTGKTLLIRHLVRALQDRRIHYALAA PTGRAARILSERTGDHARTLHSLIYIFDRYQLVEEADRQTDEPLSLQLHFALRSAEHDAR LIIVDEASMVSDTAGEEELYRFGSGRLLNDLLTFARLIPKRDRPPTTRLLFVGDPAQLPP VGQSVSPALSAQYLRDTFGLSAETAHLRSVYRQRKGHPILETATALRNALEKGHYHTFRL PEQPPDLRPVGLEEAIETTATDFRRQNPSVLLCRTNALARKLNAAVRARLWGREGLPPQP GDLLLVNRNAPLHGLFNGDLVLVETVGPLEHRRVGRRGRPPVDLYFRDVELLYPHEKPRN RIRCKLLENLLESPDGQLSPDIIQALLIDFYRRHPSLKHGSSEFRLMLANDAYFNALHVR YGYAMTVHKAQGGEWKRATVVFNDWRHFRHAEFFRWAYTAITRAREELLTIGAPSFEALS DMRWQPAPSVPAPEQAAENATRFPLKALETYHQRLSEALTAAGIETTGVELLQYAVRYHL ARADRTTRIQYYYRGDGQISRIVTLGGADDPELTQQAYALFERILSEPPADSGELPENPL LREFLERAHLRLEGSGIRIVHWKEMPYALRLYFSADGENVTIDFYYNRRGVWTHAQEVGR SSSGALFARIQSLLQADS

[0610] Sequence ID 120 (>B1×365; Cyanothec ATCC51142) MSQSVVVPDELGEIITAVIEFYQDAVDKIEPKIVFLELRKNVVDWVSRTQLKIEEKEIQA TGLTRQQQTAYKEMINFIENSSEQYFRLSGYAGTGKSFLMAKVIEWLKQEDYKYSVAAPT NKAAKNLTQIARSQGIKIEATTVAKLLKLQPTIDVDTGQQSFEFNSEKELELKDYDVIII DEYSMLNKDNFRDLQQAVKGGESKFIFVGDSSQLPPVKEKEPIVANHPDIRKSANLTQIV RYDGEIVKVAESIRRNPRWNHQTYPFETVADGTIIKLNTEDWLQQALSHFEKEDWLSNPD YVRMITWRNKTADKYNQAIREALYGENVEQLVVGDRLIAKKPVFRSLPGGKKKEKKIILN NSEECKVIETPKINYNEKYKWEFYQVKVRTDEGGMIELRILTSESEEKRQKKLKELAKRA REEENYSEKKKQWAIYYELDELFDNMAYAYALTCHKAQGSSIDNVFLLVSDMHYCRDKTK MIYTGLTRAKKCCYVG

[0611] Sequence ID 121 (>Q2S429; Salinibacter ruber) MSTFADAPFTEDQEEAYDHVYDRLAQGERFTGLRGYAGTGKTYLVSRLVEQLLDEDCTVT VCAPTHKAVQVLSDELGDAPVQMQTLHSFLGLRLQPKQDGEYELVAEEERNFAEGVVIVD EASMIGREEWSHIQDAPFWVQWLFVGDPAQLPPVNEDPSPALDVPGPTLETIHRQAADNP ILELATKIRTGADGRFGSTFEDGKGVAVTRNREEFLDSILRAFDADAFAEDATHARVLAY RNKTVRRYNREIRAERYGADADRFVEGEWLVGTETWYYDGVQRLTNSEEVRVKKAQVETF EADDQSEWTVWELKIRTPGRGLTRTIHVLHEEERERYENALERRRGKAEDDPSKWDRFFE LRERFARVDYAYATTVHRAQGSTYDTVFVDHRDLRVCRGEERGALLYVAVTRPSRRLALLV

[0612] Sequence ID 122 (>B6BJ43(UPI000183B2F5); Sullfurimonas gotlandica GD1) MKILNKETYKLSLHQEEVFTQIVSQLDTKVSSILKSTNIEDYLLSLTGPAGTGKTFLTTQ IAKYLVEKRKESEYPMSSDFDFTITAPTHKAVGVLSKLLRENNIQSSCKTIHSFLGIKPF IDYTTGEEKFVVDKTNKRKDRTSILIVDESSMIGNTLYEYILEAIEDKRVNVVLFIGDPY QLLPIENSKNEIYDLPNRFFLSEVVRQAENSYIIRVATKLRERIKNQDFISLQQFFQENM EDEITFFHNKEAFLEDFYKEEEWYKENKILATYKNKDVDAFNKIIRNKFWEQKGNTTPST LLAGDMIRFKDAYTVGDITIYHNGQELQLGSTEVKYHDSLHIEYWECKSIYALEQQVFRV VNPDSEAVFNQKLQSLATKAKQAKFPDNKKLWKLYYETRNMFANVQYIHASTIHKLQGST YDVSYIDIFSLVHNHYMSDEEKYRLLYVAITRASKDIKIFMSAFDRTSDEKVIINNQNSE TMNTLKQLHDIDIILKDLDL

[0613] Sequence ID 123 (>M4MBC3; Vibrio phage Henriette 12B8) MADFELTLGQKTVLGEVISTILKPVNLNDTSRFHTMHGPAGSGKTTVLQRIISQIPAYKT IGFCSPTHKSVKVIRRMAREAGISHRVDIRTIHSALGLVMKPVRGDEVLVKEPFAEERIY DVLIIDEAGMLNDELIMYILESQSSKVIFVGDMCQIGPIQSNLPEEDGYTPTSTDDVSKV FTEVEMMSALTEVVRQAEGSPIIQLATEFRLAQDDIYADLPRIVTNTTPDGNGIITMPNG NWVDSAVARFQSDQFKEDPDHCRIVCYTNAMVDLCNDLVRKRLFGADVPEWLEDEILVAQ EMGSTWNNADELRIVSIDDHFDQQYEVPCWRMQLESVEDHKLHNALVVKGDYIEDFKFRL NAIAERANTDKNMSGMHWKEFWGMRKKFNTFKNVYAGTAHKSQGSTFDYTYVFTPDFYKF GATMTIKRLLYTAITRSRYTTYFAMNTGAQ

[0614] Sequence ID 124 (>I6XGX8; Vibrio phage phi-pp2) MGLTNCQQGAMDAFLESDGHMTISGPAGSGKTFLMKSILEALESKGKNVTMVTPTHQAKN VLHKATGQEVSTIHSLLKIHPDTYEDQKHFTQSGEVEGLDEIDVLVVEEASMVDEELFQI TGRTMPRKCRILAVGDKYQLQPVKHDPGVISPFFTKFTTFEMNEVVRQAKDNPLIQVATE VRNGQWLRTNWSKERRQGVLHVPNVNKMLDTYLSKVNSPEDLLDYRILAYTNDCVDTFNG IIREHVYNTSEPFIPGEYLVTQMPVMVSNGKYPVCVIENGEVVKILDVRQKTIDGMLPKV DNEAFDVAVLTVEKEDGNVYEFTVLWDDLQKERFARYLSVAAGTYKSMRGNTKRYWRAFW GLKEQMIETKSLGASTVHKSQGTTVKGVCLYTQDMGYAEPEILQQLVYVGLTRPTDWALY N

[0615] Sequence ID 125 (>E5DRP6; Aeromonas phage 65) MSESEITLTPSQNMAVNEVKNGTGHITISGPPGSGKTFLVKYLIKMLGDELGTVLAAPTH QAKIVLTEMSGIEACTIHSLMKIHPETLEDIQIFDQSKLPDLSNIRYLIVEEASMHSKTL FKITMKSIPPTCRIIAIGDKDQIQPEEHAQGELSPYFTDPRFSQIRLTDIMRQSLDNPII QVATKIREGGWIEPNWNRDTKTGVYKVSGITDLVNSYLRAVKTPEDLTKYRFLAYTNKVV NKVNSIVREHVYKTKLPFIEGEKIVLQEPVMVEHEDDTIETIFTNGEVVTINEIEVFDRT IRIDGSPEFKVNAAKLSVSSDYSGIEHDFCVLYGSESRLEFEYQLSESAGNIKQMGKGGN QRSAWKSFWAAKKMFIETKSLGASTIHKSQGSTVKGVWLALHDIHYADEELKQQLVYVGV TRPTDFCLYFDGTK

[0616] Sequence ID 126 (>I6×H64; Aeromonas phage CC2) MAVDAVQSGTGHITISGPPGSGKTFLVKYIIKMLGDELGTVLAAPTHQAKIVLTEMSGIE ACTIHSLMKIHPETLEDIQIFDQSKMPDLSTVRYLIIEEASMHSKALFNITMKSIPPTCR IIAIGDKDQIQPVDHAPGELSPYFTDSRFTQIRMTDIMRQSLDNPIIQVATTIREGGWIY QNWNKEKKSGVYKVKSITDLINSYLRVVKTPEDLTKYRFLAFTNKVVDKVNSIVRKHVYK TDLPFIEGEKLVLQEPVMVEYDDDTIETIFTNGEVVTVDEIEVSDMNIRIDGSPAFSISV AKLKVTSDFSGVTHDIMSVYGEDSKAEFNYQLSEAAAVIKQMQRGQTKAAWASFWDAKKT FTETKSLGACTIHKSQGSTVKGVWLGLHDISYADTDLQQQLVYVGVTRPTDFCLYFDGSK

[0617] Sequence ID 127 (>K4FBD0; Cronobacter phage vB CsaM GAP161) MSELTFDDLSDDQKSAHDRVIHNIQNAIHTTITGGPGVGKTTLVKFVFNTLKGLGISGIW LTAPTHQAKNVLAAAATGMDATTIHSALKISPVTNEELRVFEQQKGKKAPDLSTCRVFVVE EVSMVDMDLFRIIRRSIPSNAVILGLGDKDQIRPVNADGRVELSPFFDEEIFDVIRMDKI MRQAEGNPIIQVSRAVRDGKMLKPMSVGDLGVFQHANAVDFLRQYFRRVKTPDDLIENRM FAYTNDNVDKLNATIRKHLYKTTEPFILDEVIVMQEPLVQEMRLNGQIFTEIVYNNNEKI RVLEIIPRREVIKAEKCDEKIEIEFYLLKTVSLEEETEAQIQVVVDPVMKDRLGNYLAYV ASTYKRIKQQTGYKAPWHSFWAIKNKFQDVKPLPVCTYHKSQGSTYDHAYMYTRDAYAFA DYDLCKQLIYVGVTRARYTVDYV

[0618] Sequence ID 128 (>D5JF67; Klebsiella phage KP15) MSELTFDDLSEDQKNAHDRVIKNIRNKIHTTITGGPGVGKTTLVKFVFETLKKLGISGIW LTAPTHQAKNVLSEAVGMDATTIHSALKISPVTNEELRVFEQQKGKKAADLSECRVFVVE EVSMVDKELFRIIKRTIPSCAVILGLGDKDQIRPVNTEGITELSPFFDEEIFDVIRMDKI MRQAEGNPIIQVSRAIRDGKPLMPLMNGELGVMKHENASDFLRRYFSRVKTPDDLNNNRM FAYTNANVDKLNAVIRKHLYKTDQPFIVGEVVVMQEPLVTEGRVNGVSFVEVIYNNNEQI KILEIIPRSDTIKADRCDPVQIDYFLMKTESMFEDTKADIQVIADPVMQERLGDYLNYVA FQYKKMKQETGYKAPWYSFWQIKNKFQTVKALPVCTYHKGQGSTYDHSYMYTRDAYAYAD YELCKQLLYVGTTRARFTVDYV

[0619] Sequence ID 129 (>J7HXT5; Stenotrophomonas phage IME13) MVTYDDLTVGQKDAIEKALQAMRTKRHITIRGPAGSGKTTMTRFLLERLFQTGQQGIVLT APTHQAKKELSKHALRKSYTIQSVLKINPSTLEENQIFEQKGTPDFSKTRVLICDEVSFY TRKLFDILMRNVPSHCVVIGIGDKAQIRGVSEDDTHELSPFFTDNRFEQVELTEVKRHQG PIIEVATDIRNGKWIYEKLDDSGNGVKQFHTVKDFLSKYFERTKTPNDLLENNRIMAYTNN SVDKLNSVIRKQLYGANAAPFLPDEILVMQEPLMFDIDIGGQTLKEVIFNNGQNVRVINV KPSRKTLKAKGVGEIEVECTMLECESYEEDEDDYRRAWFTVVHDQNTQYAINEFLSIIAE KYRSREVFPNWKDFWAIRNTFVKVRPLGAMTFHKSQGSTFDNAYLFTPCLHQYCRDPDVA QELIYVGNTRARKNVCFV

[0620] Sequence ID 130 (>E5EYE6; Acinetobacter phage Ac42) MNFEDLTEGQKNAYTAAIKAIETVPSSSAEKRHLTINGPAGTGKTTLTKFLIAELIRRGE RGVYLAAPTHQAKKVLSQHAGMEASTIHSLLKINPTTYEDSTTFEQKDVPDMSECRVLIC DEASMYDLKLFQILMSSIPLCCTVIALGDIAQIRPVEPGAFEGQVSPFFTYEKFEQVSLT EVMRSNAPIIDVATSIRTGNWIYENVIDGAGVHNLTSERSVKSFMEKYFSIVKTPEDLFE NRLLAFTNKSVDDLNKIVRKKIYNTLEPFIDGEVLVMQEPLIKSYTYEGKKVSEIVFNNG EMVKVLCCSQTSDEISVRGCSTKYMVRYWQLDLQSLDDPDLTGSINVIVDEAEINKLNLV LGKSAEQFKSGAVKAAWADWWKLKRNFHKVKALPCSTIHKSQGTSVDNVFLYTPCIHKAD SQLAQQLLYVGATRARHNVYYI

[0621] Sequence ID 131 (>E3SFA5; Shigella phage SP18) MIKFEDLNTGQKEAFDYITEAIQRRSGECITLNGPAGTGKTTLTKFVIDHLVRNGVMGIV LAAPTHQAKKVLSKLSGQTANTIHSILKINPTTYEDQNIFEQREMPDMSKCNVLVCDEAS MYDGSLFKIICNSVPEWCTILGIGDMHQLQPVDPGSTQQKISPFFTHPKFKQIHLTEVMR SNAPIIEVATEIRNGGWFRDCMYDGHGVQGFTSQTALKDFMVNYFGIVKDADMLMENRMMY AYTNKSVEKLNNIIRRKLYETDKAFLPYEVLVMQEPHMKELEFEGKKFSETIFNNGQLVR IKDCKYTSTILRCKGESHQLVINYWDLEVESIDEDEEYQVDRIKVLPEDQQPKFQAYLAK VADTYKQMKAAGKRPEWKDFWKARRTFLKVRALPVSTIHKAQGVSVDKAFIYTPCIHMAE ASLASQLAYVGITRARYDAYYV

[0622] Sequence ID 132 (>I7J3V8; Yersinia phage phiR1-RT) MITYDDLTDGQKSAFDNTMEAIKNKKGHITINGPAGTGKTTLTKFIIDHLIKTGEAGIIL CAPTHQAKKVLSKLSGMDASTIHSVLKINPTTYEENQIFEQREVPDLAACRVLICDEASF YDRKLFGIILATVPSWCTVIALGDKDQLRPVTPGESEQQLSPFFSHAKFKQVHLTEIKRS NGPIIQVATDIRNGGWLSENIVDGEGVHAFNSNTALKDFMIRYFDVVKTADDLIESRMLA YTNKSVDKLNGIIRRKLYETDKPFINGEVLVMQEPLMKELEFDGKKFHEIVFNNGQLVKI LYASETSTFISARNVPGEYMIRYWNLEVETADSDDDYATSQIQVICDPAEMTKFQMFLAK TADTYKNSGVKAYWKDFWSVKNKFKKVKALPVSTIHKSQGCTVNNTFLYTPCIHMADAQL AKQLLYVGATRARTNLYYI

[0623] Sequence ID 133 (>M1EA88; Salmonella phage S16) MITFEQLTSGQKLAFDETIRAIKEKKNHVTINGPAGTGKTTLTKFIMEHLVSTGETGIIL TAPTHAAKKVLTKLSGMEANTIHKILKINPTTYEESMLFEQKEVPDLASCRVLICDEASM WDRKLFKILMASIPKWCTIVAIGDVAQIRPVDPGETEAHISPFFIHKDFKQLNLTEVMRS NAPIIDVATDIRNGSWIYEKTVDGHGVHGFTSTTALKDFMMQYFSIVKSPEDLFENRMLA FTNKSVDKLNSIIRRRLYQTEEAFVVGEVIVMQEPLMRELVFEGKKFHETLFTNGQYVRI LSADYTSSFLGAKGVSGEHLIRHWVLDVETYDDEEYAREKINVISDEQEMNKFQFFLAKT ADTYKNWNKGGKAPWSEFWDAKRKFHKVKALPCSTFHKAQGISVDSSFIYTPCIHVSSDN KFKLELLYVGATRGRHDVFFV

[0624] The following examples illustrate the present invention. [Examples]

[0625] Detailed methods for preparing and testing mutant CsG pores and mutant CsgG / CsGF complexes are described in International Publications 2016 / 034591, 2017 / 149316, 2017 / 149317, 2017 / 149318, 2018 / 211241, and 2019 / 002893 (all incorporated herein by reference in their entirety). Detailed methods for preparing modified Dda helicases are described in International Publications 2015 / 055981, 2015 / 166276, and 2016 / 055777 (all incorporated herein by reference in their entirety).

[0626] Example 1 This example describes a method for comparing the velocity, precision, and velocity-diffusion ratio characteristics of a variant polynucleotide-binding protein that controls polynucleotide movement with those of a control variant polynucleotide-binding protein that controls polynucleotide movement, using a nanopore as described in International Publication No. 2019 / 002893.

[0627] Preparation of barcoded 3.6kb analytes Double-stranded 3.6kb DNA analytes were prepared using specific primers and PCR. The PCR products were subjected to NEBNext end repair and NEBNext dA tailing modules (New England Biolabs (NEB)) to induce 3'dA overhangs. Barcodes were introduced into the analytes using EXP-PBC001 (Oxford Nanopore Technologies) according to the manufacturer's guidelines.

[0628] Preparation of variant sequencing adapters Recombinant expression vectors encoding polynucleotide-binding protein variants described in International Publication No. 2016 / 055777 and PCT / EP2023 / 059821, and possessing N-terminal affinity and solubility tags, were used to transform chemically competent E. coli cells. The cells were plated onto LB agar plates containing antibiotics. Colonies from the agar plates were inoculated into LB growth medium and grown to an OD of 0.400–0.800, then induced and further grown at 18°C ​​for 16 hours. Cells were lysed using Bugbuster extraction reagent (Merck 70921) in the presence of lysozyme, benzoase, and protease inhibitors, or lysed by sonication in the presence of benzoase and protease inhibitors. The supernatant was further purified by affinity chromatography. Purified variant polynucleotide-binding proteins were bound to sequencing Y adapters described in International Publication No. 2015 / 110813 (which is incorporated herein by reference in its entirety) in 50 mM Hepes pH 8.0, 100 mM potassium acetate, and 1 mM EDTA at ambient temperature for 10 minutes. TMAD (SIGMA) was added to a final concentration of 100 μM, and incubated at 34°C for 1 hour. 10 mM ATP, 10 mM MgCl2, and 0.5 M NaCl were added, and incubated at ambient temperature for 10 minutes. The variant polynucleotide-binding protein-binding sequencing adapters were purified using Sera-Mag SpeedBeads (Thermo Scientific). These were variant sequencing adapters.

[0629] Preparation of a control sequence determination adapter Variants of polynucleotide-binding proteins described in International Publication No. 2016 / 055777 were used as controls for each variant position. The control polynucleotide-binding proteins were purified and loaded into sequencing adapters as described above. These were the control sequencing adapters.

[0630] Library creation Variant sequencing adapters and control sequencing adapters were ligated to barcoded 3.6kb analytes, with each variant ligated to a different barcode and each control to a different barcode. The variant and control libraries were pooled. The pooled libraries were prepared for sequencing and run on a MinION flow cell according to the manufacturer's guidelines (Oxford Nanopore Technologies). Up to six variants were run on a single MinION flow cell along with their controls, which were internal flow cell controls.

[0631] Electrical measurement Electromechanics were acquired using FLO-PRO114M Promethion Flow Cells and PromethION (Oxford Nanopore Technologies). A standard sequencing script was executed, and raw data was collected into bulk FAST5 files using MinKNOW software (Oxford Nanopore Technologies).

[0632] Data Analysis The DNA library was sequenced using a standard base-carrying algorithm from Guppy (Oxford Nanopore Technologies). The sequenced reads were demultiplexed using Guppy (Oxford Nanopore Technologies). More than 500 reads for each variant and control were mapped to a 3.6kb analyte reference sequence.

[0633] The speed of individual DNA strands as they passed through the pore was calculated by dividing the number of bases mapped to the reference by the reading duration (measured in bases per second). The median speed (bases / second) was the median speed of multiple individual DNA strands as they passed through the pore. The median speed of the variant was divided by the median speed of the control. This was the speed ratio. The speed ratio was subtracted from 1 and multiplied by 100. This was the change in speed %. Therefore, a positive change in speed % indicated that the variant moved the DNA more rapidly than the control.

[0634] The variation in velocity as multiple individual DNA strands pass through the pore was measured by calculating the interquartile range. Therefore, a small interquartile range indicates a narrow velocity distribution, while a large interquartile range indicates a broad velocity distribution. The normalized velocity distribution was calculated by dividing the interquartile range of velocity by the median velocity. The normalized velocity distribution of the variant was divided by the normalized velocity distribution of the control, which was the velocity diffusion ratio. Subtracting the velocity diffusion ratio from 1 and multiplying by 100 gave the velocity diffusion % change. Therefore, a negative velocity diffusion % change indicated that the variant had a narrower velocity distribution than the control.

[0635] The precision of individual DNA strands was calculated by mapping the base-called sequence to a reference. The median precision was the median precision of multiple individual DNA strands. The median precision of the variant was divided by the median precision of the control. This was the precision ratio. The precision ratio was subtracted from 1 and multiplied by 100. This was the precision % change. Therefore, a positive precision % change indicated that the variant was more accurate than the control.

[0636] The results are shown in Table 8 below. Column 1 identifies variants based on sequence number 118. Columns 2-4 show the percentage change compared to the control Dda (no mutation). [Table 21] TIFF2026539008000023.tif236152 TIFF2026539008000024.tif236152 TIFF2026539008000025.tif236152 Table 8: Changes in velocity, precision, and velocity diffusion ratio of the modified helicase of the present invention (TIFF2026539008000026.tif159152)

Claims

1. A modified DNA-dependent ATPase (Dda) helicase, wherein the helicase (a) has the following amino acid positions in Dda 1993: F3, D4, I16, K24, K25, H26, H27, V28, P33, T42, F44, I46, A48, A60, P62, A65, K67, K68, I69, K72, K76, S79, I84, P104, K108, V117, Y120, R122, L124, I132, P 134, W135, T137, N144, K145, E154, A157, Y158, P161, K166, Q170, T174, V176, N180, A1 81, V190, Y197, V200, V201, R207, T213, A214, L215, M219, V220, I225, K227, L229, V23 7, M238, K247, L248, I251, R253, K254, F257, D262, V265, D282, I289, Q295, Y304, S306 , V309, V314, G316, L319, R321, T329, G331, D333, L349, F352, T362, N365, N367, G369, G370, P373, A380, Q383, S385, P391, S393, F395, M401, S402, V403, D404, R405, A406, I413, H414, V418, E419, A421, Q422, V427, V429, G432, Y434, D435 and F437 and / or (b) containing one or more of the following substitutions at the positions corresponding to the following amino acid positions in Dda 1993: T2N, T2K, T2S, T2D, T2I, T2L, T2E, T2F, T2G, T2H, T2Q, T2R, T2A, T2M, T2P or T2V, E47D, E47G, E47H, E47N, E47P, E47Q, E47S, E47T, E47A or E47R, E54I, E54V, E54K, E54Y, E54T, E54L, E54N, E54A, E54F, E54M, E54D, E54H, E54P, E54Q, E54R or E54S, T55F, T55V, T55H, T55I, T55L, T55M, T55W, T55Y, T55A, T55P, T55Q or T55R, - S83E, S83D, S83A, S83P, S83G, or S83M, - K86N, K86G, K86D, K86E, K86H, K86Q, K86R, K86S, K86T, K86M or K86P, - N88K, N88E, N88T, N88S, N88V, N88Q, N88A, N88L, N88D, N88G, N88G, N88I, or N88P, - P89G, P89K, P89M, P89Q, P89R, or P89D, - V90E, V90D, V90K, V90Q, V90N, V90S, V90A, V90I, V90L, V90M, V90P, V90R, V90F, V90Y, V90H or V90G, T91E, T91D, T91R, T91K, T91Y, T91H, T91P, T91A, T91V, T91L, T91I, T91S or T91M, Y92K, Y92E, Y92R, Y92P, Y92I, or Y92M, E93P, E93D, E93G, E93A, E93L, E93K, E93Q, E93S, E93T, E93H, E93N or E93R, - V96K, V96T, V96P, V96D, V96G, V96S, V96I, V96N, V96A, V96H or V96M, F98M or F98I, - K101R, K101T, K101S, K101V, K101E, K101I, K101G, K101L, K101M, K101P, K101Q, K101D, K101H or K101N, - V103K, V103N, V103L, V103I, V103T, V103R, V103Y, V103S, V103D, V103A, V103E, V103H, V103M, V103P, V103Q, or V103F, C114K or C114R, - D151G, D151V, D151N, D151K, D151T, D151A, D151H, D151P, D151Q, D151R or D151S, G153E, G153S, G153D, G153T, G153N, G153K, G153A, G153Q, G153R, G153L, G153H or G153P, - N155K, N155P, N155S, N155E, N155D, N155G, N155T, N155A, N155V, N155L, N155I, N155H, N155M, N155Q, or N155R, T156H, T156Q, T156R, or T156W, K177A or K177P, - W195F, W195Y, W195P, W195K, W195E, W195I, W195L, W195D, W195S, W195G, W195T, W195V, W195Q, W195N, W195R, W195M, or W195H, I196P, I196L, I196D, I196A, I196E, I196K, I196Q, I196S, I196T, I196F, I196M, I196V or I196Y, D198N, D198P, D198E, D198G, D198H, D198K, D198Q, D198R, D198S or D198T, T210A, T210M, T210P, T210Q, T210I, T210L, T210V, or T210F, N221P, N221S, or N221G, - K243R, K243E, K243D, K243A, K243S, K243M, K243N, K243P, K243T or K243Y, E258G, E258K, E258N, E258P, E258D, E258S, E258A, E258H, E258Q, E258R, or E258T, F276T, F276S, F276L, F276P, F276E, F276D, F276N or F276Q, - I281E, I281V, I281K, I281A, I281D, I281H, I281N, I281P, I281Q, I281R, I281S, I281T, I281F, I281L, I281M or I281Y, N292E, N292A, N292S, N292D, N292K, N292H, N292R, N292Q, or N292T, E301K, E301D, E301N, E301S, E301A, E301H, E301M, E301P, E301Q, E301R, or E301T, F308K, F308P, F308R, F308T, F308G, F308E, F308S, F308V, F308A, F308Y, F308N, F308M, F308D, F308H, F308Q or F308W, - Y335P, Y335K, Y335E, Y335F, Y335T, Y335Q, Y335S, Y335R, Y335D, Y335V, Y335N, Y335G, Y335H, Y335M, or Y335W, - Y336E, Y336H, Y336K, Y336I, Y336G, Y336S, Y336T, Y336D, Y336V, Y336P, Y336N, Y336R, Y336Q, Y336A, Y336F, Y336M, or Y336W, - R337E, R337K, R337T, R337Q, R337P, R337V, R337F, R337S, R337D, R337G, R337Y, R337A, R337H, or R337N, Y350P, - L354K, L354E, L354D, L354V, L354Y, L354R, L354S, L354N, L354H, L354M, L354P, L354T, L354F, or L354I, K358G or K358P, -T359V, T359M, T359A, T359I, T359Y, T359F, T359E, T359K, T359N, T359D, T359P, T359Q, T359R, T359S, T359W, or T359G, - K364N, K364Q, K364D, K364E, K364G, K364H, K364S, K364T, K364M, K364P, K364Y, K364I, K364L or K364V, - W366D, W366N, W366K, W366A, W366S, W366I, W366E, W366R, W366M, W366T, W366Q, W366Y, W366G, W366F, W366V, W366P, or W366H, - K368A, K368E, K368S, K368G, K368D, K368F, K368M, K368T, K368V, K368Y, K368H, K368N, K368P, K368Q or K368R, and A modified DNA-dependent ATPase (Dda) helicase in which one or more positions corresponding to S382R, S382N, S382K, S382E, S382Q, S382A, S382H, S382M, S382T, S382D, S382G, or S382P are modified or substituted.

2. A modified DNA-dependent ATPase (Dda) helicase according to claim 1, - The amino acid position corresponding to position F3 of Dda 1993 is substituted with K, Y, I, E, G, L, A, S, D, R, V, T, N, H, M, P, Q or W. - The position corresponding to amino acid position D4 in Dda 1993 is substituted with I, L, K, P, S, E, Y, T, F, M, V, A, G, H, N, or Q. - The position corresponding to amino acid position I16 in Dda 1993 is substituted with G, A, E, L, K, D, N, S, F, M, T, V or Y. - The position corresponding to amino acid position K24 in Dda 1993 is substituted with G, P, A, D, N, S, E, H, M, Q, R, or T. - The position corresponding to amino acid position K25 in Dda 1993 is substituted with A, N, G, D, E, I, L, M, P, Q, R, S, T, V or H. - The position corresponding to amino acid position H26 of Dda 1993 is substituted with L, K, R, Q, S, M, A, T, N, P, G, E, I, V, F, Y, or D. - The position corresponding to amino acid position H27 in Dda 1993 is substituted with F, I, V, L, Y, A, T, S, M, W, D, E, K, N, Q, or R. - The position corresponding to amino acid position V28 in Dda 1993 is substituted with I, F, A, L, M, T, or Y. - The position corresponding to amino acid position P33 in Dda 1993 is substituted with A, Y, F, G, E, I, K, L, M, Q, R, S, T, V, D, H or W. - The position corresponding to amino acid position T42 in Dda 1993 is substituted with I, L, A, F, M, V, Y, D, E, K, N, P, Q, R or S. - The position corresponding to amino acid position F44 of Dda 1993 is substituted with K, A, R, Y, G, H, T, S, Q, L, N, E, M, V, D, P, I, or W. - The position corresponding to amino acid position I46 in Dda 1993 is substituted with V, A, F, L, M, T, or Y. - The position corresponding to amino acid position A48 in Dda 1993 is substituted with K, H, Y, R, E, N, Q, S, T, D, M, P, G, I, L, V, F, or W. - The position corresponding to amino acid position A60 in Dda 1993 is substituted with T, D, E, I, K, L, M, N, P, Q, R, S, V or G. - The position corresponding to amino acid position P62 in Dda 1993 is substituted with S, A, D, E, G, H, K, M, N, Q, R or T. - The position corresponding to amino acid position A65 in Dda 1993 is substituted with V, Q, K, G, R, Y, L, I, F, T, M, H, E, P, S, D or N. The position corresponding to amino acid position K67 in Dda 1993 is substituted with A, V, T, S, R, M, E, G, I, L, P, Q, D, H, N, F, or Y. - The amino acid position corresponding to position K68 of Dda 1993 is substituted with A, N, E, G, I, L, M, P, Q, R, S, T, V, D, or H. - The position corresponding to amino acid position I69 in Dda 1993 is substituted with E, V, R, Q, N, A, K, T, S, D, L, H, M, P, F, or Y. - The position corresponding to amino acid position K72 of Dda 1993 is substituted with A, E, G, I, L, M, P, Q, R, S, T, V, D, H, or N. - The position corresponding to amino acid position K76 in Dda 1993 is substituted with M, Y, F, I, V, R, A, L, Q, S, T, W, D, E, H, N, or P. - The position corresponding to amino acid position S79 of Dda 1993 is substituted with T, K, R, V, E, A, D, I, L, M, N, P, Q, G, or H. - The position corresponding to amino acid position I84 in Dda 1993 is substituted with L, V, F, A, M, T, or Y. - The position corresponding to amino acid position P104 of Dda 1993 is substituted with Y, K, E, F, H, I, L, M, Q, V, W, A, D, S, or T. - The position corresponding to amino acid position K108 in Dda 1993 is substituted with Y, E, D, H, N, S, G, F, I, L, M, Q, V, W, A, P, R, or T. - The amino acid position V117 of Dda 1993 is substituted with A, S, E, G, I, K, L, M, P, Q, R, T, F, or Y. - The position corresponding to amino acid position Y120 of Dda 1993 is substituted with V, L, I, M, F, A, T, S, H, Q, or W. - The position corresponding to amino acid position R122 of Dda 1993 is substituted with E, K, N, D, L, T, S, A, V, I, P, Q, H, or M. - The position corresponding to amino acid position L124 in Dda 1993 is substituted with T, A, D, E, I, K, M, N, P, Q, R, S, V, F or Y. - The position corresponding to amino acid position I132 in Dda 1993 is substituted with T, V, L, A, D, E, K, M, N, P, Q, R, S, F or Y. - The amino acid position P134 of Dda 1993 is substituted with D, E, K, S, L, A, R, I, N, V, T, G, H, or Q. - The position corresponding to amino acid position W135 in Dda 1993 is substituted with D, H, T, N, E, G, S, K, Y, Q, R, F, A, P, or M. - The position corresponding to amino acid position T137 in Dda 1993 is substituted with K, R, I, V, A, D, E, H, M, N, P, Q, S, or L. - The position corresponding to amino acid position N144 of Dda 1993 is substituted with S, P, K, T, R, E, A, D, I, L, Q, Y, H, V, M, or G. - The position corresponding to amino acid position K145 in Dda 1993 is substituted with D, A, H, R, G, N, E, P, Q, S, T, or M. - The position corresponding to amino acid position E154 in Dda 1993 is substituted with N, S, V, I, T, D, G, H, K, Q, R, A or P. - The position corresponding to amino acid position A157 of Dda 1993 is substituted with E, D, S, K, P, N, H, Q, R, T, G, I, L, M or V. - The position corresponding to amino acid position Y158 of Dda 1993 is substituted with Q, S, E, L, D, A, I, K, F, N, G, R, V, T, H, P, M, or W. - The position corresponding to amino acid position P161 in Dda 1993 is substituted with E, D, K, S, N, R, Q, T, A, or H. - The position corresponding to amino acid position K166 in Dda 1993 is substituted with N, P, D, E, G, H, Q, R, S, T, A or M. - The position corresponding to amino acid position Q170 of Dda 1993 is substituted with K, I, V, T, S, E, R, N, H, Y, F, A, D, M or P. - The position corresponding to amino acid position T174 in Dda 1993 is substituted with S, A, D, E, G, H, K, M, N, P, Q, R, I, L or V. - The amino acid position corresponding to position V176 of Dda 1993 is substituted with I, G, P, A, T, R, S, Q, K, L, E, F, M or Y. - The position corresponding to amino acid position N180 in Dda 1993 is substituted with D, E, K, A, G, H, P, Q, S, T, or R. - The position corresponding to amino acid position A181 of Dda 1993 is substituted with G, N, L, S, R, T, D, K, Q, H, E, I, M, P, or V. - The amino acid position corresponding to position V190 of Dda 1993 is substituted with I, A, F, L, M, T, or Y. - The position corresponding to amino acid position Y197 in Dda 1993 is substituted with K, P, R, S, E, G, D, T, L, N, I, V, F, A, H, M, Q, or W. - The position corresponding to amino acid position V200 in Dda 1993 is substituted with I, T, F, K, D, L, N, E, S, Y, P, A or M. - The amino acid position corresponding to position V201 of Dda 1993 is substituted with F, Y, I, K, L, H, M, W, A, or T. - The position corresponding to amino acid position R207 of Dda 1993 is substituted with I, H, K, V, F, Y, L, T, E, A, M, N, Q, S, or D. - The position corresponding to amino acid position T213 in Dda 1993 is substituted with D, N, E, K, S, G, A, Q, H, P, I, L, M, R, or V. - The position corresponding to amino acid position A214 in Dda 1993 is substituted with G, S, E, K, D, L, N, I, T, V, M, P, Q, R, or H. - The position corresponding to amino acid position L215 of Dda 1993 is substituted with Y, I, E, F, D, H, M, Q, V, W, A, T, K, N, P, R or S. - The position corresponding to amino acid position M219 in Dda 1993 is substituted with L, I, V, A, F, Y, K, D, E, S, T, Q, R, or W. - The position corresponding to amino acid position V220 in Dda 1993 is substituted with K, E, N, A, D, R, S, T, Q, L, I, G, H, M, P, F, or Y. - The position corresponding to amino acid position I225 in Dda 1993 is substituted with V, K, T, D, N, S, E, G, R, Q, P, A, H, L, Y, F or M. - The position corresponding to amino acid position K227 in Dda 1993 is substituted with G, A, D, N, S, E, H, M, P, Q, R or T. - The position corresponding to amino acid position L229 in Dda 1993 is substituted with S, K, V, I, N, E, D, T, G, A, R, Q, H, M, P, F, or Y. - The position corresponding to amino acid position V237 in Dda 1993 is substituted with M, I, A, L, F, K, Q, R, S, T, W, or Y. - The position corresponding to amino acid position M238 in Dda 1993 is substituted with I, L, V, F, A, T, Y, K, Q, R, S, or W. - The position corresponding to amino acid position K247 in Dda 1993 is substituted with N, E, R, D, G, H, Q, S, T, A, M or P. - The amino acid position L248 of Dda 1993 is substituted with F, I, H, M, V, W, Y, A, or T. - The position corresponding to amino acid position I251 of Dda 1993 is substituted with F, L, E, Y, A, T, H, M, V or W. - The position corresponding to amino acid position R253 in Dda 1993 is substituted with Q, A, D, E, H, K, M, N, P, S, T or Y. - The position corresponding to amino acid position K254 in Dda 1993 is substituted with N, S, D, E, G, H, Q, R, T, A, M or P. - The amino acid position corresponding to position F257 of Dda 1993 is substituted with Y, H, I, L, M, Q, V, or W. - The position corresponding to amino acid position D262 in Dda 1993 is substituted with P, E, A, K, Q, S, T, G, H or N. - The position corresponding to amino acid position V265 in Dda 1993 is substituted with E, P, A, K, S, G, D, N, T, H, Q, R, F, I, L, M or Y, - The position corresponding to amino acid position D282 in Dda 1993 is substituted with P, A, E, K, Q, S, T, G, H or N. - The position corresponding to amino acid position I289 in Dda 1993 is substituted with L, V, M, K, E, G, A, F, T, or Y. - The position corresponding to amino acid position Q295 of Dda 1993 is substituted with D, E, M, S, G, H, K, N, P, T, A, R or Y. - The position corresponding to amino acid position Y304 of Dda 1993 is substituted with K, E, L, P, D, N, S, G, A, R, T, Q, H, V, I, M, F, or W. - The position corresponding to amino acid position S306 of Dda 1993 is substituted with E, Y, D, K, T, G, F, V, N, A, H, P, Q, R or M. - The position corresponding to amino acid position V309 of Dda 1993 is substituted with F, K, I, H, L, M, W, Y, A, or T. - The position corresponding to amino acid position V314 in Dda 1993 is substituted with I, K, E, L, A, F, M, T, or Y. - The position corresponding to amino acid position G316 in Dda 1993 is substituted with E, K, D, V, I, N, L, A, H, P, Q, R, S or T. - The position corresponding to amino acid position L319 in Dda 1993 is substituted with E, K, I, V, T, N, D, G, A, H, P, Q, R, S, F, M or Y. - The position corresponding to amino acid position R321 in Dda 1993 is substituted with K, N, E, V, I, D, L, A, H, M, P, Q, S or T. - The position corresponding to amino acid position T329 in Dda 1993 is substituted with P, S, G, K, A, E, D, I, V, L, N, R, Y, F, Q, or M. - The position corresponding to amino acid position G331 in Dda 1993 is substituted with D, E, K, L, S, I, N, T, V, H, P, Q or A. - The position corresponding to amino acid position D333 in Dda 1993 is substituted with G, K, E, I, A, N, S, H, P, Q or T. - The position corresponding to amino acid position L349 in Dda 1993 is substituted with E, N, K, Q, A, T, S, D, V, R, I, H, P, F, M or Y. - The position corresponding to amino acid position F352 in Dda 1993 is substituted with Y, L, K, E, R, I, A, N, D, H, M, Q, V, or W. - The position corresponding to amino acid position T362 in Dda 1993 is substituted with A, I, V, L, E, K, M, D, R, Y, N, Q, S, F, G or P. - The position corresponding to amino acid position N365 of Dda 1993 is substituted with K, E, A, S, R, D, H, M, P, Q, T, or G. - The position corresponding to amino acid position N367 in Dda 1993 is substituted with S, K, L, E, A, T, I, V, Q, R, Y, F, M, D, G, H, or P. - The position corresponding to amino acid position G369 in Dda 1993 is substituted with E, K, D, N, S, T, R, L, I, A, Y, H, P, or Q. - The position corresponding to amino acid position G370 in Dda 1993 is substituted with K, V, E, I, S, A, N, D, H, M, P, Q, R or T. - The position corresponding to amino acid position P373 in Dda 1993 is substituted with H, L, N, K, M, Y, F, I, V, S, E, T, A, R, D, G, Q, or W. - The position corresponding to amino acid position A380 of Dda 1993 is substituted with V, L, T, I, K, M, F, Y, E, G, P, Q, R or S. - The position corresponding to amino acid position Q383 in Dda 1993 is substituted with L, T, M, Y, K, F, I, V, R, A, E, S, N, D, G, H, or P. - The position corresponding to amino acid position S385 of Dda 1993 is substituted with I, T, A, Y, K, H, R, F, L, M, V, D, E, G, N, P or Q. - The position corresponding to amino acid position P391 in Dda 1993 is substituted with G, Y, F, H, A, V, D, N, S, E, K, Q, or T. - The position corresponding to amino acid position S393 of Dda 1993 is substituted with I, V, L, T, E, D, M, F, A, Y, G, H, K, N, P, Q or R, - The amino acid position F395 of Dda 1993 is substituted with I, V, Y, L, T, A, M, H or W. - The position corresponding to amino acid position M401 of Dda 1993 is substituted with L, S, V, I, G, D, E, R, Q, A, W, N, T, F, Y, K, H, or P. The position corresponding to amino acid position S402 in Dda 1993 is substituted with T, V, R, I, K, L, E, H, Q, M, A, D, N, P, or G. - The amino acid position corresponding to position V403 of Dda 1993 is substituted with F, Y, I, H, L, M, W, A, or T. - The position corresponding to amino acid position D404 in Dda 1993 is substituted with N, K, R, E, G, H, Q, S, T, or P. - The position corresponding to amino acid position R405 in Dda 1993 is substituted with N, K, D, E, G, H, Q, S, T, A, M or P. The position corresponding to amino acid position A406 in Dda 1993 is substituted with T, V, I, D, E, K, L, M, N, P, Q, R, S, G, F, or Y. - The position corresponding to amino acid position I413 in Dda 1993 is substituted with E, L, K, S, D, G, N, P, Y, F, T, R, A, H, Q, M, or V. - The position corresponding to amino acid position H414 in Dda 1993 is substituted with Y, D, F, Q, K, N, S, E, G, P, R, T, L, I, A, M, V, or W. - The position corresponding to amino acid position V418 in Dda 1993 is substituted with K, E, P, R, D, T, A, S, N, L, I, Y, G, H, M, Q, or F. - The position corresponding to amino acid position E419 in Dda 1993 is substituted with Q, D, A, H, K, M, N, P, R, S, T or Y. - The position corresponding to amino acid position A421 in Dda 1993 is substituted with Q, L, R, N, S, K, D, E, H, M, P, T, Y, G, I, V, or F. - The position corresponding to amino acid position Q422 in Dda 1993 is substituted with K, R, L, N, A, D, E, H, M, P, S, T, or Y. - The position corresponding to amino acid position V427 in Dda 1993 is substituted with T, E, D, A, I, K, L, M, N, P, Q, R, S, F or Y. - The position corresponding to amino acid position V429 in Dda 1993 is substituted with I, L, A, F, M, T, or Y. - The position corresponding to amino acid position G432 in Dda 1993 is substituted with P, A, S, T, D, E, K, Q or N. - The position corresponding to amino acid position Y434 in Dda 1993 is substituted with K, I, V, R, E, T, N, D, L, S, Q, H, G, A, M, P, F, or W. - The position corresponding to amino acid position D435 in Dda 1993 is substituted with E, Q, A, H, K, N, P, R, S, T or G, and / or A modified Dda helicase in which the amino acid position corresponding to position F437 in Dda 1993 is substituted with Y, I, H, L, M, Q, V, or W.

3. The helicase according to claim 1 or 2 and a construct comprising a further polynucleotide binding portion, wherein the helicase is bound to the polynucleotide binding portion and the construct has the ability to control the movement of the analyte.

4. The structure according to claim 3, comprising two or more helicases according to claim 1 or 2.

5. A polynucleotide comprising a sequence encoding the helicase described in claim 1 or 2, or a construct described in claim 3 or 4.

6. A vector comprising the polynucleotide according to claim 5, operably linked to a promoter.

7. A host cell containing the vector according to claim 6.

8. A method for producing a helicase according to claim 1 or 2 or a construct according to claim 3 or 4, comprising expressing a polynucleotide according to claim 5, transfecting a cell with a vector according to claim 6, or culturing a host cell according to claim 7.

9. A method for controlling the movement of an analyte, comprising bringing the analyte into contact with a helicase described in claim 1 or 2 or a structure described in claim 3 or 4, thereby controlling the movement of the analyte.

10. The method according to claim 9, for controlling the movement of an analyte through a transmembrane pore.

11. A method for characterizing a target analyte, (a) The target analyte is brought into contact with a transmembrane pore and the helicase described in claim 1 or 2 or the structure described in claim 3 or 4, so that the helicase or the structure controls the movement of the target analyte through the pore; and (b) A method comprising the step of obtaining one or more measurements as the target analyte moves toward the pore, wherein the measurements represent one or more properties of the target analyte, thereby characterizing the target analyte.

12. (a) bringing the target analyte into contact with the transmembrane pore and the helicase according to claim 1 or 2 or the structure according to claim 3 or 4 so that the helicase or the structure controls the movement of the target analyte through the pore; and (b) The method of claim 11, comprising the step of measuring the current passing through the pore as the target analyte moves toward the pore, wherein the current exhibits one or more properties of the target analyte, thereby characterizing the target analyte.

13. The method according to claim 11 or 12, wherein the target analyte is a polynucleotide.

14. The method according to any one of claims 11 to 23, wherein the pore is a transmembrane protein pore or a solid pore.

15. A method for forming a sensor for characterizing a target analyte, comprising forming a composite between (a) a pore and (b) a helicase according to claim 1 or 2 or a construct according to claim 3 or 4, thereby forming a sensor for characterizing the target analyte.

16. The method according to claim 15, wherein the composite is formed by covalently bonding the pore to the helicase or construct.

17. A sensor for characterizing a target analyte, comprising (a) a pore and (b) a composite of a helicase according to claim 1 or 2 or a construct according to claim 3 or 4.

18. Use of the helicase according to claim 1 or 2 or the structure according to claim 3 or 4 for controlling the movement of a target analyte through a pore.

19. A kit for characterizing target analytes, (a) the pore and helicase described in claim 1 or 2 or the structure described in claim 3 or 4; or (b) A kit comprising the helicase according to claim 1 or 2, or the structure according to claim 3 or 4, and one or more load parts.

20. An apparatus for characterizing a target analyte in a sample, comprising (a) a plurality of pores and (b) a plurality of helicases according to claim 1 or 2 or a plurality of constructs according to claim 3 or 4.

21. A method for producing a helicase according to claim 1 or 2, (a) Provision of helicase; and (b) A method comprising modifying the helicase to produce the helicase described in claim 1 or 2.

22. (c) The method according to claim 21, further comprising determining whether the obtained helicase can control the movement of polynucleotides.

23. A method for producing a construct according to claim 3 or 4, comprising attaching the helicase described in claim 1 or 2 to an additional polynucleotide binding portion to produce the construct.

24. A series of two or more helicases bound to a polynucleotide, wherein at least one of the two or more helicases is the helicase described in claim 1 or 2.

25. A method for improving the movement of a target analyte to a transmembrane pore when its movement is controlled by a DNA-dependent ATPase (Dda) helicase, wherein the DNA-dependent ATPase (Dda) helicase improves the movement of the target analyte to the transmembrane pore, the modification according to claim 1 or 2.